Medications for human use with a single active ingredient starting with the letter H-N.

Médicaments à usage humain contenant un seul ingrédient actif commençant par la lettre H-N.

Last Update: 2021-05-03
Product Name;
DIN;
Active ingredient(s) and concentration;
Number of active ingredients: Number of active ingredients;
Original market date;
Route(s) of administration;
Dosage form(s);
AHFS;
Schedule;
Company
Monograph
HIBERIX;
02239200;
haemophilus influenzae type b-prp and tetanus toxoid conjugate (prp-t) 10 mcg / 0.5 ml;
2012-10-25;
Intramuscular;
Powder For Solution;
80:12.00 – VACCINES;
Schedule D;
GLAXOSMITHKLINE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=62657
ULTRAVATE;
01962728;
halobetasol propionate 0.05 % / w/w;
1993-12-31;
Topical;
Ointment;
84:06.00 – ANTI-INFLAMMATORY AGENTS;
Prescription;
BAUSCH HEALTH, CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=13909
ULTRAVATE;
01962701;
halobetasol propionate 0.05 % / w/w;
1993-12-31;
Topical;
Cream;
84:06.00 – ANTI-INFLAMMATORY AGENTS;
Prescription;
BAUSCH HEALTH, CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=13917
HALOPERIDOL LA;
02130300;
haloperidol (haloperidol decanoate) 100 mg / ml;
1994-12-31;
Intramuscular;
Liquid;
28:16.08.08 – BUTYROPHENONES;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=16902
TEVA-HALOPERIDOL;
00363685;
haloperidol 0.5 mg;
1986-12-31;
Oral;
Tablet;
28:16.08.08 – BUTYROPHENONES;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=7128
TEVA-HALOPERIDOL;
00363677;
haloperidol 1 mg;
1986-12-31;
Oral;
Tablet;
28:16.08.08 – BUTYROPHENONES;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=7129
TEVA-HALOPERIDOL;
00713449;
haloperidol 10 mg;
1986-12-31;
Oral;
Tablet;
28:16.08.08 – BUTYROPHENONES;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=7131
TEVA-HALOPERIDOL;
00363669;
haloperidol 2 mg;
1986-12-31;
Oral;
Tablet;
28:16.08.08 – BUTYROPHENONES;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=7130
TEVA-HALOPERIDOL;
00768820;
haloperidol 20 mg;
1988-12-31;
Oral;
Tablet;
28:16.08.08 – BUTYROPHENONES;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=8477
TEVA-HALOPERIDOL;
00363650;
haloperidol 5 mg;
1984-12-31;
Oral;
Tablet;
28:16.08.08 – BUTYROPHENONES;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=5859
HALOPERIDOL INJ 5MG/ML USP;
00808652;
haloperidol 5 mg / ml;
1989-12-31;
Intramuscular;
Liquid;
28:16.08.08 – BUTYROPHENONES;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=10026
HALOPERIDOL INJECTION;
02366010;
haloperidol 5 mg / ml;
2011-09-19;
Intramuscular;
Solution;
28:16.08.08 – BUTYROPHENONES;
Prescription;
OMEGA LABORATORIES LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85088
HALOPERIDOL INJECTION, USP;
02406411;
haloperidol 5 mg / ml;
2014-10-20;
Intramuscular;
Solution;
28:16.08.08 – BUTYROPHENONES;
Prescription;
FRESENIUS KABI CANADA LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=89112
TOPICAL HAPTEN GEL;
02466333;
haptens 100 % / w/w;
2017-09-13;
Topical;
Gel;
92:05.00* – ALLERGENIC EXTRACTS;
Schedule D;
DORMER LABORATORIES INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95467
TOPICAL HAPTEN LIQUID;
02466368;
haptens 100 % / w/w;
2017-09-13;
Topical;
Liquid;
92:05.00* – ALLERGENIC EXTRACTS;
Schedule D;
DORMER LABORATORIES INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95470
TOPICAL HAPTEN LIQUID;
02466341;
haptens 20 % / w/w;
2017-09-13;
Topical;
Liquid;
92:05.00* – ALLERGENIC EXTRACTS;
Schedule D;
DORMER LABORATORIES INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95469
TOPICAL HAPTEN GEL;
02466325;
haptens 50 % / w/w;
2017-09-13;
Topical;
Gel;
92:05.00* – ALLERGENIC EXTRACTS;
Schedule D;
DORMER LABORATORIES INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95465
HELIUM 100%;
00572888;
helium 100 %;
1911-12-31;
Inhalation;
Gas;
92:92.00 – OTHER MISCELLANEOUS THERAPEUTIC AGENTS;
Ethical;
AIR LIQUIDE CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=5688
HELIUM USP 99%;
02014475;
helium 99 %;
1993-12-31;
Inhalation;
Gas;
92:92.00 – OTHER MISCELLANEOUS THERAPEUTIC AGENTS;
Ethical;
PRAXAIR CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=13883
PANHEMATIN;
02478765;
hemin 268 mg / vial;
2018-12-05;
Intravenous;
Powder For Solution;
-;
Prescription , Schedule D;
RECORDATI RARE DISEASES CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96951
HEPARIN LEO 100UNIT/ML;
00727520;
heparin sodium 100 unit / ml;
1984-12-31;
0-Unassigned;
Liquid;
20:12.04.16 – HEPARINS;
Ethical;
LEO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=8042
HEPARIN LEO INJ 1000UNIT/ML;
00453811;
heparin sodium 1000 unit / ml;
1987-12-31;
Intravenous , Subcutaneous;
Liquid;
20:12.04.16 – HEPARINS;
Ethical;
LEO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=10526
HEPARIN SODIUM INJECTION, USP;
02264315;
heparin sodium 1000 unit / ml;
2005-05-26;
Intravenous , Subcutaneous;
Solution;
20:12.04.16 – HEPARINS;
Ethical;
FRESENIUS KABI CANADA LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=74976
HEPARIN SODIUM INJECTION USP (MULTIDOSE VIAL-WITH PRESERVATIVE);
02303086;
heparin sodium 1000 unit / ml;
2008-05-19;
Intravenous , Subcutaneous;
Solution;
20:12.04.16 – HEPARINS;
Ethical;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78841
HEPARIN SODIUM INJECTION, USP;
02264307;
heparin sodium 10000 unit / ml;
2005-05-27;
Intravenous , Subcutaneous;
Solution;
20:12.04.16 – HEPARINS;
Ethical;
FRESENIUS KABI CANADA LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=74973
HEPARIN SODIUM INJECTION USP (MULTIDOSE VIAL-WITH PRESERVATIVE);
02303108;
heparin sodium 10000 unit / ml;
2008-05-19;
Intravenous , Subcutaneous;
Solution;
20:12.04.16 – HEPARINS;
Ethical;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78843
HEPARIN SODIUM INJECTION USP;
02382326;
heparin sodium 10000 unit / ml;
2013-03-01;
Intravenous , Subcutaneous;
Solution;
20:12.04.16 – HEPARINS;
Ethical;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86817
HEPARIN SODIUM INJECTION, USP;
02392453;
heparin sodium 10000 unit / ml;
2013-05-20;
Intravenous , Subcutaneous;
Solution;
20:12.04.16 – HEPARINS;
Ethical;
FRESENIUS KABI CANADA LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87773
HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION;
01990748;
heparin sodium 2 unit / ml;
1994-12-31;
Intravenous;
Solution;
20:12.04.16 – HEPARINS;
Ethical;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=17227
HEPARIN SODIUM INJECTION USP;
02456958;
heparin sodium 5000 unit / 0.5 ml;
2016-11-17;
Subcutaneous;
Solution;
20:12.04.16 – HEPARINS;
Ethical;
STERINOVA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94407
HAVRIX – SUS IM 1440 ELISA UNITS/ML;
02187078;
hepatitis a vaccine – inactivated 1440 unit / ml;
1996-12-31;
Intramuscular;
Suspension;
80:12.00 – VACCINES;
Schedule D;
GLAXOSMITHKLINE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=20256
AVAXIM;
02237792;
hepatitis a vaccine – inactivated 160 unit / 0.5 ml;
1999-05-27;
Intramuscular;
Suspension;
80:12.00 – VACCINES;
Schedule D;
SANOFI PASTEUR LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=61149
VAQTA;
02229702;
hepatitis a vaccine – inactivated 50 unit / ml;
1996-11-10;
Intramuscular;
Suspension;
80:12.00 – VACCINES;
Schedule D;
MERCK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=47865
HAVRIX 720 JUNIOR;
02231056;
hepatitis a vaccine – inactivated 720 unit / 0.5 ml;
1997-09-23;
Intramuscular;
Suspension;
80:12.00 – VACCINES;
Schedule D;
GLAXOSMITHKLINE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=50339
HYPERHEP B S/D;
02230738;
hepatitis b immunoglobulin (human) 220 unit / ml;
1997-07-08;
Intramuscular;
Solution;
80:04.00 – SERUMS;
Schedule D;
GRIFOLS THERAPEUTICS LLC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=50001
HYPERHEP B S/D;
02379465;
hepatitis b immunoglobulin (human) 220 unit / ml;
2013-01-15;
Intramuscular;
Solution;
80:04.00 – SERUMS;
Schedule D;
GRIFOLS THERAPEUTICS LLC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86536
HEPAGAM B;
02290979;
hepatitis b immunoglobulin (human) 312 unit / ml;
2007-08-13;
Intramuscular , Intravenous;
Solution;
80:04.00 – SERUMS;
Schedule D;
SAOL THERAPEUTICS RESEARCH LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=77637
RECOMBIVAX HB;
02243676;
hepatitis b surface antigen (recombinant) 10 mcg / ml;
2001-04-11;
Intramuscular;
Solution;
80:12.00 – VACCINES;
Schedule D;
MERCK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=67606
ENGERIX-B;
02487020;
hepatitis b surface antigen (recombinant) 10 mcg / 0.5 ml;
2019-10-07;
Intramuscular;
Suspension;
80:12.00 – VACCINES;
Schedule D;
GLAXOSMITHKLINE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97717
ENGERIX-B;
02487039;
hepatitis b surface antigen (recombinant) 20 mcg / 1 ml;
2019-11-15;
Intramuscular;
Suspension;
80:12.00 – VACCINES;
Schedule D;
GLAXOSMITHKLINE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97718
RECOMBIVAX HB;
02245977;
hepatitis b surface antigen (recombinant) 40 mcg / ml;
2002-10-24;
Intramuscular;
Solution;
80:12.00 – VACCINES;
Schedule D;
MERCK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=70103
CYSVIEW;
02436639;
hexaminolevulinate hydrochloride 100 mg / vial;
2015-12-14;
Intravesical;
Kit , Powder For Solution;
36:89.00* – OTHER DIAGNOSTIC AGENTS;
Prescription;
BIOSYENT PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92096
STREPSILS ANAESTHETIC FORMULA;
02243888;
hexylresorcinol 2.4 mg;
2001-10-01;
Oral;
Lozenge;
52:04.92 – MISCELLANEOUS ANTI-INFECTIVES;
Otc;
RB HEALTH (CANADA) INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=67829
BRADOSOL LOZENGES EXTRA STRENGTH 3.5MG;
00895466;
hexylresorcinol 3.5 mg;
1991-12-31;
Oral;
Lozenge;
52:04.92 – MISCELLANEOUS ANTI-INFECTIVES;
Otc;
COLUMBIA LABORATORIES CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=11321
HISTATROL;
00609706;
histamine phosphate 0.275 mg / ml;
1984-12-31;
Intradermal;
Solution;
36:89.00* – OTHER DIAGNOSTIC AGENTS;
Ethical;
ALK-ABELLO INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=5538
HISTATROL;
00609692;
histamine phosphate 2.75 mg / ml;
1984-12-31;
Percutaneous;
Solution;
36:89.00* – OTHER DIAGNOSTIC AGENTS;
Ethical;
ALK-ABELLO INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=5537
HYMENOPTERA VENOM PRODUCT – HONEY BEE VENOM (550 MCG);
02220075;
honey bee venom protein 550 mcg / vial;
1997-12-16;
Subcutaneous;
Powder For Solution;
92:05.00* – ALLERGENIC EXTRACTS;
Schedule D;
JUBILANT HOLLISTERSTIER LLC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=43270
OCTAPLASMA;
02270013;
human plasma proteins 14 g / 200 ml;
2012-05-31;
Intravenous;
Solution;
20:28.16 – HEMOSTATICS;
Schedule D;
OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES M B H
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=75541
APO-HYDRALAZINE;
00441619;
hydralazine hydrochloride 10 mg;
1990-12-31;
Oral;
Tablet;
24:08.20 – DIRECT VASODILATORS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=11047
JAMP-HYDRALAZINE;
02457865;
hydralazine hydrochloride 10 mg;
2017-08-28;
Oral;
Tablet;
24:08.20 – DIRECT VASODILATORS;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94490
MINT-HYDRALAZINE;
02468778;
hydralazine hydrochloride 10 mg;
2018-04-13;
Oral;
Tablet;
24:08.20 – DIRECT VASODILATORS;
Prescription;
MINT PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95730
APRESOLINE;
00723754;
hydralazine hydrochloride 20 mg / ml;
1992-12-31;
Intravenous;
Solution;
24:08.20 – DIRECT VASODILATORS;
Prescription;
STERIMAX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=12237
APO-HYDRALAZINE;
00441627;
hydralazine hydrochloride 25 mg;
1991-12-31;
Oral;
Tablet;
24:08.20 – DIRECT VASODILATORS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=11626
JAMP-HYDRALAZINE;
02457873;
hydralazine hydrochloride 25 mg;
2017-08-28;
Oral;
Tablet;
24:08.20 – DIRECT VASODILATORS;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94491
MINT-HYDRALAZINE;
02468786;
hydralazine hydrochloride 25 mg;
2018-02-16;
Oral;
Tablet;
24:08.20 – DIRECT VASODILATORS;
Prescription;
MINT PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95731
APO-HYDRALAZINE;
00441635;
hydralazine hydrochloride 50 mg;
1991-12-31;
Oral;
Tablet;
24:08.20 – DIRECT VASODILATORS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=11627
JAMP-HYDRALAZINE;
02457881;
hydralazine hydrochloride 50 mg;
2017-08-28;
Oral;
Tablet;
24:08.20 – DIRECT VASODILATORS;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94492
MINT-HYDRALAZINE;
02468794;
hydralazine hydrochloride 50 mg;
2018-02-16;
Oral;
Tablet;
24:08.20 – DIRECT VASODILATORS;
Prescription;
MINT PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95732
PMS-HYDROCHLOROTHIAZIDE;
02274086;
hydrochlorothiazide 12.5 mg;
2005-12-22;
Oral;
Tablet;
40:28.20 – THIAZIDE DIURETICS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=75953
APO-HYDROCHLOROTHIAZIDE;
02327856;
hydrochlorothiazide 12.5 mg;
2009-07-02;
Oral;
Tablet;
40:28.20 – THIAZIDE DIURETICS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=81335
MINT-HYDROCHLOROTHIAZIDE;
02425947;
hydrochlorothiazide 12.5 mg;
2014-07-23;
Oral;
Tablet;
40:28.20 – THIAZIDE DIURETICS;
Prescription;
MINT PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=91057
TEVA-HYDROCHLOROTHIAZIDE;
00021474;
hydrochlorothiazide 25 mg;
1968-12-31;
Oral;
Tablet;
40:28.20 – THIAZIDE DIURETICS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=778
APO-HYDROCHLOROTHIAZIDE;
00326844;
hydrochlorothiazide 25 mg;
1975-12-31;
Oral;
Tablet;
40:28.20 – THIAZIDE DIURETICS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=4281
PMS-HYDROCHLOROTHIAZIDE;
02247386;
hydrochlorothiazide 25 mg;
2003-12-10;
Oral;
Tablet;
40:28.20 – THIAZIDE DIURETICS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=71631
HYDROCHLOROTHIAZIDE;
02360594;
hydrochlorothiazide 25 mg;
2011-02-08;
Oral;
Tablet;
40:28.20 – THIAZIDE DIURETICS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84556
MINT-HYDROCHLOROTHIAZIDE;
02426196;
hydrochlorothiazide 25 mg;
2014-07-23;
Oral;
Tablet;
40:28.20 – THIAZIDE DIURETICS;
Prescription;
MINT PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=91079
HYDROCHLOROTHIAZIDE;
02486962;
hydrochlorothiazide 25 mg;
2019-08-14;
Oral;
Tablet;
40:28.20 – THIAZIDE DIURETICS;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97711
TEVA-HYDROCHLOROTHIAZIDE;
00021482;
hydrochlorothiazide 50 mg;
1968-12-31;
Oral;
Tablet;
40:28.20 – THIAZIDE DIURETICS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=812
APO-HYDROCHLOROTHIAZIDE;
00312800;
hydrochlorothiazide 50 mg;
1974-12-31;
Oral;
Tablet;
40:28.20 – THIAZIDE DIURETICS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=4280
PMS-HYDROCHLOROTHIAZIDE;
02247387;
hydrochlorothiazide 50 mg;
2003-12-10;
Oral;
Tablet;
40:28.20 – THIAZIDE DIURETICS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=71632
HYDROCHLOROTHIAZIDE;
02360608;
hydrochlorothiazide 50 mg;
2011-02-08;
Oral;
Tablet;
40:28.20 – THIAZIDE DIURETICS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84557
PDP-HYDROCODONE;
02324253;
hydrocodone bitartrate 5 mg / 5 ml;
2009-03-21;
Oral;
Syrup;
48:08.00 – ANTITUSSIVES;
Narcotic (Cdsa I);
PENDOPHARM DIVISION OF PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80973
SOLU-CORTEF 1 GM ACT-O-VIAL;
00030635;
hydrocortisone (hydrocortisone sodium succinate) 1 g / vial;
1967-12-31;
Intramuscular , Intravenous;
Powder For Solution;
68:04.00 – ADRENALS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=2222
SOLU-CORTEF 100 MG ACT-O-VIAL;
00030600;
hydrocortisone (hydrocortisone sodium succinate) 100 mg / vial;
1958-12-31;
Intramuscular , Intravenous;
Powder For Solution;
68:04.00 – ADRENALS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=2219
SOLU-CORTEF 250 MG ACT-O-VIAL;
00030619;
hydrocortisone (hydrocortisone sodium succinate) 250 mg / vial;
1962-12-31;
Intramuscular , Intravenous;
Powder For Solution;
68:04.00 – ADRENALS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=2220
SOLU-CORTEF 500 MG ACT-O-VIAL;
00030627;
hydrocortisone (hydrocortisone sodium succinate) 500 mg / vial;
1966-12-31;
Intramuscular , Intravenous;
Powder For Solution;
68:04.00 – ADRENALS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=2221
CORTEF TABLETS 10MG;
00030910;
hydrocortisone 10 mg;
1954-12-31;
Oral;
Tablet;
68:04.00 – ADRENALS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=432
CORTENEMA;
02112736;
hydrocortisone 100 mg / 60 ml;
1995-12-31;
Rectal;
Enema;
56:36.00 – ANTI-INFLAMMATORY AGENTS;
Prescription;
APTALIS PHARMA CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=18968
SANDOZ HYDROCORTISONE;
02469421;
hydrocortisone 2.5 % / w/w;
2019-06-04;
Topical;
Cream;
84:06.00 – ANTI-INFLAMMATORY AGENTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95822
CORTEF TABLETS 20 MG;
00030929;
hydrocortisone 20 mg;
1954-12-31;
Oral;
Tablet;
68:04.00 – ADRENALS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=433
HYDROVAL CREAM 0.2%;
02242984;
hydrocortisone valerate 0.2 %;
2000-12-18;
Topical;
Cream;
84:06.00 – ANTI-INFLAMMATORY AGENTS;
Prescription;
TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=66824
HYDROVAL OINTMENT 0.2%;
02242985;
hydrocortisone valerate 0.2 %;
2000-12-18;
Topical;
Ointment;
84:06.00 – ANTI-INFLAMMATORY AGENTS;
Prescription;
TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=66825
DILAUDID;
00705438;
hydromorphone hydrochloride 1 mg;
1986-12-31;
Oral;
Tablet;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PURDUE PHARMA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=6889
PMS-HYDROMORPHONE TAB 1MG;
00885444;
hydromorphone hydrochloride 1 mg;
1991-12-31;
Oral;
Tablet;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=11413
TEVA-HYDROMORPHONE;
02319403;
hydromorphone hydrochloride 1 mg;
2011-11-16;
Oral;
Tablet;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80489
APO-HYDROMORPHONE;
02364115;
hydromorphone hydrochloride 1 mg;
2012-12-18;
Oral;
Tablet;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84905
PMS HYDROMORPHONE SIROP 1MG/ML;
01916386;
hydromorphone hydrochloride 1 mg / ml;
1991-12-31;
Oral;
Syrup;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=11870
HYDROMORPHONE HP 10;
02145928;
hydromorphone hydrochloride 10 mg / ml;
1995-12-31;
Intramuscular , Intravenous , Subcutaneous;
Solution;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=18323
HYDROMORPHONE HYDROCHLORIDE INJECTION USP;
02382636;
hydromorphone hydrochloride 10 mg / ml;
2014-06-11;
Intramuscular , Intravenous , Subcutaneous;
Solution;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86845
HYDROMORPHONE HYDROCHLORIDE INJECTION HP 10;
02460610;
hydromorphone hydrochloride 10 mg / ml;
2017-02-06;
Intramuscular , Intravenous , Subcutaneous;
Solution;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
STERIMAX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94804
HYDROMORPHONE HYDROCHLORIDE INJECTION, USP;
02491680;
hydromorphone hydrochloride 10 mg / ml;
2020-11-10;
Intramuscular , Intravenous , Subcutaneous;
Solution;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
FRESENIUS KABI CANADA LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98169
HYDROMORPHONE HYDROCHLORIDE INJECTION HP FORTE;
02468468;
hydromorphone hydrochloride 100 mg / ml;
2018-06-20;
Intramuscular , Intravenous , Subcutaneous;
Solution;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
STERIMAX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95689
HYDROMORPHONE HP FORTE INJECTION;
02244797;
hydromorphone hydrochloride 1000 mg / 10 ml;
2001-12-10;
Intramuscular , Intravenous , Subcutaneous;
Solution;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=68787
HYDROMORPH CONTIN-CONTROLLED RELEASE CAP – 12MG;
02125366;
hydromorphone hydrochloride 12 mg;
1996-12-31;
Oral;
Capsule (Sustained-Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PURDUE PHARMA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=20171
HYDROMORPH CONTIN-CONTROLLED RELEASE CAP – 18MG;
02243562;
hydromorphone hydrochloride 18 mg;
2001-07-03;
Oral;
Capsule (Sustained-Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PURDUE PHARMA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=67480
DILAUDID;
00125083;
hydromorphone hydrochloride 2 mg;
1984-12-31;
Oral;
Tablet;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PURDUE PHARMA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=5939
PMS-HYDROMORPHONE TAB 2MG;
00885436;
hydromorphone hydrochloride 2 mg;
1991-12-31;
Oral;
Tablet;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=11428
TEVA-HYDROMORPHONE;
02319411;
hydromorphone hydrochloride 2 mg;
2011-11-16;
Oral;
Tablet;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80490
APO-HYDROMORPHONE;
02364123;
hydromorphone hydrochloride 2 mg;
2012-12-18;
Oral;
Tablet;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84906
HYDROMORPHONE HYDROCHLORIDE INJECTION USP;
02145901;
hydromorphone hydrochloride 2 mg / ml;
1995-12-31;
Intramuscular , Intravenous , Subcutaneous;
Solution;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=18315
HYDROMORPHONE HYDROCHLORIDE INJECTION;
02460602;
hydromorphone hydrochloride 2 mg / ml;
2017-02-06;
Intramuscular , Intravenous , Subcutaneous;
Solution;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
STERIMAX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94803
HYDROMORPHONE HYDROCHLORIDE INJECTION, USP;
02491699;
hydromorphone hydrochloride 2 mg / ml;
2020-11-10;
Intramuscular , Intravenous , Subcutaneous;
Solution;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
FRESENIUS KABI CANADA LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98170
HYDROMORPHONE HP 20;
02145936;
hydromorphone hydrochloride 20 mg / ml;
1995-12-31;
Intramuscular , Intravenous , Subcutaneous;
Solution;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=18325
HYDROMORPHONE HYDROCHLORIDE INJECTION USP;
02485532;
hydromorphone hydrochloride 20 mg / 50 ml;
2019-09-18;
Intravenous;
Solution;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
STERINOVA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97577
HYDROMORPH CONTIN-CONTROLLED RELEASE CAP – 24MG;
02125382;
hydromorphone hydrochloride 24 mg;
1996-12-31;
Oral;
Capsule (Sustained-Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PURDUE PHARMA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=20172
HYDROMORPH CONTIN-CONTROLLED RELEASE CAP – 3MG;
02125323;
hydromorphone hydrochloride 3 mg;
1995-12-31;
Oral;
Capsule (Sustained-Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PURDUE PHARMA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=18556
HYDROMORPH CONTIN-CONTROLLED RELEASE CAP – 30MG;
02125390;
hydromorphone hydrochloride 30 mg;
1998-02-16;
Oral;
Capsule (Sustained-Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PURDUE PHARMA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=43838
DILAUDID;
00125121;
hydromorphone hydrochloride 4 mg;
1984-12-31;
Oral;
Tablet;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PURDUE PHARMA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=5940
PMS-HYDROMORPHONE TAB 4MG;
00885401;
hydromorphone hydrochloride 4 mg;
1991-12-31;
Oral;
Tablet;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=11425
TEVA-HYDROMORPHONE;
02319438;
hydromorphone hydrochloride 4 mg;
2011-11-16;
Oral;
Tablet;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80491
APO-HYDROMORPHONE;
02364131;
hydromorphone hydrochloride 4 mg;
2012-12-18;
Oral;
Tablet;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84907
HYDROMORPH CONTIN;
02359502;
hydromorphone hydrochloride 4.5 mg;
2011-04-14;
Oral;
Capsule (Sustained-Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PURDUE PHARMA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84452
HYDROMORPHONE HYDROCHLORIDE INJECTION USP;
02485540;
hydromorphone hydrochloride 40 mg / 100 ml;
2019-08-28;
Intravenous;
Solution;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
STERINOVA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97578
HYDROMORPHONE HP 50;
02146126;
hydromorphone hydrochloride 50 mg / ml;
1995-12-31;
Intramuscular , Intravenous , Subcutaneous;
Solution;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=18324
HYDROMORPHONE HYDROCHLORIDE INJECTION HP 50;
02469413;
hydromorphone hydrochloride 50 mg / ml;
2018-08-21;
Intramuscular , Intravenous , Subcutaneous;
Solution;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
STERIMAX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95820
HYDROMORPH CONTIN-CONTROLLED RELEASE CAP – 6MG;
02125331;
hydromorphone hydrochloride 6 mg;
1995-12-31;
Oral;
Capsule (Sustained-Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PURDUE PHARMA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=18558
DILAUDID;
00786543;
hydromorphone hydrochloride 8 mg;
1989-12-31;
Oral;
Tablet;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PURDUE PHARMA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=9509
PMS-HYDROMORPHONE TAB 8MG;
00885428;
hydromorphone hydrochloride 8 mg;
1991-12-31;
Oral;
Tablet;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=11363
TEVA-HYDROMORPHONE;
02319446;
hydromorphone hydrochloride 8 mg;
2011-11-16;
Oral;
Tablet;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80492
APO-HYDROMORPHONE;
02364158;
hydromorphone hydrochloride 8 mg;
2012-12-18;
Oral;
Tablet;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84908
HYDROMORPH CONTIN;
02359510;
hydromorphone hydrochloride 9 mg;
2011-04-14;
Oral;
Capsule (Sustained-Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PURDUE PHARMA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84453
ERFA HYDROQUINONE;
02491702;
hydroquinone 4 % / w/w;
2020-03-13;
Topical;
Gel;
84:50.04 – DEPIGMENTING AGENTS;
Prescription;
ERFA CANADA 2012 INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98171
CYANOKIT;
02375370;
hydroxocobalamin 5 g / vial;
2012-10-19;
Intravenous;
Powder For Solution;
92:12.00 – ANTIDOTES;
Prescription;
SERB S.A.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86078
PLAQUENIL;
02017709;
hydroxychloroquine sulfate 200 mg;
1957-12-31;
Oral;
Tablet;
08:30.08 – ANTIMALARIALS;
Prescription;
SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=14735
APO-HYDROXYQUINE;
02246691;
hydroxychloroquine sulfate 200 mg;
2002-12-13;
Oral;
Tablet;
08:30.08 – ANTIMALARIALS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=70886
MINT-HYDROXYCHLOROQUINE;
02424991;
hydroxychloroquine sulfate 200 mg;
2014-06-10;
Oral;
Tablet;
08:30.08 – ANTIMALARIALS;
Prescription;
MINT PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90966
JAMP HYDROXYCHLOROQUINE SULFATE;
02491427;
hydroxychloroquine sulfate 200 mg;
2020-02-06;
Oral;
Tablet;
08:30.08 – ANTIMALARIALS;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98143
VOLUVEN;
02278057;
hydroxyethyl starch 130/0.4 6 %;
2006-09-18;
Intravenous;
Solution;
40:12.00 – REPLACEMENT PREPARATIONS;
Prescription;
FRESENIUS KABI CANADA LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=76364
VOLULYTE;
02357291;
hydroxyethyl starch 130/0.4 6 %;
2011-05-16;
Intravenous;
Solution;
40:12.00 – REPLACEMENT PREPARATIONS;
Prescription;
FRESENIUS KABI CANADA LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84242
HYDREA CAP 500MG;
00465283;
hydroxyurea 500 mg;
1979-12-31;
Oral;
Capsule;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
BRISTOL-MYERS SQUIBB CANADA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=3453
MYLAN-HYDROXYUREA;
02242920;
hydroxyurea 500 mg;
2001-02-22;
Oral;
Capsule;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
MYLAN PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=66754
APO-HYDROXYUREA;
02247937;
hydroxyurea 500 mg;
2003-10-22;
Oral;
Capsule;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=72247
HYDROXYZINE;
00646059;
hydroxyzine hydrochloride 10 mg;
1986-12-31;
Oral;
Capsule;
28:24.92 – MISCELLANEOUS ANXIOLYTICS SEDATIVES AND HYPNOTICS;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=7393
NOVO-HYDROXYZIN;
00738824;
hydroxyzine hydrochloride 10 mg;
1987-12-31;
Oral;
Capsule;
28:24.92 – MISCELLANEOUS ANXIOLYTICS SEDATIVES AND HYPNOTICS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=7442
ATARAX SYRUP 2MG/ML;
00024694;
hydroxyzine hydrochloride 10 mg / 5 ml;
1956-12-31;
Oral;
Syrup;
28:24.92 – MISCELLANEOUS ANXIOLYTICS SEDATIVES AND HYPNOTICS;
Prescription;
ERFA CANADA 2012 INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=316
HYDROXYZINE;
00646024;
hydroxyzine hydrochloride 25 mg;
1986-12-31;
Oral;
Capsule;
28:24.92 – MISCELLANEOUS ANXIOLYTICS SEDATIVES AND HYPNOTICS;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=7392
NOVO-HYDROXYZIN;
00738832;
hydroxyzine hydrochloride 25 mg;
1987-12-31;
Oral;
Capsule;
28:24.92 – MISCELLANEOUS ANXIOLYTICS SEDATIVES AND HYPNOTICS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=7443
HYDROXYZINE;
00646016;
hydroxyzine hydrochloride 50 mg;
1986-12-31;
Oral;
Capsule;
28:24.92 – MISCELLANEOUS ANXIOLYTICS SEDATIVES AND HYPNOTICS;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=7391
NOVO-HYDROXYZIN;
00738840;
hydroxyzine hydrochloride 50 mg;
1987-12-31;
Oral;
Capsule;
28:24.92 – MISCELLANEOUS ANXIOLYTICS SEDATIVES AND HYPNOTICS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=7444
HYDROXYZINE HYDROCHLORIDE INJECTION USP;
00742813;
hydroxyzine hydrochloride 50 mg / ml;
1987-12-31;
Intramuscular;
Liquid;
28:24.92 – MISCELLANEOUS ANXIOLYTICS SEDATIVES AND HYPNOTICS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=8118
BUSCOPAN;
00363812;
hyoscine butylbromide 10 mg;
1976-12-31;
Oral;
Tablet;
12:08.08 – ANTIMUSCARINICS ANTISPASMODICS;
Ethical;
SANOFI CONSUMER HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=2481
BUSCOPAN;
00363839;
hyoscine butylbromide 20 mg / ml;
1976-12-31;
Intramuscular , Intravenous , Subcutaneous;
Solution;
12:08.08 – ANTIMUSCARINICS ANTISPASMODICS;
Prescription;
SANOFI CONSUMER HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=2483
HYOSCINE BUTYLBROMIDE INJECTION SANDOZ STANDARD;
02229868;
hyoscine butylbromide 20 mg / ml;
1997-08-25;
Intramuscular , Intravenous , Subcutaneous;
Solution;
12:08.08 – ANTIMUSCARINICS ANTISPASMODICS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=48226
LACRISERT;
02250624;
hyprolose 5 mg / insert;
2004-05-25;
Ophthalmic;
Insert;
52:13.00* – ARTIFICIAL TEARS;
Ethical;
BAUSCH HEALTH, CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=73543
ISOPTO TEARS 0.5%;
00000809;
hypromellose 0.5 %;
1969-12-31;
Ophthalmic;
Solution;
52:13.00* – ARTIFICIAL TEARS;
Otc;
ALCON CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=793
ISOPTO TEARS 1%;
00000817;
hypromellose 1 %;
1970-12-31;
Ophthalmic;
Solution;
52:13.00* – ARTIFICIAL TEARS;
Otc;
ALCON CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=794
GENTEAL;
02231289;
hypromellose 3 mg / ml;
1997-10-17;
Ophthalmic;
Solution;
52:13.00* – ARTIFICIAL TEARS;
Otc;
ALCON CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=50599
IMBRUVICA;
02434407;
ibrutinib 140 mg;
2014-11-19;
Oral;
Capsule;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
JANSSEN INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=91874
JUNIOR STRENGTH ADVIL;
02246403;
ibuprofen 100 mg;
2003-03-31;
Oral;
Tablet (Chewable);
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
GLAXOSMITHKLINE CONSUMER HEALTHCARE ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=70575
JUNIOR STRENGTH ADVIL FEVER FROM COLDS OR FLU;
02328429;
ibuprofen 100 mg;
2009-11-05;
Oral;
Tablet (Chewable);
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
GLAXOSMITHKLINE CONSUMER HEALTHCARE ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=81395
CHILDREN’S ADVIL;
02232297;
ibuprofen 100 mg / 5 ml;
1997-11-03;
Oral;
Suspension;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
GLAXOSMITHKLINE CONSUMER HEALTHCARE ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=51742
CHILDREN’S MOTRIN;
02242365;
ibuprofen 100 mg / 5 ml;
2000-09-15;
Oral;
Suspension;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=66076
CHILDREN’S IBUPROFEN SUSPENSION;
02280175;
ibuprofen 100 mg / 5 ml;
2007-08-30;
Oral;
Suspension;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
PERRIGO INTERNATIONAL
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=76585
CHILDREN’S ADVIL FEVER FROM COLDS OR FLU;
02328437;
ibuprofen 100 mg / 5 ml;
2009-11-05;
Oral;
Suspension;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
GLAXOSMITHKLINE CONSUMER HEALTHCARE ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=81396
CHILDREN’S EUROPROFEN;
02354799;
ibuprofen 100 mg / 5 ml;
2011-02-14;
Oral;
Suspension;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
PENDOPHARM DIVISION OF PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83995
NOVO-PROFEN;
00629324;
ibuprofen 200 mg;
1985-12-31;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=6320
APO-IBUPROFEN;
00441643;
ibuprofen 200 mg;
1984-12-31;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=10294
ADVIL CAPLETS;
01933531;
ibuprofen 200 mg;
1992-12-31;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
GLAXOSMITHKLINE CONSUMER HEALTHCARE ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=13452
ADVIL TABLETS;
01933558;
ibuprofen 200 mg;
1993-12-31;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
GLAXOSMITHKLINE CONSUMER HEALTHCARE ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=13625
MOTRIN 200MG;
02186934;
ibuprofen 200 mg;
1972-12-31;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19585
ADVIL GEL CAPLETS;
02230541;
ibuprofen 200 mg;
1997-05-05;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
GLAXOSMITHKLINE CONSUMER HEALTHCARE ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=49613
ADVIL LIQUI-GELS;
02241769;
ibuprofen 200 mg;
2000-10-02;
Oral;
Capsule;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
GLAXOSMITHKLINE CONSUMER HEALTHCARE ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=65432
IBUPROFEN CAPLETS 200 MG;
02272857;
ibuprofen 200 mg;
2006-04-07;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
VITA HEALTH PRODUCTS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=75836
MOTRIN LIQUID GELS 200MG;
02297582;
ibuprofen 200 mg;
2007-10-31;
Oral;
Capsule;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78292
IBUPROFEN TABLETS;
02314754;
ibuprofen 200 mg;
2010-03-05;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80029
IBUPROFEN CAPLETS;
02314762;
ibuprofen 200 mg;
2010-03-05;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80030
IBUPROFEN LIQUID CAPSULES;
02357275;
ibuprofen 200 mg;
2011-03-31;
Oral;
Capsule;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
VITA HEALTH PRODUCTS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84240
IBUPROFEN TABLETS;
02368072;
ibuprofen 200 mg;
2017-01-26;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
VITA HEALTH PRODUCTS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85289
IBUPROFEN CAPLETS;
02368080;
ibuprofen 200 mg;
2017-01-26;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
VITA HEALTH PRODUCTS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85290
IBUPROFEN LIQUID GEL CAPSULES;
02376598;
ibuprofen 200 mg;
2016-09-15;
Oral;
Capsule;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86208
IBUPROFEN CAPLETS;
02439727;
ibuprofen 200 mg;
2016-02-26;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92412
ADVIL MINI-GELS;
02485400;
ibuprofen 200 mg;
2019-07-30;
Oral;
Capsule;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
GLAXOSMITHKLINE CONSUMER HEALTHCARE ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97565
IBUPROFEN LIQUID GELS;
02494353;
ibuprofen 200 mg;
2021-03-22;
Oral;
Capsule;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98438
APO-IBUPROFEN;
00441651;
ibuprofen 300 mg;
1983-12-31;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=5433
MOTRIN 300MG;
02242632;
ibuprofen 300 mg;
2002-05-15;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=66413
IBUPROFEN;
02439697;
ibuprofen 300 mg;
2016-09-21;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92409
INFANTS’ MOTRIN;
02238626;
ibuprofen 40 mg / ml;
1998-10-14;
Oral;
Drops;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=62054
ADVIL PEDIATRIC DROPS;
02242522;
ibuprofen 40 mg / ml;
2000-10-23;
Oral;
Drops;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
GLAXOSMITHKLINE CONSUMER HEALTHCARE ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=66270
ADVIL PEDIATRIC DROPS FEVER FROM COLDS OR FLU;
02328445;
ibuprofen 40 mg / ml;
2010-08-06;
Oral;
Drops;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
GLAXOSMITHKLINE CONSUMER HEALTHCARE ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=81397
APO-IBUPROFEN;
00506052;
ibuprofen 400 mg;
1983-12-31;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=5432
NOVO-PROFEN;
00629340;
ibuprofen 400 mg;
1985-12-31;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=6322
MOTRIN 400MG;
02242658;
ibuprofen 400 mg;
2002-05-15;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=66438
ADVIL EXTRA STRENGTH CAPLETS;
02244577;
ibuprofen 400 mg;
2002-05-14;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
GLAXOSMITHKLINE CONSUMER HEALTHCARE ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=68562
ADVIL EXTRA STRENGTH LIQUI-GELS;
02248231;
ibuprofen 400 mg;
2004-06-21;
Oral;
Capsule;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
GLAXOSMITHKLINE CONSUMER HEALTHCARE ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=72567
EXTRA STRENGTH IBUPROFEN;
02314770;
ibuprofen 400 mg;
2010-02-01;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80031
ADVIL MUSCLE AND JOINT;
02355701;
ibuprofen 400 mg;
2011-11-07;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
GLAXOSMITHKLINE CONSUMER HEALTHCARE ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84091
EXTRA STRENGTH IBUPROFEN LIQUID CAPSULES;
02357283;
ibuprofen 400 mg;
2011-06-10;
Oral;
Capsule;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
VITA HEALTH PRODUCTS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84241
IBUPROFEN EXTRA STRENGTH CAPLETS;
02368099;
ibuprofen 400 mg;
2011-08-05;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
VITA HEALTH PRODUCTS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85291
MUSCLE & JOINT;
02374226;
ibuprofen 400 mg;
2013-05-16;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
VITA HEALTH PRODUCTS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85942
EXTRA STRENGTH IBUPROFEN LIQUID GEL CAPSULES;
02376601;
ibuprofen 400 mg;
2012-07-15;
Oral;
Capsule;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86209
IBUPROFEN MUSCLE AND JOINT;
02377101;
ibuprofen 400 mg;
2012-09-12;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86271
MOTRIN LIQUID GELS 400 MG;
02378310;
ibuprofen 400 mg;
2012-07-30;
Oral;
Capsule;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86413
JAMP-IBUPROFEN;
02401290;
ibuprofen 400 mg;
2014-01-07;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88621
ADVIL ARTHRITIS PAIN;
02415623;
ibuprofen 400 mg;
2014-07-07;
Oral;
Capsule;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
GLAXOSMITHKLINE CONSUMER HEALTHCARE ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90021
IBUPROFEN CAPLETS;
02439735;
ibuprofen 400 mg;
2015-12-23;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92413
APO IBUPROFEN TAB 600MG;
00585114;
ibuprofen 600 mg;
1984-12-31;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=5917
TEVA-PROFEN;
00629359;
ibuprofen 600 mg;
1985-12-31;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=6323
ADVIL 12 HOUR;
02443562;
ibuprofen 600 mg;
2016-08-22;
Oral;
Tablet (Extended-Release);
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
GLAXOSMITHKLINE CONSUMER HEALTHCARE ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92825
CORVERT;
02242470;
ibutilide fumarate 0.1 mg / ml;
2000-11-28;
Intravenous;
Solution;
24:04.04.20 – CLASS III ANTIARRYTHMICS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=66196
FIRAZYR;
02425696;
icatibant (icatibant acetate) 10 mg / ml;
2014-07-14;
Subcutaneous;
Solution;
92:32.00 – COMPLEMENT INHIBITORS;
Prescription;
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=91034
VASCEPA;
02495244;
icosapent ethyl 1 g;
2020-02-07;
Oral;
Capsule;
24:06.92 – MISCELLANEOUS ANTILIPEMIC AGENTS;
Prescription;
HLS THERAPEUTICS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98517
IDARUBICIN;
02410028;
idarubicin hydrochloride 1 mg / vial;
2014-11-04;
Intravenous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=89467
PRAXBIND;
02454343;
idarucizumab 50 mg / ml;
2016-05-24;
Intravenous;
Solution;
20:28.92 – ANTIHEMORRHAGIC AGENTS, MISCELLANEOUS;
Prescription , Schedule D;
BOEHRINGER INGELHEIM (CANADA) LTD LTEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94091
ZYDELIG;
02438798;
idelalisib 100 mg;
2015-04-21;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
GILEAD SCIENCES CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92318
ZYDELIG;
02438801;
idelalisib 150 mg;
2015-04-21;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
GILEAD SCIENCES CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92319
ELAPRASE;
02296314;
idursulfase 2 mg / ml;
2007-08-01;
Intravenous;
Solution;
44:00.00 – ENZYMES;
Prescription , Schedule D;
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78165
IFEX;
02241357;
ifosfamide 1 g / vial;
2001-03-20;
Intravenous;
Powder For Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
BAXTER CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=64989
IFEX;
02241356;
ifosfamide 3 g / vial;
2001-01-25;
Intravenous;
Powder For Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
BAXTER CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=64988
GLEEVEC;
02253275;
imatinib (imatinib mesylate) 100 mg;
2005-04-05;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
NOVARTIS PHARMACEUTICALS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=73824
APO-IMATINIB;
02355337;
imatinib (imatinib mesylate) 100 mg;
2013-04-19;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84058
NAT-IMATINIB;
02397285;
imatinib (imatinib mesylate) 100 mg;
2014-04-29;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
NATCO PHARMA (CANADA) INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88225
TEVA-IMATINIB;
02399806;
imatinib (imatinib mesylate) 100 mg;
2013-04-02;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88465
ACH-IMATINIB;
02490986;
imatinib (imatinib mesylate) 100 mg;
2020-11-24;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
ACCORD HEALTHCARE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98101
MINT-IMATINIB;
02492334;
imatinib (imatinib mesylate) 100 mg;
2020-06-19;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
MINT PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98235
JAMP IMATINIB;
02495066;
imatinib (imatinib mesylate) 100 mg;
2021-04-27;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98501
IMATINIB;
02504596;
imatinib (imatinib mesylate) 100 mg;
2021-04-07;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=99400
GLEEVEC;
02253283;
imatinib (imatinib mesylate) 400 mg;
2004-10-25;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
NOVARTIS PHARMACEUTICALS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=73825
APO-IMATINIB;
02355345;
imatinib (imatinib mesylate) 400 mg;
2013-04-19;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84059
NAT-IMATINIB;
02397293;
imatinib (imatinib mesylate) 400 mg;
2014-04-29;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
NATCO PHARMA (CANADA) INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88226
TEVA-IMATINIB;
02399814;
imatinib (imatinib mesylate) 400 mg;
2013-05-22;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88466
PMS-IMATINIB;
02431122;
imatinib (imatinib mesylate) 400 mg;
2015-05-26;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=91556
ACH-IMATINIB;
02490994;
imatinib (imatinib mesylate) 400 mg;
2020-11-24;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
ACCORD HEALTHCARE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98102
MINT-IMATINIB;
02492342;
imatinib (imatinib mesylate) 400 mg;
2020-06-19;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
MINT PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98236
JAMP IMATINIB;
02495074;
imatinib (imatinib mesylate) 400 mg;
2021-04-27;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98502
IMATINIB;
02504618;
imatinib (imatinib mesylate) 400 mg;
2021-04-07;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=99401
CEREZYME;
02241751;
imiglucerase 400 unit / vial;
2000-06-14;
Intravenous;
Powder For Solution;
44:00.00 – ENZYMES;
Prescription , Schedule D;
SANOFI GENZYME, A DIVISION OF SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=65414
IMIPRAMINE;
00360201;
imipramine hydrochloride 10 mg;
1976-12-31;
Oral;
Tablet;
28:16.04.28 – TRICYCLICS AND OTHER NOREPINEPHRINE-REUPTAKE INHIBITORS;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=2444
IMIPRAMINE;
00312797;
imipramine hydrochloride 25 mg;
1975-12-31;
Oral;
Tablet;
28:16.04.28 – TRICYCLICS AND OTHER NOREPINEPHRINE-REUPTAKE INHIBITORS;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=2211
IMIPRAMINE;
00326852;
imipramine hydrochloride 50 mg;
1975-12-31;
Oral;
Tablet;
28:16.04.28 – TRICYCLICS AND OTHER NOREPINEPHRINE-REUPTAKE INHIBITORS;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=2212
IMIPRAMINE;
00644579;
imipramine hydrochloride 75 mg;
1989-12-31;
Oral;
Tablet;
28:16.04.28 – TRICYCLICS AND OTHER NOREPINEPHRINE-REUPTAKE INHIBITORS;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=10008
ZYCLARA;
02340445;
imiquimod 3.75 % / w/w;
2010-01-27;
Topical;
Cream;
84:92.00 – MISC. SKIN AND MUCOUS MEMBRANE AGENTS;
Prescription;
BAUSCH HEALTH, CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=82603
VYLOMA;
02365561;
imiquimod 3.75 % / w/w;
2011-04-19;
Topical;
Cream;
84:92.00 – MISC. SKIN AND MUCOUS MEMBRANE AGENTS;
Prescription;
BAUSCH HEALTH, CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85046
ALDARA P;
02239505;
imiquimod 5 %;
1999-07-05;
Topical;
Cream;
84:92.00 – MISC. SKIN AND MUCOUS MEMBRANE AGENTS;
Prescription;
BAUSCH HEALTH, CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=62979
TARO-IMIQUIMOD PUMP;
02482983;
imiquimod 5 % / w/w;
2019-01-23;
Topical;
Cream;
84:92.00 – MISC. SKIN AND MUCOUS MEMBRANE AGENTS;
Prescription;
TARO PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97338
GAMMAGARD LIQUID;
02279444;
immunoglobulin (human) 10 %;
2007-08-08;
Intravenous;
Solution;
80:04.00 – SERUMS;
Schedule D;
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=76503
PRIVIGEN;
02304619;
immunoglobulin (human) 10 %;
2009-01-08;
Intravenous;
Solution;
80:04.00 – SERUMS;
Schedule D;
CSL BEHRING CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78988
GAMMAGARD S/D;
02231471;
immunoglobulin (human) 10 g / vial;
1997-08-22;
Intravenous;
Solution , Kit , Powder For Solution;
80:04.00 – SERUMS;
Schedule D;
SHIRE PHARMA CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=50795
GAMUNEX;
02247724;
immunoglobulin (human) 10 g / 100 ml;
2003-10-22;
Intravenous , Subcutaneous;
Solution;
80:04.00 – SERUMS;
Schedule D;
GRIFOLS THERAPEUTICS LLC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=72002
IGIVNEX;
02277921;
immunoglobulin (human) 10 g / 100 ml;
2006-05-24;
Intravenous , Subcutaneous;
Solution;
80:04.00 – SERUMS;
Schedule D;
GRIFOLS THERAPEUTICS LLC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=76352
OCTAGAM 10%;
02380145;
immunoglobulin (human) 100 mg / ml;
2013-04-04;
Intravenous;
Solution;
80:04.00 – SERUMS;
Schedule D;
OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES M B H
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86598
PANZYGA;
02456087;
immunoglobulin (human) 100 mg / ml;
2016-12-21;
Intravenous;
Solution;
80:04.00 – SERUMS;
Schedule D;
OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES M B H
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94293
GAMASTAN;
02486598;
immunoglobulin (human) 18 %;
2020-03-27;
Intramuscular;
Solution;
80:04.00 – SERUMS;
Schedule D;
GRIFOLS THERAPEUTICS LLC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97678
HIZENTRA;
02370352;
immunoglobulin (human) 200 mg / ml;
2011-10-13;
Subcutaneous;
Solution;
80:04.00 – SERUMS;
Schedule D;
CSL BEHRING CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85549
CUVITRU;
02461692;
immunoglobulin (human) 200 mg / ml;
2017-12-21;
Subcutaneous;
Solution;
80:04.00 – SERUMS;
Schedule D;
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94943
HIZENTRA;
02463059;
immunoglobulin (human) 200 mg / ml;
2017-09-21;
Subcutaneous;
Solution;
80:04.00 – SERUMS;
Schedule D;
CSL BEHRING CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95095
HIZENTRA;
02463067;
immunoglobulin (human) 200 mg / ml;
2017-09-21;
Subcutaneous;
Solution;
80:04.00 – SERUMS;
Schedule D;
CSL BEHRING CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95096
GAMMAGARD S/D;
02231470;
immunoglobulin (human) 5 g / vial;
1997-08-22;
Intravenous;
Solution , Kit , Powder For Solution;
80:04.00 – SERUMS;
Schedule D;
SHIRE PHARMA CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=50794
CUTAQUIG;
02472996;
immunoglobulin g (human) 1 g / 6 ml;
2018-08-08;
Subcutaneous;
Solution;
80:04.00 – SERUMS;
Schedule D;
OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES M B H
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96234
CUTAQUIG;
02473011;
immunoglobulin g (human) 2 g / 12 ml;
2018-08-17;
Subcutaneous;
Solution;
80:04.00 – SERUMS;
Schedule D;
OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES M B H
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96236
CUTAQUIG;
02473046;
immunoglobulin g (human) 4 g / 24 ml;
2018-08-15;
Subcutaneous;
Solution;
80:04.00 – SERUMS;
Schedule D;
OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES M B H
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96238
CUTAQUIG;
02473054;
immunoglobulin g (human) 8 g / 48 ml;
2018-08-17;
Subcutaneous;
Solution;
80:04.00 – SERUMS;
Schedule D;
OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES M B H
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96239
IXIARO;
02333279;
inact.japanese encephal virus(attenuat. strain sa14-14-2 produced in vero cells) 6 mcg / 0.5 ml;
2009-12-29;
Intramuscular;
Suspension;
80:12.00 – VACCINES;
Schedule D;
VALNEVA AUSTRIA GMBH
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=81890
XEOMIN;
02324032;
incobotulinumtoxina 100 unit / vial;
2009-07-21;
Intraglandular , Intramuscular;
Powder For Solution;
92:92.00 – OTHER MISCELLANEOUS THERAPEUTIC AGENTS;
Prescription , Schedule D;
MERZ PHARMACEUTICALS GMBH
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80952
XEOMIN COSMETIC;
02383489;
incobotulinumtoxina 100 unit / vial;
2012-07-05;
Intramuscular;
Powder For Solution;
92:92.00 – OTHER MISCELLANEOUS THERAPEUTIC AGENTS;
Schedule D;
MERZ PHARMACEUTICALS GMBH
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86922
XEOMIN;
02371081;
incobotulinumtoxina 50 unit / vial;
2012-07-04;
Intraglandular , Intramuscular;
Powder For Solution;
92:92.00 – OTHER MISCELLANEOUS THERAPEUTIC AGENTS;
Prescription , Schedule D;
MERZ PHARMACEUTICALS GMBH
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85628
ONBREZ BREEZHALER;
02376938;
indacaterol (indacaterol maleate) 75 mcg;
2012-03-05;
Inhalation;
Capsule;
12:12.08.12 – SELECTIVE BETA 2-ADRENERGIC AGONISTS;
Prescription;
NOVARTIS PHARMACEUTICALS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86250
LOZIDE;
02179709;
indapamide 1.25 mg;
1995-12-31;
Oral;
Tablet;
40:28.24 – THIAZIDE-LIKE DIURETICS;
Prescription;
SERVIER CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19089
MYLAN-INDAPAMIDE;
02240067;
indapamide 1.25 mg;
1999-05-10;
Oral;
Tablet;
40:28.24 – THIAZIDE-LIKE DIURETICS;
Prescription;
MYLAN PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=63577
APO-INDAPAMIDE 1.25 MG TABLETS;
02245246;
indapamide 1.25 mg;
2002-11-08;
Oral;
Tablet;
40:28.24 – THIAZIDE-LIKE DIURETICS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=69270
MYLAN-INDAPAMIDE;
02153483;
indapamide 2.5 mg;
1995-12-31;
Oral;
Tablet;
40:28.24 – THIAZIDE-LIKE DIURETICS;
Prescription;
MYLAN PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=18065
APO-INDAPAMIDE 2.5MG TABLETS;
02223678;
indapamide 2.5 mg;
1996-10-02;
Oral;
Tablet;
40:28.24 – THIAZIDE-LIKE DIURETICS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=43381
SPY AGENT GREEN;
02483653;
indocyanine green 25 mg / vial;
2019-06-04;
Interstitial , Intravenous;
Powder For Solution;
36:68.00 – ROENTGENOGRAPHY;
Ethical;
NOVADAQ TECHNOLOGIES ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97402
SPY AGENT GREEN KIT FOR SPY ELITE;
02483661;
indocyanine green 25 mg / vial;
2019-06-04;
Interstitial , Intravenous;
Kit , Powder For Solution;
36:68.00 – ROENTGENOGRAPHY;
Ethical;
NOVADAQ TECHNOLOGIES ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97403
SPY AGENT GREEN KIT FOR ADVANCED IMAGING MODALITY (AIM) AND PINPOINT;
02483688;
indocyanine green 25 mg / vial;
2019-06-04;
Interstitial , Intravenous;
Kit , Powder For Solution;
36:68.00 – ROENTGENOGRAPHY;
Ethical;
NOVADAQ TECHNOLOGIES ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97404
SPY AGENT GREEN LYMPHATICS KIT FOR ADVANCED IMAGING MODALITY (AIM) AND PINPOINT;
02483696;
indocyanine green 25 mg / vial;
2019-06-04;
Interstitial , Intravenous;
Kit , Powder For Solution;
36:68.00 – ROENTGENOGRAPHY;
Ethical;
NOVADAQ TECHNOLOGIES ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97405
INDOCYANINE GREEN FOR INJECTION, USP;
02485796;
indocyanine green 25 mg / vial;
2019-06-11;
Intravenous;
Powder For Solution;
36:18.00 – CARDIAC FUNCTION , 36:44.00 – LIVER FUNCTION;
Ethical;
DIAGNOSTIC GREEN GMBH
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97602
INDOCYANINE GREEN FOR INJECTION KIT;
02485826;
indocyanine green 25 mg / vial;
2019-06-11;
Intravenous;
Kit , Powder For Solution;
36:18.00 – CARDIAC FUNCTION , 36:44.00 – LIVER FUNCTION;
Ethical;
DIAGNOSTIC GREEN GMBH
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97604
SPY AGENT GREEN KIT FOR SPY-PHI;
02498677;
indocyanine green 25 mg / vial;
2020-12-03;
Interstitial , Intravenous;
Kit , Powder For Solution;
36:68.00 – ROENTGENOGRAPHY;
Ethical;
NOVADAQ TECHNOLOGIES ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98842
SANDOZ INDOMETHACIN;
02231800;
indomethacin 100 mg / sup;
1997-11-17;
Rectal;
Suppository;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=51233
TEVA-INDOMETHACIN;
00337420;
indomethacin 25 mg;
1980-12-31;
Oral;
Capsule;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=4129
MINT-INDOMETHACIN;
02461811;
indomethacin 25 mg;
2017-04-03;
Oral;
Capsule;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
MINT PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94956
TEVA-INDOMETHACIN;
00337439;
indomethacin 50 mg;
1980-12-31;
Oral;
Capsule;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=4130
MINT-INDOMETHACIN;
02461536;
indomethacin 50 mg;
2017-04-03;
Oral;
Capsule;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
MINT PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94917
SANDOZ INDOMETHACIN;
02231799;
indomethacin 50 mg / sup;
1997-11-17;
Rectal;
Suppository;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=51232
REMICADE;
02244016;
infliximab 100 mg / vial;
2001-06-14;
Intravenous;
Powder For Solution;
92:36.00 – DISEASE-MODIFYING ANTIRHEUMATIC AGENTS;
Prescription , Schedule D;
JANSSEN INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=67959
INFLECTRA;
02419475;
infliximab 100 mg / vial;
2014-09-04;
Intravenous;
Powder For Solution;
92:36.00 – DISEASE-MODIFYING ANTIRHEUMATIC AGENTS;
Prescription , Schedule D;
CELLTRION HEALTHCARE CO LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90410
RENFLEXIS;
02470373;
infliximab 100 mg / vial;
2018-03-22;
Intravenous;
Powder For Solution;
92:36.00 – DISEASE-MODIFYING ANTIRHEUMATIC AGENTS;
Prescription , Schedule D;
SAMSUNG BIOEPIS CO., LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95936
AVSOLA;
02496933;
infliximab 100 mg / vial;
2020-06-01;
Intravenous;
Powder For Solution;
92:36.00 – DISEASE-MODIFYING ANTIRHEUMATIC AGENTS;
Prescription , Schedule D;
AMGEN CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98681
IMUNOVIR;
02240713;
inosine pranobex 500 mg;
2000-01-25;
Oral;
Tablet;
08:18.92 – MISCELLANEOUS ANTIVIRALS;
Prescription;
KORA HEALTHCARE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=64296
TEGSEDI;
02481383;
inotersen (inotersen sodium) 284 mg / 1.5 ml;
2019-01-07;
Subcutaneous;
Solution;
92:18.00 – ANTISENSE OLIGONUCLEOTIDES;
Prescription;
AKCEA THERAPEUTICS, INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97187
BESPONSA;
02473909;
inotuzumab ozogamicin 0.9 mg / vial;
2018-05-03;
Intravenous;
Powder For Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription , Schedule D;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96383
NOVORAPID;
02244353;
insulin aspart 100 unit / ml;
2001-10-31;
Subcutaneous;
Solution;
68:20.08 – INSULINS;
Schedule D;
NOVO NORDISK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=68321
NOVORAPID;
02245397;
insulin aspart 100 unit / ml;
2002-06-12;
Subcutaneous;
Solution;
68:20.08 – INSULINS;
Schedule D;
NOVO NORDISK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=69441
NOVORAPID;
02377209;
insulin aspart 100 unit / ml;
2012-05-04;
Subcutaneous;
Solution;
68:20.08 – INSULINS;
Schedule D;
NOVO NORDISK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86282
FIASP;
02460408;
insulin aspart 100 unit / ml;
2017-03-03;
Subcutaneous;
Solution;
68:20.08 – INSULINS;
Schedule D;
NOVO NORDISK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94775
FIASP;
02460416;
insulin aspart 100 unit / ml;
2017-03-03;
Subcutaneous;
Solution;
68:20.08 – INSULINS;
Schedule D;
NOVO NORDISK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94776
FIASP;
02460424;
insulin aspart 100 unit / ml;
2017-03-03;
Subcutaneous;
Solution;
68:20.08 – INSULINS;
Schedule D;
NOVO NORDISK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94777
TRURAPI;
02506564;
insulin aspart 100 unit / ml;
2021-03-30;
Subcutaneous;
Solution;
68:20.08 – INSULINS;
Schedule D;
SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=99592
TRURAPI;
02506572;
insulin aspart 100 unit / ml;
2021-03-30;
Subcutaneous;
Solution;
68:20.08 – INSULINS;
Schedule D;
SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=99593
HUMULIN R (KWIKPEN);
02415089;
insulin biosynthetic human br 100 unit / ml;
2014-03-03;
Intramuscular , Subcutaneous;
Solution;
68:20.08 – INSULINS;
Schedule D;
ELI LILLY CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=89971
TRESIBA;
02467879;
insulin degludec 100 unit / ml;
2017-09-15;
Subcutaneous;
Solution;
68:20.08.16 – LONG-ACTING INSULINS;
Schedule D;
NOVO NORDISK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95623
TRESIBA;
02467887;
insulin degludec 200 unit / ml;
2017-09-15;
Subcutaneous;
Solution;
68:20.08.16 – LONG-ACTING INSULINS;
Schedule D;
NOVO NORDISK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95624
LEVEMIR PENFILL;
02271842;
insulin detemir 100 unit / ml;
2005-11-14;
Subcutaneous;
Solution;
68:20.08 – INSULINS;
Schedule D;
NOVO NORDISK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=75736
LEVEMIR FLEXTOUCH;
02412829;
insulin detemir 100 unit / ml;
2013-11-25;
Subcutaneous;
Solution;
68:20.08 – INSULINS;
Schedule D;
NOVO NORDISK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=89748
LANTUS;
02245689;
insulin glargine 100 unit / ml;
2002-07-24;
Subcutaneous;
Solution;
68:20.08 – INSULINS;
Schedule D;
SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=69790
LANTUS;
02251930;
insulin glargine 100 unit / ml;
2006-05-04;
Subcutaneous;
Solution;
68:20.08 – INSULINS;
Schedule D;
SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=73683
LANTUS;
02294338;
insulin glargine 100 unit / ml;
2007-09-24;
Subcutaneous;
Solution;
68:20.08 – INSULINS;
Schedule D;
SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=77967
BASAGLAR;
02444844;
insulin glargine 100 unit / ml;
2015-12-18;
Subcutaneous;
Solution;
68:20.08 – INSULINS;
Schedule D;
ELI LILLY CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93005
BASAGLAR;
02461528;
insulin glargine 100 unit / ml;
2017-08-18;
Subcutaneous;
Solution;
68:20.08 – INSULINS;
Schedule D;
ELI LILLY CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94916
TOUJEO SOLOSTAR;
02441829;
insulin glargine 300 unit / ml;
2015-07-15;
Subcutaneous;
Solution;
68:20.08 – INSULINS;
Schedule D;
SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92621
TOUJEO DOUBLESTAR;
02493373;
insulin glargine 300 unit / ml;
2020-02-04;
Subcutaneous;
Solution;
68:20.08 – INSULINS;
Schedule D;
SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98339
APIDRA;
02279460;
insulin glulisine (recombinant dna origin) 100 unit / ml;
2008-09-22;
Subcutaneous;
Solution;
68:20.08 – INSULINS;
Schedule D;
SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=76506
APIDRA;
02279479;
insulin glulisine (recombinant dna origin) 100 unit / ml;
2009-10-01;
Subcutaneous;
Solution;
68:20.08 – INSULINS;
Schedule D;
SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=76507
APIDRA;
02294346;
insulin glulisine (recombinant dna origin) 100 unit / ml;
2008-09-22;
Subcutaneous;
Solution;
68:20.08 – INSULINS;
Schedule D;
SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=77968
HUMULIN R CARTRIDGE;
01959220;
insulin injection human biosynthetic 100 unit / ml;
1992-12-31;
Intramuscular , Intravenous , Subcutaneous;
Solution;
68:20.08 – INSULINS;
Schedule D;
ELI LILLY CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=12569
NOVOLIN GE TORONTO;
02024233;
insulin injection human biosynthetic 100 unit / ml;
1993-12-31;
Intramuscular , Intravenous , Subcutaneous;
Solution;
68:20.08 – INSULINS;
Schedule D;
NOVO NORDISK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=14260
NOVOLIN GE TORONTO PENFILL;
02024284;
insulin injection human biosynthetic 100 unit / ml;
1993-12-31;
Intramuscular , Intravenous , Subcutaneous;
Solution;
68:20.08 – INSULINS;
Schedule D;
NOVO NORDISK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=14459
ENTUZITY KWIKPEN;
02466864;
insulin injection human biosynthetic 500 unit / ml;
2017-10-20;
Subcutaneous;
Solution;
68:20.08 – INSULINS;
Schedule D;
ELI LILLY CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95524
HYPURIN REGULAR INSULIN PORK;
02275872;
insulin injection pork 100 unit / ml;
2006-04-01;
Intramuscular , Intravenous , Subcutaneous;
Solution;
68:20.08 – INSULINS;
Schedule D;
WOCKHARDT UK LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=76153
HUMULIN N (CARTRIDGE);
01959239;
insulin isophane human biosynthetic 100 unit / ml;
1992-12-31;
Subcutaneous;
Suspension;
68:20.08 – INSULINS;
Schedule D;
ELI LILLY CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=12570
NOVOLIN GE NPH;
02024225;
insulin isophane human biosynthetic 100 unit / ml;
1993-12-31;
Subcutaneous;
Suspension;
68:20.08 – INSULINS;
Schedule D;
NOVO NORDISK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=14261
NOVOLIN GE NPH PENFILL;
02024268;
insulin isophane human biosynthetic 100 unit / ml;
1993-12-31;
Subcutaneous;
Suspension;
68:20.08 – INSULINS;
Schedule D;
NOVO NORDISK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=14266
HUMULIN N (KWIKPEN);
02403447;
insulin isophane human biosynthetic 100 unit / ml;
2013-09-13;
Subcutaneous;
Suspension;
68:20.08 – INSULINS;
Schedule D;
ELI LILLY CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88825
HYPURIN NPH INSULIN ISOPHANE PORK;
02275864;
insulin isophane injection pork 100 unit / ml;
2006-04-01;
Intramuscular , Subcutaneous;
Suspension;
68:20.08 – INSULINS;
Schedule D;
WOCKHARDT UK LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=76152
HUMALOG;
02229704;
insulin lispro 100 unit / ml;
1996-11-15;
Intramuscular , Intravenous , Subcutaneous;
Solution;
68:20.08 – INSULINS;
Schedule D;
ELI LILLY CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=47871
HUMALOG (CARTRIDGE);
02229705;
insulin lispro 100 unit / ml;
1996-11-27;
Intramuscular , Intravenous , Subcutaneous;
Solution;
68:20.08 – INSULINS;
Schedule D;
ELI LILLY CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=47872
HUMALOG (KWIKPEN);
02403412;
insulin lispro 100 unit / ml;
2013-08-14;
Intramuscular , Intravenous , Subcutaneous;
Solution;
68:20.08 – INSULINS;
Schedule D;
ELI LILLY CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88822
ADMELOG;
02469898;
insulin lispro 100 unit / ml;
2019-11-22;
Subcutaneous;
Solution;
68:20.08 – INSULINS;
Schedule D;
SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95877
ADMELOG SOLOSTAR;
02469871;
insulin lispro 100 unit / ml;
2019-11-22;
Subcutaneous;
Solution;
68:20.08 – INSULINS;
Schedule D;
SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95880
ADMELOG;
02469901;
insulin lispro 100 unit / ml;
2019-11-22;
Subcutaneous;
Solution;
68:20.08 – INSULINS;
Schedule D;
SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95881
HUMALOG;
02470152;
insulin lispro 100 unit / ml;
2018-04-06;
Subcutaneous;
Solution;
68:20.08 – INSULINS;
Schedule D;
ELI LILLY CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95912
HUMALOG 200 UNITS/ML KWIKPEN;
02439611;
insulin lispro 200 unit / ml;
2015-09-14;
Subcutaneous;
Solution;
68:20.08 – INSULINS;
Schedule D;
ELI LILLY CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92402
HUMULIN N;
00587737;
insulin nph human dna origin 100 unit / ml;
1983-12-31;
Subcutaneous;
Suspension;
68:20.08 – INSULINS;
Schedule D;
ELI LILLY CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=5326
HUMULIN R;
00586714;
insulin semi synthetic human 100 unit / ml;
1983-12-31;
Intramuscular , Intravenous , Subcutaneous;
Solution;
68:20.08 – INSULINS;
Schedule D;
ELI LILLY CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=5325
INTRON A;
02238675;
interferon alfa-2b 10000000 unit / ml;
1998-12-10;
Intramuscular , Intravenous , Subcutaneous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS , 08:18.20 – INTERFERONS;
Prescription , Schedule D;
MERCK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=62106
INTRON A;
02238674;
interferon alfa-2b 6000000 unit / ml;
1998-12-10;
Intramuscular , Intravenous , Subcutaneous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS , 08:18.20 – INTERFERONS;
Prescription , Schedule D;
MERCK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=62105
REBIF;
02318261;
interferon beta-1a 132 mcg / 1.5 ml;
2009-05-14;
Subcutaneous;
Solution;
92:20.00 – Immunomodulatory Agents;
Prescription , Schedule D;
EMD SERONO, A DIVISION OF EMD INC., CANADA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80377
REBIF;
02237319;
interferon beta-1a 22 mcg / 0.5 ml;
1998-02-23;
Subcutaneous;
Solution;
92:20.00 – Immunomodulatory Agents;
Prescription , Schedule D;
EMD SERONO, A DIVISION OF EMD INC., CANADA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=60641
AVONEX;
02269201;
interferon beta-1a 30 mcg / 0.5 ml;
2005-12-02;
Intramuscular;
Solution;
92:20.00 – Immunomodulatory Agents;
Prescription , Schedule D;
BIOGEN CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=75459
REBIF;
02237320;
interferon beta-1a 44 mcg / 0.5 ml;
1998-02-24;
Subcutaneous;
Solution;
92:20.00 – Immunomodulatory Agents;
Prescription , Schedule D;
EMD SERONO, A DIVISION OF EMD INC., CANADA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=60642
REBIF;
02318253;
interferon beta-1a 66 mcg / 1.5 ml;
2009-05-14;
Subcutaneous;
Solution;
92:20.00 – Immunomodulatory Agents;
Prescription , Schedule D;
EMD SERONO, A DIVISION OF EMD INC., CANADA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80376
BETASERON;
02169649;
interferon beta-1b 0.3 mg / vial;
1995-12-31;
Subcutaneous;
Powder For Solution;
92:20.00 – Immunomodulatory Agents;
Prescription , Schedule D;
BAYER INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19241
EXTAVIA;
02337819;
interferon beta-1b 0.3 mg / vial;
2010-05-05;
Subcutaneous;
Powder For Solution;
92:20.00 – Immunomodulatory Agents;
Prescription , Schedule D;
NOVARTIS PHARMACEUTICALS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=82345
MICRO I;
01974548;
iodide (sodium iodide) 100 mcg / ml;
1993-12-31;
Intravenous;
Liquid;
40:12.00 – REPLACEMENT PREPARATIONS;
Ethical;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=13600
LIPIODOL ULTRA FLUID;
00386685;
iodine (ethiodized oil) 380 mg / g;
1977-12-31;
Intracavitary , Parenteral (Unspecified);
Liquid;
36:68.00 – ROENTGENOGRAPHY;
Ethical;
GUERBET
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=2570
VISIPAQUE 270;
02145766;
iodixanol 550 mg / ml;
1995-12-31;
Intra-Arterial , Intravenous;
Solution;
36:68.00 – ROENTGENOGRAPHY;
Ethical;
GE HEALTHCARE CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=18685
VISIPAQUE 320;
02145774;
iodixanol 652 mg / ml;
1995-12-31;
Intra-Arterial , Intravenous;
Solution;
36:68.00 – ROENTGENOGRAPHY;
Ethical;
GE HEALTHCARE CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=18694
OMNIPAQUE 180;
02172720;
iohexol 388 mg / ml;
1998-03-08;
Subarachnoidal;
Solution;
36:68.00 – ROENTGENOGRAPHY;
Ethical;
GE HEALTHCARE CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=44184
OMNIPAQUE 240;
02172739;
iohexol 518 mg / ml;
1998-05-26;
Subarachnoidal , Intravascular;
Solution;
36:68.00 – ROENTGENOGRAPHY;
Ethical;
GE HEALTHCARE CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=44185
OMNIPAQUE 300;
02172747;
iohexol 647 mg / ml;
1998-03-05;
Subarachnoidal , Intravascular;
Solution;
36:68.00 – ROENTGENOGRAPHY;
Ethical;
GE HEALTHCARE CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=44186
OMNIPAQUE 350;
02172755;
iohexol 755 mg / ml;
1998-03-05;
Intravascular;
Solution;
36:68.00 – ROENTGENOGRAPHY;
Ethical;
GE HEALTHCARE CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=44187
ISOVUE 200 INJECTION;
02229013;
iopamidol 41 %;
1998-01-08;
Intravenous;
Liquid;
36:68.00 – ROENTGENOGRAPHY;
Ethical;
BRACCO IMAGING CANADA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=43504
ISOVUE 300 INJECTION;
02229021;
iopamidol 61 %;
1998-01-08;
Intravascular;
Liquid;
36:68.00 – ROENTGENOGRAPHY;
Ethical;
BRACCO IMAGING CANADA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=43505
ISOVUE MULTIPACK-300;
02242122;
iopamidol 61 %;
2001-07-30;
Intravascular;
Liquid;
36:68.00 – ROENTGENOGRAPHY;
Ethical;
BRACCO IMAGING CANADA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=65800
ISOVUE 370 INJECTION;
02229048;
iopamidol 76 %;
1998-01-08;
Intravascular;
Liquid;
36:68.00 – ROENTGENOGRAPHY;
Ethical;
BRACCO IMAGING CANADA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=43506
ISOVUE MULTIPACK-370;
02242121;
iopamidol 76 %;
2001-07-30;
Intravascular;
Liquid;
36:68.00 – ROENTGENOGRAPHY;
Ethical;
BRACCO IMAGING CANADA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=65799
ULTRAVIST 300;
02078600;
iopromide 62 %;
1994-12-31;
Intravascular;
Solution;
36:68.00 – ROENTGENOGRAPHY;
Ethical;
BAYER INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=16179
ULTRAVIST 370;
02078619;
iopromide 77 %;
1994-12-31;
Intravascular;
Solution;
36:68.00 – ROENTGENOGRAPHY;
Ethical;
BAYER INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=16180
CYSTO-CONRAY II;
00397466;
iothalamate meglumine 172 mg / ml;
1978-12-31;
Urethral;
Solution;
36:68.00 – ROENTGENOGRAPHY;
Ethical;
LIEBEL-FLARSHEIM CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=2949
CONRAY 60;
00131237;
iothalamate meglumine 600 mg / ml;
1951-12-31;
Intravascular;
Solution;
36:68.00 – ROENTGENOGRAPHY;
Ethical;
LIEBEL-FLARSHEIM CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=899
OPTIRAY 320;
01900854;
ioversol 68 %;
1990-12-31;
Intravascular;
Solution;
36:68.00 – ROENTGENOGRAPHY;
Ethical;
LIEBEL-FLARSHEIM CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=11328
OPTIRAY 320 (ULTRAJECT);
02035626;
ioversol 68 %;
1995-02-05;
Intravascular;
Solution;
36:68.00 – ROENTGENOGRAPHY;
Ethical;
LIEBEL-FLARSHEIM CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=43604
YERVOY;
02379384;
ipilimumab 5 mg / ml;
2012-03-08;
Intravenous;
Liquid;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription , Schedule D;
BRISTOL-MYERS SQUIBB CANADA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86525
PMS-IPRATROPIUM;
02231135;
ipratropium bromide 125 mcg / ml;
1997-10-29;
Inhalation;
Solution;
12:08.08 – ANTIMUSCARINICS ANTISPASMODICS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=50442
ATROVENT HFA;
02247686;
ipratropium bromide 20 mcg / act;
2004-03-24;
Inhalation;
Metered-Dose Aerosol;
12:08.08 – ANTIMUSCARINICS ANTISPASMODICS;
Prescription;
BOEHRINGER INGELHEIM (CANADA) LTD LTEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=71950
PMS-IPRATROPIUM;
02239627;
ipratropium bromide 21 mcg / act;
1999-04-15;
Nasal;
Solution;
12:08.08 – ANTIMUSCARINICS ANTISPASMODICS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=63098
APO-IPRAVENT SOLUTION – INH 250MCG/ML;
02126222;
ipratropium bromide 250 mcg / ml;
1994-12-31;
Inhalation;
Solution;
12:08.08 – ANTIMUSCARINICS ANTISPASMODICS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=16947
TEVA-IPRATROPIUM STERINEBS;
02216221;
ipratropium bromide 250 mcg / ml;
1998-03-04;
Inhalation;
Solution;
12:08.08 – ANTIMUSCARINICS ANTISPASMODICS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=43176
PMS-IPRATROPIUM;
02231136;
ipratropium bromide 250 mcg / ml;
1997-07-15;
Inhalation;
Solution;
12:08.08 – ANTIMUSCARINICS ANTISPASMODICS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=50443
PMS-IPRATROPIUM;
02231244;
ipratropium bromide 250 mcg / ml;
1997-10-29;
Inhalation;
Solution;
12:08.08 – ANTIMUSCARINICS ANTISPASMODICS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=50551
PMS-IPRATROPIUM;
02231245;
ipratropium bromide 250 mcg / ml;
1997-10-29;
Inhalation;
Solution;
12:08.08 – ANTIMUSCARINICS ANTISPASMODICS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=50552
IPRAVENT;
02246084;
ipratropium bromide 42 mcg / act;
2002-12-03;
Nasal;
Solution;
12:08.08 – ANTIMUSCARINICS ANTISPASMODICS;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=70219
AVAPRO;
02237924;
irbesartan 150 mg;
1998-07-22;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=61289
TEVA-IRBESARTAN;
02316404;
irbesartan 150 mg;
2011-03-21;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80191
PMS-IRBESARTAN;
02317079;
irbesartan 150 mg;
2011-03-24;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80258
SANDOZ IRBESARTAN;
02328488;
irbesartan 150 mg;
2011-03-21;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=81400
IRBESARTAN;
02365200;
irbesartan 150 mg;
2011-05-27;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85005
IRBESARTAN;
02372371;
irbesartan 150 mg;
2011-10-18;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85751
IRBESARTAN;
02385295;
irbesartan 150 mg;
2012-06-10;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
SIVEM PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87093
TARO-IRBESARTAN;
02406829;
irbesartan 150 mg;
2013-07-24;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
SUN PHARMA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=89150
JAMP-IRBESARTAN;
02418207;
irbesartan 150 mg;
2014-01-15;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90278
AVAPRO;
02237925;
irbesartan 300 mg;
1998-07-22;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=61290
TEVA-IRBESARTAN;
02316412;
irbesartan 300 mg;
2011-03-21;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80192
PMS-IRBESARTAN;
02317087;
irbesartan 300 mg;
2011-03-24;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80259
SANDOZ IRBESARTAN;
02328496;
irbesartan 300 mg;
2011-03-21;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=81401
IRBESARTAN;
02365219;
irbesartan 300 mg;
2011-05-27;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85006
IRBESARTAN;
02372398;
irbesartan 300 mg;
2011-10-18;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85752
IRBESARTAN;
02385309;
irbesartan 300 mg;
2012-06-10;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
SIVEM PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87094
TARO-IRBESARTAN;
02406837;
irbesartan 300 mg;
2013-07-24;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
SUN PHARMA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=89151
JAMP-IRBESARTAN;
02418215;
irbesartan 300 mg;
2014-01-15;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90279
AVAPRO;
02237923;
irbesartan 75 mg;
1998-06-22;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=61288
TEVA-IRBESARTAN;
02316390;
irbesartan 75 mg;
2011-03-21;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80190
PMS-IRBESARTAN;
02317060;
irbesartan 75 mg;
2011-03-24;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80257
SANDOZ IRBESARTAN;
02328461;
irbesartan 75 mg;
2011-03-21;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=81399
IRBESARTAN;
02365197;
irbesartan 75 mg;
2011-05-27;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85004
IRBESARTAN;
02372347;
irbesartan 75 mg;
2011-10-18;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85748
IRBESARTAN;
02385287;
irbesartan 75 mg;
2012-06-10;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
SIVEM PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87092
TARO-IRBESARTAN;
02406810;
irbesartan 75 mg;
2013-07-24;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
SUN PHARMA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=89149
JAMP-IRBESARTAN;
02418193;
irbesartan 75 mg;
2014-01-15;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90277
ONIVYDE;
02467135;
irinotecan (irinotecan sucrose octasulfate) 4.3 mg / ml;
2017-10-04;
Intravenous;
Suspension;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
SERVIER CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95553
IRINOTECAN HYDROCHLORIDE INJECTION USP;
02357585;
irinotecan hydrochloride (irinotecan hydrochloride trihydrate) 20 mg / ml;
2013-05-06;
Intravenous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
ACCORD HEALTHCARE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84269
IRINOTECAN HYDROCHLORIDE INJECTION;
02412187;
irinotecan hydrochloride (irinotecan hydrochloride trihydrate) 20 mg / ml;
2015-05-28;
Intravenous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
TELIGENT PHARMA, INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=89675
IRINOTECAN HYDROCHLORIDE INJECTION USP;
02258218;
irinotecan hydrochloride 20 mg / ml;
2006-02-01;
Intravenous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=74343
IRINOTECAN FOR INJECTION;
02312409;
irinotecan hydrochloride 20 mg / ml;
2008-10-31;
Intravenous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=79791
IRINOTECAN;
02410419;
irinotecan hydrochloride 20 mg / ml;
2014-03-07;
Intravenous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=89508
MONOFERRIC;
02477777;
iron (iron isomaltoside 1000) 100 mg / ml;
2018-10-17;
Intravenous;
Solution;
20:04.04 – IRON PREPARATIONS;
Prescription;
PHARMACOSMOS A/S
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96866
VENOFER;
02243716;
iron (iron sucrose) 20 mg / ml;
2001-06-05;
Intravenous;
Solution;
20:04.04 – IRON PREPARATIONS;
Prescription;
AMERICAN REGENT, INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=67648
PMS-IRON SUCROSE;
02502917;
iron (iron sucrose) 20 mg / ml;
2021-01-12;
Intravenous;
Solution;
20:04.04 – IRON PREPARATIONS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=99244
FERRLECIT;
02243333;
iron (sodium ferric gluconate complex in sucrose injection) 12.5 mg / ml;
2005-03-02;
Intravenous;
Liquid;
20:04.04 – IRON PREPARATIONS;
Prescription;
SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=67236
VELPHORO;
02471574;
iron (sucroferric oxyhydroxide) 500 mg;
2019-11-20;
Oral;
Tablet (Chewable);
40:18.19 – PHOSPHATE-REMOVING AGENTS;
Prescription;
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96073
SARCLISA;
02498235;
isatuximab 100 mg / 5 ml;
2020-07-03;
Intravenous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription , Schedule D;
SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98801
SARCLISA;
02498243;
isatuximab 500 mg / 25 ml;
2020-07-03;
Intravenous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription , Schedule D;
SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98802
CRESEMBA;
02483971;
isavuconazole (isavuconazonium sulfate) 100 mg;
2019-05-02;
Oral;
Capsule;
08:14.08 – AZOLES;
Prescription;
AVIR PHARMA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97432
CRESEMBA;
02483998;
isavuconazole (isavuconazonium sulfate) 200 mg / vial;
2019-05-31;
Intravenous;
Powder For Solution;
08:14.08 – AZOLES;
Prescription;
AVIR PHARMA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97433
FORANE;
02188856;
isoflurane 100 %;
1996-12-31;
Inhalation;
Liquid;
28:04.16 – INHALATION ANESTHETICS;
Prescription;
BAXTER CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=20160
ISOFLURANE USP;
02231929;
isoflurane 99.9 %;
1997-11-14;
Inhalation;
Liquid;
28:04.16 – INHALATION ANESTHETICS;
Prescription;
FRESENIUS KABI CANADA LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=51381
PDP-ISONIAZID;
00577790;
isoniazid 100 mg;
1984-12-31;
Oral;
Tablet;
08:16.04 – ANTITUBERCULOSIS AGENTS;
Prescription;
PENDOPHARM DIVISION OF PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=5718
PDP-ISONIAZID;
00577804;
isoniazid 300 mg;
1984-12-31;
Oral;
Tablet;
08:16.04 – ANTITUBERCULOSIS AGENTS;
Prescription;
PENDOPHARM DIVISION OF PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=5719
PDP-ISONIAZID;
00577812;
isoniazid 50 mg / 5 ml;
1984-12-31;
Oral;
Solution;
08:16.04 – ANTITUBERCULOSIS AGENTS;
Prescription;
PENDOPHARM DIVISION OF PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=5720
RESULTZ;
02279592;
isopropyl myristate 50 % / w/w;
2006-09-01;
Topical;
Solution;
84:04.12 – SCABICIDES AND PEDICULICIDES;
Otc;
ARALEZ PHARMACEUTICALS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=76520
ISOPROTERENOL HYDROCHLORIDE INJECTION USP;
00897639;
isoproterenol hydrochloride 0.2 mg / ml;
1991-12-31;
Intramuscular , Intravenous , Subcutaneous;
Solution;
12:12.08.04 – NON-SELECTIVE BETA-ADRENERGIC AGONISTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=11642
ISOPROTERENOL HYDROCHLORIDE INJECTION USP;
02502615;
isoproterenol hydrochloride 0.2 mg / ml;
2020-12-11;
Intramuscular , Intravenous , Subcutaneous;
Solution;
12:12.08.04 – NON-SELECTIVE BETA-ADRENERGIC AGONISTS;
Prescription;
MARCAN PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=99218
ISOPROTERENOL HYDROCHLORIDE INJECTION USP;
02502623;
isoproterenol hydrochloride 1 mg / 5 ml;
2021-01-06;
Intramuscular , Intravenous , Subcutaneous;
Solution;
12:12.08.04 – NON-SELECTIVE BETA-ADRENERGIC AGONISTS;
Prescription;
MARCAN PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=99219
ISDN;
00441686;
isosorbide dinitrate 10 mg;
1982-12-31;
Oral;
Tablet;
24:12.08 – NITRATES AND NITRITES;
Ethical;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=4730
ISDN;
00441694;
isosorbide dinitrate 30 mg;
1982-12-31;
Oral;
Tablet;
24:12.08 – NITRATES AND NITRITES;
Ethical;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=4731
IMDUR;
02126559;
isosorbide-5-mononitrate 60 mg;
1994-12-31;
Oral;
Tablet (Extended-Release);
24:12.08 – NITRATES AND NITRITES;
Ethical;
JUNO PHARMACEUTICALS CORP.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=16804
APO-ISMN;
02272830;
isosorbide-5-mononitrate 60 mg;
2006-03-03;
Oral;
Tablet (Extended-Release);
24:12.08 – NITRATES AND NITRITES;
Ethical;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=75834
PMS-ISMN;
02301288;
isosorbide-5-mononitrate 60 mg;
2007-11-08;
Oral;
Tablet (Extended-Release);
24:12.08 – NITRATES AND NITRITES;
Ethical;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78661
PRO-ISMN – 60;
02311321;
isosorbide-5-mononitrate 60 mg;
2008-07-04;
Oral;
Tablet (Extended-Release);
24:12.08 – NITRATES AND NITRITES;
Ethical;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=79692
ACCUTANE ROCHE;
00582344;
isotretinoin 10 mg;
1983-12-31;
Oral;
Capsule;
84:92.00 – MISC. SKIN AND MUCOUS MEMBRANE AGENTS;
Prescription;
HOFFMANN-LA ROCHE LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=5128
CLARUS;
02257955;
isotretinoin 10 mg;
2005-04-01;
Oral;
Capsule;
84:92.00 – MISC. SKIN AND MUCOUS MEMBRANE AGENTS;
Prescription;
MYLAN PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=74319
EPURIS;
02396971;
isotretinoin 10 mg;
2013-05-07;
Oral;
Capsule;
84:92.00 – MISC. SKIN AND MUCOUS MEMBRANE AGENTS;
Prescription;
CIPHER PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88198
EPURIS;
02396998;
isotretinoin 20 mg;
2013-05-07;
Oral;
Capsule;
84:92.00 – MISC. SKIN AND MUCOUS MEMBRANE AGENTS;
Prescription;
CIPHER PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88199
EPURIS;
02397005;
isotretinoin 30 mg;
2013-05-07;
Oral;
Capsule;
84:92.00 – MISC. SKIN AND MUCOUS MEMBRANE AGENTS;
Prescription;
CIPHER PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88200
ACCUTANE ROCHE;
00582352;
isotretinoin 40 mg;
1983-12-31;
Oral;
Capsule;
84:92.00 – MISC. SKIN AND MUCOUS MEMBRANE AGENTS;
Prescription;
HOFFMANN-LA ROCHE LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=5129
CLARUS;
02257963;
isotretinoin 40 mg;
2005-04-01;
Oral;
Capsule;
84:92.00 – MISC. SKIN AND MUCOUS MEMBRANE AGENTS;
Prescription;
MYLAN PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=74320
EPURIS;
02397013;
isotretinoin 40 mg;
2013-05-07;
Oral;
Capsule;
84:92.00 – MISC. SKIN AND MUCOUS MEMBRANE AGENTS;
Prescription;
CIPHER PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88201
SPORANOX ORAL SOLUTION 10MG/ML;
02231347;
itraconazole 10 mg / ml;
1997-07-28;
Oral;
Solution;
08:14.08 – AZOLES;
Prescription;
JANSSEN INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=50656
JAMP ITRACONAZOLE ORAL SOLUTION;
02484315;
itraconazole 10 mg / ml;
2019-07-31;
Oral;
Solution;
08:14.08 – AZOLES;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97463
ODAN ITRACONAZOLE;
02495988;
itraconazole 10 mg / ml;
2020-07-08;
Oral;
Solution;
08:14.08 – AZOLES;
Prescription;
ODAN LABORATORIES LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98587
SPORANOX;
02047454;
itraconazole 100 mg;
1993-12-31;
Oral;
Capsule;
08:14.08 – AZOLES;
Prescription;
JANSSEN INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=14518
MINT-ITRACONAZOLE;
02462559;
itraconazole 100 mg;
2017-05-18;
Oral;
Capsule;
08:14.08 – AZOLES;
Prescription;
MINT PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95031
LANCORA;
02459973;
ivabradine (ivabradine hydrochloride) 5 mg;
2017-03-17;
Oral;
Tablet;
24:04.92 – MISCELLANEOUS CARDIAC DRUGS;
Prescription;
SERVIER CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94728
LANCORA;
02459981;
ivabradine (ivabradine hydrochloride) 7.5 mg;
2017-03-17;
Oral;
Tablet;
24:04.92 – MISCELLANEOUS CARDIAC DRUGS;
Prescription;
SERVIER CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94729
KALYDECO;
02397412;
ivacaftor 150 mg;
2012-11-27;
Oral;
Tablet;
48:14.12 – Cystic Fibrosis Transmembrane Conductance Regulator Potentiators;
Prescription;
VERTEX PHARMACEUTICALS (CANADA) INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88237
KALYDECO;
02442612;
ivacaftor 50 mg / sachet;
2015-09-14;
Oral;
Granules;
48:14.12 – Cystic Fibrosis Transmembrane Conductance Regulator Potentiators;
Prescription;
VERTEX PHARMACEUTICALS (CANADA) INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92696
KALYDECO;
02442620;
ivacaftor 75 mg / sachet;
2015-09-14;
Oral;
Granules;
48:14.12 – Cystic Fibrosis Transmembrane Conductance Regulator Potentiators;
Prescription;
VERTEX PHARMACEUTICALS (CANADA) INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92697
ROSIVER;
02440342;
ivermectin 1 % / w/w;
2015-05-25;
Topical;
Cream;
84:04.12 – SCABICIDES AND PEDICULICIDES;
Prescription;
GALDERMA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92470
STROMECTOL;
02480557;
ivermectin 3 mg;
2018-11-06;
Oral;
Tablet;
08:08.00 – ANTHELMINTICS;
Prescription;
MERCK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97110
NINLARO;
02456796;
ixazomib (ixazomib citrate) 2.3 mg;
2016-09-21;
Oral;
Capsule;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94382
NINLARO;
02456818;
ixazomib (ixazomib citrate) 3 mg;
2016-09-21;
Oral;
Capsule;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94383
NINLARO;
02456826;
ixazomib (ixazomib citrate) 4 mg;
2016-09-21;
Oral;
Capsule;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94384
TALTZ;
02455102;
ixekizumab 80 mg / ml;
2016-08-11;
Subcutaneous;
Solution;
84:92.00 – MISC. SKIN AND MUCOUS MEMBRANE AGENTS;
Prescription , Schedule D;
ELI LILLY CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94193
TALTZ;
02455110;
ixekizumab 80 mg / ml;
2016-08-11;
Subcutaneous;
Solution;
84:92.00 – MISC. SKIN AND MUCOUS MEMBRANE AGENTS;
Prescription , Schedule D;
ELI LILLY CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94194
KETALAR;
00224391;
ketamine (ketamine hydrochloride) 10 mg / ml;
1972-12-31;
Intramuscular , Intravenous;
Solution;
28:04.92 – MISCELLANEOUS GENERAL ANESTHETICS;
Narcotic (Cdsa I);
ERFA CANADA 2012 INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=1214
KETAMINE HYDROCHLORIDE INJECTION USP;
02246795;
ketamine (ketamine hydrochloride) 10 mg / ml;
2003-02-05;
Intramuscular , Intravenous;
Solution;
28:04.00 – GENERAL ANESTHETICS;
Narcotic (Cdsa I);
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=70995
KETALAR;
00224405;
ketamine (ketamine hydrochloride) 50 mg / ml;
1972-12-31;
Intramuscular , Intravenous;
Solution;
28:04.92 – MISCELLANEOUS GENERAL ANESTHETICS;
Narcotic (Cdsa I);
ERFA CANADA 2012 INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=1215
KETAMINE HYDROCHLORIDE INJECTION USP;
02246796;
ketamine (ketamine hydrochloride) 50 mg / ml;
2003-02-04;
Intramuscular , Intravenous;
Solution;
28:04.92 – MISCELLANEOUS GENERAL ANESTHETICS;
Narcotic (Cdsa I);
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=70996
NIZORAL;
02182920;
ketoconazole 2 %;
1990-12-30;
Topical;
Shampoo;
84:04.08.08 – AZOLES;
Otc;
KRAMER LABORATORIES, INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=44259
KETODERM CREAM 2%;
02245662;
ketoconazole 2 %;
2002-05-23;
Topical;
Cream;
84:04.08.08 – AZOLES;
Prescription;
TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=69762
TEVA-KETOCONAZOLE;
02231061;
ketoconazole 200 mg;
1999-06-30;
Oral;
Tablet;
08:14.08 – AZOLES;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=50343
APO-KETOCONAZOLE;
02237235;
ketoconazole 200 mg;
1998-02-03;
Oral;
Tablet;
08:14.08 – AZOLES;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=60554
KETOPROFEN-E;
00842664;
ketoprofen 100 mg;
1989-12-31;
Oral;
Tablet (Enteric-Coated);
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=10134
KETOPROFEN SR;
02172577;
ketoprofen 200 mg;
1995-12-31;
Oral;
Tablet (Extended-Release);
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19115
KETOPROFEN-E;
00790435;
ketoprofen 50 mg;
1989-12-31;
Oral;
Tablet (Enteric-Coated);
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=10135
ACULAR LS;
02248722;
ketorolac tromethamine 0.4 %;
2004-03-08;
Ophthalmic;
Solution;
52:08.20 – NONSTEROIDAL ANTI-INFLAMMATORY AGENTS;
Prescription;
ALLERGAN INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=73086
ACUVAIL;
02369362;
ketorolac tromethamine 0.45 % / w/v;
2012-01-10;
Ophthalmic;
Solution;
52:08.20 – NONSTEROIDAL ANTI-INFLAMMATORY AGENTS;
Prescription;
ALLERGAN INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85428
ACULAR LIQ 0.5%;
01968300;
ketorolac tromethamine 0.5 %;
1992-12-31;
Ophthalmic;
Solution;
52:08.20 – NONSTEROIDAL ANTI-INFLAMMATORY AGENTS;
Prescription;
ALLERGAN INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=13121
KETOROLAC;
02245821;
ketorolac tromethamine 0.5 %;
2002-12-06;
Ophthalmic;
Solution;
52:08.20 – NONSTEROIDAL ANTI-INFLAMMATORY AGENTS;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=69937
TORADOL;
02162660;
ketorolac tromethamine 10 mg;
1995-12-31;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19348
APO-KETOROLAC;
02229080;
ketorolac tromethamine 10 mg;
1998-07-03;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=43510
MINT-KETOROLAC;
02461455;
ketorolac tromethamine 10 mg;
2019-06-28;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
MINT PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94908
MAR-KETOROLAC;
02465124;
ketorolac tromethamine 10 mg;
2017-08-16;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
MARCAN PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95332
TORADOL IM;
02162644;
ketorolac tromethamine 10 mg / ml;
1996-10-16;
Intramuscular;
Solution;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
ATNAHS PHARMA UK LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=44090
KETOROLAC TROMETHAMINE INJECTION USP;
02239944;
ketorolac tromethamine 30 mg / ml;
1999-05-21;
Intramuscular;
Liquid;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=63447
KETOROLAC TROMETHAMINE INJECTION, USP;
02244947;
ketorolac tromethamine 30 mg / ml;
2002-05-23;
Intramuscular;
Liquid;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
FRESENIUS KABI CANADA LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=68945
KETOROLAC TROMETHAMINE INJECTION USP;
02390582;
ketorolac tromethamine 30 mg / ml;
2014-05-29;
Intramuscular;
Solution;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87600
KETOROLAC TROMETHAMINE INJECTION, USP;
02443376;
ketorolac tromethamine 30 mg / ml;
2016-04-26;
Intramuscular;
Solution;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
JUNO PHARMACEUTICALS CORP.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92801
ZADITOR;
02242324;
ketotifen (ketotifen fumarate) 0.25 mg / ml;
2000-08-01;
Ophthalmic;
Solution;
52:02.00 – ANTIALLERGIC AGENTS;
Prescription;
LABORATOIRES THEA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=66035
KETOTIFEN OPHTHALMIC SOLUTION;
02400871;
ketotifen (ketotifen fumarate) 0.25 mg / ml;
2013-03-07;
Ophthalmic;
Solution;
52:02.00 – ANTIALLERGIC AGENTS;
Prescription;
STERIMAX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88567
ZADITEN;
00577308;
ketotifen (ketotifen fumarate) 1 mg;
1990-12-31;
Oral;
Tablet;
04:92.00 – OTHER ANTIHISTAMINES;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=10832
ZADITEN;
00600784;
ketotifen (ketotifen fumarate) 1 mg / 5 ml;
1990-12-31;
Oral;
Syrup;
04:92.00 – OTHER ANTIHISTAMINES;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=10860
TRANDATE;
02106272;
labetalol hydrochloride 100 mg;
1996-07-30;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
PALADIN LABS INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=29542
APO-LABETALOL;
02243538;
labetalol hydrochloride 100 mg;
2001-03-16;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=67456
RIVA-LABETALOL;
02489406;
labetalol hydrochloride 100 mg;
2019-09-04;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
LABORATOIRE RIVA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97949
TRANDATE;
02106280;
labetalol hydrochloride 200 mg;
1997-04-01;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
PALADIN LABS INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=29543
APO-LABETALOL;
02243539;
labetalol hydrochloride 200 mg;
2001-06-01;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=67457
RIVA-LABETALOL;
02489414;
labetalol hydrochloride 200 mg;
2019-09-04;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
LABORATOIRE RIVA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97950
LABETALOL HYDROCHLORIDE INJECTION USP;
02231689;
labetalol hydrochloride 5 mg / ml;
1998-03-17;
Intravenous;
Liquid;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=51066
LABETALOL HYDROCHLORIDE INJECTION USP;
02391090;
labetalol hydrochloride 5 mg / ml;
2015-06-02;
Intravenous;
Solution;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87646
LABETALOL HYDROCHLORIDE INJECTION;
02457040;
labetalol hydrochloride 5 mg / ml;
2018-06-02;
Intravenous;
Solution;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
OMEGA LABORATORIES LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94413
VIMPAT;
02357666;
lacosamide 10 mg / ml;
2011-09-20;
Intravenous;
Solution;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
UCB CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84276
VIMPAT;
02357623;
lacosamide 100 mg;
2010-10-21;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
UCB CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84273
TEVA-LACOSAMIDE;
02472910;
lacosamide 100 mg;
2018-10-01;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96225
SANDOZ LACOSAMIDE;
02474689;
lacosamide 100 mg;
2018-10-01;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96486
AURO-LACOSAMIDE;
02475340;
lacosamide 100 mg;
2018-10-01;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
AURO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96572
PHARMA-LACOSAMIDE;
02478218;
lacosamide 100 mg;
2018-10-01;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96893
MAR-LACOSAMIDE;
02487810;
lacosamide 100 mg;
2019-10-04;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
MARCAN PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97797
JAMP-LACOSAMIDE;
02488396;
lacosamide 100 mg;
2020-03-06;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97849
MINT-LACOSAMIDE;
02490552;
lacosamide 100 mg;
2019-11-25;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
MINT PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98059
VIMPAT;
02357631;
lacosamide 150 mg;
2010-10-21;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
UCB CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84274
TEVA-LACOSAMIDE;
02472929;
lacosamide 150 mg;
2018-10-01;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96226
SANDOZ LACOSAMIDE;
02474697;
lacosamide 150 mg;
2018-10-01;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96487
AURO-LACOSAMIDE;
02475359;
lacosamide 150 mg;
2018-10-01;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
AURO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96573
PHARMA-LACOSAMIDE;
02478226;
lacosamide 150 mg;
2018-10-01;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96894
MAR-LACOSAMIDE;
02487829;
lacosamide 150 mg;
2019-10-04;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
MARCAN PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97798
JAMP-LACOSAMIDE;
02488418;
lacosamide 150 mg;
2020-03-06;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97850
MINT-LACOSAMIDE;
02490560;
lacosamide 150 mg;
2019-11-25;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
MINT PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98060
VIMPAT;
02357658;
lacosamide 200 mg;
2010-10-21;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
UCB CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84275
TEVA-LACOSAMIDE;
02472937;
lacosamide 200 mg;
2018-10-01;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96228
SANDOZ LACOSAMIDE;
02474700;
lacosamide 200 mg;
2018-10-01;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96488
AURO-LACOSAMIDE;
02475367;
lacosamide 200 mg;
2018-10-01;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
AURO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96574
PHARMA-LACOSAMIDE;
02478234;
lacosamide 200 mg;
2018-10-01;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96895
MAR-LACOSAMIDE;
02487837;
lacosamide 200 mg;
2019-10-04;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
MARCAN PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97799
JAMP-LACOSAMIDE;
02488426;
lacosamide 200 mg;
2020-03-07;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97851
MINT-LACOSAMIDE;
02490579;
lacosamide 200 mg;
2019-11-25;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
MINT PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98061
VIMPAT;
02357615;
lacosamide 50 mg;
2010-10-21;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
UCB CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84272
TEVA-LACOSAMIDE;
02472902;
lacosamide 50 mg;
2018-10-01;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96224
SANDOZ LACOSAMIDE;
02474670;
lacosamide 50 mg;
2018-10-01;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96485
AURO-LACOSAMIDE;
02475332;
lacosamide 50 mg;
2018-10-01;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
AURO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96571
PHARMA-LACOSAMIDE;
02478196;
lacosamide 50 mg;
2018-10-01;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96892
MAR-LACOSAMIDE;
02487802;
lacosamide 50 mg;
2019-10-04;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
MARCAN PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97796
JAMP-LACOSAMIDE;
02488388;
lacosamide 50 mg;
2020-03-06;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97848
MINT-LACOSAMIDE;
02490544;
lacosamide 50 mg;
2019-11-25;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
MINT PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98058
RATIO-LACTULOSE;
00854409;
lactulose 667 mg / ml;
1986-12-31;
Oral;
Solution;
40:10.00 – AMMONIA DETOXICANTS;
Otc;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=12699
PMS-LACTULOSE SYR 667MG/ML;
00703486;
lactulose 667 mg / ml;
1996-10-16;
Oral;
Solution;
40:10.00 – AMMONIA DETOXICANTS;
Otc;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=38260
APO-LACTULOSE;
02242814;
lactulose 667 mg / ml;
2001-02-19;
Oral;
Solution;
40:10.00 – AMMONIA DETOXICANTS;
Otc;
BAJAJ MEDICAL, LLC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=66642
PHARMA-LACTULOSE;
02247383;
lactulose 667 mg / ml;
2004-06-23;
Oral;
Solution;
40:10.00 – AMMONIA DETOXICANTS;
Otc;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=71628
JAMP-LACTULOSE;
02295881;
lactulose 667 mg / ml;
2008-06-20;
Oral;
Solution;
40:10.00 – AMMONIA DETOXICANTS;
Otc;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78124
TEVA-LACTULOSE;
02331551;
lactulose 667 mg / ml;
2010-11-15;
Oral;
Solution;
40:10.00 – AMMONIA DETOXICANTS;
Otc;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=81724
LACTULOSE;
02412268;
lactulose 667 mg / ml;
2013-10-09;
Oral;
Solution;
40:10.00 – AMMONIA DETOXICANTS;
Otc;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=89682
PMS-LACTULOSE-PHARMA;
02469391;
lactulose 667 mg / ml;
2018-04-02;
Oral;
Solution;
40:10.00 – AMMONIA DETOXICANTS;
Otc;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95818
3TC;
02192691;
lamivudine 10 mg / ml;
1995-12-31;
Oral;
Solution;
08:18.08.20 – NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS;
Prescription;
VIIV HEALTHCARE ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19615
HEPTOVIR;
02239193;
lamivudine 100 mg;
1998-12-02;
Oral;
Tablet;
08:18.08.20 – NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS;
Prescription;
GLAXOSMITHKLINE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=62649
APO-LAMIVUDINE HBV;
02393239;
lamivudine 100 mg;
2012-09-21;
Oral;
Tablet;
08:18.08.20 – NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87847
3TC;
02192683;
lamivudine 150 mg;
1995-12-31;
Oral;
Tablet;
08:18.08.20 – NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS;
Prescription;
VIIV HEALTHCARE ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19614
APO-LAMIVUDINE;
02369052;
lamivudine 150 mg;
2012-05-18;
Oral;
Tablet;
08:18.08.20 – NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85400
JAMP LAMIVUDINE;
02507110;
lamivudine 150 mg;
2021-03-16;
Oral;
Tablet;
08:18.08.20 – NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=99652
3TC;
02247825;
lamivudine 300 mg;
2003-09-09;
Oral;
Tablet;
08:18.08.20 – NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS;
Prescription;
VIIV HEALTHCARE ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=72120
APO-LAMIVUDINE;
02369060;
lamivudine 300 mg;
2012-05-18;
Oral;
Tablet;
08:18.08.20 – NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85401
JAMP LAMIVUDINE;
02507129;
lamivudine 300 mg;
2021-03-16;
Oral;
Tablet;
08:18.08.20 – NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=99653
HEPTOVIR;
02239194;
lamivudine 5 mg / ml;
1999-03-30;
Oral;
Solution;
08:18.08.20 – NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS;
Prescription;
GLAXOSMITHKLINE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=62650
LAMICTAL;
02142104;
lamotrigine 100 mg;
1995-12-31;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
GLAXOSMITHKLINE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=17201
APO-LAMOTRIGINE;
02245209;
lamotrigine 100 mg;
2002-03-18;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=69224
PMS-LAMOTRIGINE;
02246898;
lamotrigine 100 mg;
2003-04-14;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=71125
TEVA-LAMOTRIGINE;
02248233;
lamotrigine 100 mg;
2004-01-16;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=72569
MYLAN-LAMOTRIGINE;
02265508;
lamotrigine 100 mg;
2005-04-01;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
MYLAN PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=75096
LAMOTRIGINE-100;
02302985;
lamotrigine 100 mg;
2008-03-08;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78830
LAMOTRIGINE;
02343029;
lamotrigine 100 mg;
2010-02-16;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=82851
AURO-LAMOTRIGINE;
02381362;
lamotrigine 100 mg;
2012-06-13;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
AURO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86719
LAMOTRIGINE;
02428210;
lamotrigine 100 mg;
2014-10-08;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
SIVEM PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=91269
LAMICTAL;
02142112;
lamotrigine 150 mg;
1995-12-31;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
GLAXOSMITHKLINE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=17160
APO-LAMOTRIGINE;
02245210;
lamotrigine 150 mg;
2002-03-18;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=69225
PMS-LAMOTRIGINE;
02246899;
lamotrigine 150 mg;
2003-04-14;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=71126
TEVA-LAMOTRIGINE;
02248234;
lamotrigine 150 mg;
2004-01-16;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=72570
MYLAN-LAMOTRIGINE;
02265516;
lamotrigine 150 mg;
2005-04-01;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
MYLAN PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=75097
LAMOTRIGINE-150;
02302993;
lamotrigine 150 mg;
2008-03-07;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78831
LAMOTRIGINE;
02343037;
lamotrigine 150 mg;
2010-02-16;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=82852
AURO-LAMOTRIGINE;
02381370;
lamotrigine 150 mg;
2012-06-13;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
AURO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86720
LAMOTRIGINE;
02428229;
lamotrigine 150 mg;
2014-10-08;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
SIVEM PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=91270
LAMICTAL;
02243803;
lamotrigine 2 mg;
2001-09-13;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
GLAXOSMITHKLINE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=67741
LAMICTAL;
02142082;
lamotrigine 25 mg;
1995-12-31;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
GLAXOSMITHKLINE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=17203
APO-LAMOTRIGINE;
02245208;
lamotrigine 25 mg;
2002-03-18;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=69223
PMS-LAMOTRIGINE;
02246897;
lamotrigine 25 mg;
2003-04-14;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=71124
TEVA-LAMOTRIGINE;
02248232;
lamotrigine 25 mg;
2004-01-16;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=72568
MYLAN-LAMOTRIGINE;
02265494;
lamotrigine 25 mg;
2005-04-01;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
MYLAN PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=75095
LAMOTRIGINE-25;
02302969;
lamotrigine 25 mg;
2008-03-07;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78826
LAMOTRIGINE;
02343010;
lamotrigine 25 mg;
2010-02-16;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=82850
AURO-LAMOTRIGINE;
02381354;
lamotrigine 25 mg;
2012-06-13;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
AURO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86718
LAMOTRIGINE;
02428202;
lamotrigine 25 mg;
2014-10-08;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
SIVEM PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=91268
LAMICTAL;
02240115;
lamotrigine 5 mg;
1999-06-02;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
GLAXOSMITHKLINE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=63629
TAKHZYRO;
02480948;
lanadelumab 300 mg / 2 ml;
2018-10-31;
Subcutaneous;
Solution;
92:32.00 – COMPLEMENT INHIBITORS;
Prescription , Schedule D;
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97159
TAKHZYRO;
02505614;
lanadelumab 300 mg / 2 ml;
2021-01-18;
Subcutaneous;
Solution;
92:32.00 – COMPLEMENT INHIBITORS;
Prescription , Schedule D;
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=99498
SOMATULINE AUTOGEL;
02283417;
lanreotide (lanreotide acetate) 120 mg / syr;
2007-02-22;
Subcutaneous;
Solution (Extended Release);
92:92.00 – OTHER MISCELLANEOUS THERAPEUTIC AGENTS;
Prescription;
IPSEN BIOPHARMACEUTICALS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=76902
SOMATULINE AUTOGEL;
02283395;
lanreotide (lanreotide acetate) 60 mg / syr;
2007-02-22;
Subcutaneous;
Solution (Extended Release);
92:92.00 – OTHER MISCELLANEOUS THERAPEUTIC AGENTS;
Prescription;
IPSEN BIOPHARMACEUTICALS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=76900
SOMATULINE AUTOGEL;
02283409;
lanreotide (lanreotide acetate) 90 mg / syr;
2007-02-22;
Subcutaneous;
Solution (Extended Release);
92:92.00 – OTHER MISCELLANEOUS THERAPEUTIC AGENTS;
Prescription;
IPSEN BIOPHARMACEUTICALS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=76901
PREVACID;
02165503;
lansoprazole 15 mg;
1995-12-31;
Oral;
Capsule (Delayed Release);
56:28.36 – PROTON-PUMP INHIBITORS;
Prescription;
TAKEDA PHARMACEUTICALS AMERICA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=18515
PREVACID FASTAB;
02249464;
lansoprazole 15 mg;
2006-11-24;
Oral;
Tablet (Delayed-Release);
56:28.36 – PROTON-PUMP INHIBITORS;
Prescription;
TAKEDA PHARMACEUTICALS AMERICA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=73429
TEVA-LANSOPRAZOLE;
02280515;
lansoprazole 15 mg;
2009-11-02;
Oral;
Capsule (Delayed Release);
56:28.36 – PROTON-PUMP INHIBITORS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=76617
APO-LANSOPRAZOLE;
02293811;
lansoprazole 15 mg;
2009-06-03;
Oral;
Capsule (Delayed Release);
56:28.36 – PROTON-PUMP INHIBITORS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=77919
MYLAN-LANSOPRAZOLE;
02353830;
lansoprazole 15 mg;
2010-06-18;
Oral;
Capsule (Delayed Release);
56:28.36 – PROTON-PUMP INHIBITORS;
Prescription;
MYLAN PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83904
LANSOPRAZOLE;
02357682;
lansoprazole 15 mg;
2010-11-23;
Oral;
Capsule (Delayed Release);
56:28.36 – PROTON-PUMP INHIBITORS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84278
SANDOZ LANSOPRAZOLE;
02385643;
lansoprazole 15 mg;
2012-07-03;
Oral;
Capsule (Delayed Release);
56:28.36 – PROTON-PUMP INHIBITORS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87127
LANSOPRAZOLE;
02385767;
lansoprazole 15 mg;
2012-06-11;
Oral;
Capsule (Delayed Release);
56:28.36 – PROTON-PUMP INHIBITORS;
Prescription;
SIVEM PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87138
TARO-LANSOPRAZOLE;
02402610;
lansoprazole 15 mg;
2013-03-22;
Oral;
Capsule (Delayed Release);
56:28.36 – PROTON-PUMP INHIBITORS;
Prescription;
SUN PHARMA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88746
RIVA-LANSOPRAZOLE;
02422808;
lansoprazole 15 mg;
2014-06-12;
Oral;
Capsule (Delayed Release);
56:28.36 – PROTON-PUMP INHIBITORS;
Prescription;
LABORATOIRE RIVA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90746
LANSOPRAZOLE;
02433001;
lansoprazole 15 mg;
2015-01-13;
Oral;
Capsule (Delayed Release);
56:28.36 – PROTON-PUMP INHIBITORS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=91737
M-LANSOPRAZOLE;
02489805;
lansoprazole 15 mg;
2019-12-13;
Oral;
Capsule (Delayed Release);
56:28.36 – PROTON-PUMP INHIBITORS;
Prescription;
MANTRA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97988
PREVACID;
02165511;
lansoprazole 30 mg;
1995-12-31;
Oral;
Capsule (Delayed Release);
56:28.36 – PROTON-PUMP INHIBITORS;
Prescription;
TAKEDA PHARMACEUTICALS AMERICA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=18516
PREVACID FASTAB;
02249472;
lansoprazole 30 mg;
2005-12-01;
Oral;
Tablet (Delayed-Release);
56:28.36 – PROTON-PUMP INHIBITORS;
Prescription;
TAKEDA PHARMACEUTICALS AMERICA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=73430
TEVA-LANSOPRAZOLE;
02280523;
lansoprazole 30 mg;
2009-11-02;
Oral;
Capsule (Delayed Release);
56:28.36 – PROTON-PUMP INHIBITORS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=76618
APO-LANSOPRAZOLE;
02293838;
lansoprazole 30 mg;
2009-06-03;
Oral;
Capsule (Delayed Release);
56:28.36 – PROTON-PUMP INHIBITORS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=77920
MYLAN-LANSOPRAZOLE;
02353849;
lansoprazole 30 mg;
2010-06-18;
Oral;
Capsule (Delayed Release);
56:28.36 – PROTON-PUMP INHIBITORS;
Prescription;
MYLAN PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83905
LANSOPRAZOLE;
02357690;
lansoprazole 30 mg;
2010-11-22;
Oral;
Capsule (Delayed Release);
56:28.36 – PROTON-PUMP INHIBITORS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84279
LANSOPRAZOLE;
02366282;
lansoprazole 30 mg;
2011-06-07;
Oral;
Capsule (Delayed Release);
56:28.36 – PROTON-PUMP INHIBITORS;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85113
SANDOZ LANSOPRAZOLE;
02385651;
lansoprazole 30 mg;
2012-07-03;
Oral;
Capsule (Delayed Release);
56:28.36 – PROTON-PUMP INHIBITORS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87128
TARO-LANSOPRAZOLE;
02402629;
lansoprazole 30 mg;
2013-03-22;
Oral;
Capsule (Delayed Release);
56:28.36 – PROTON-PUMP INHIBITORS;
Prescription;
SUN PHARMA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88747
LANSOPRAZOLE;
02410389;
lansoprazole 30 mg;
2013-10-23;
Oral;
Capsule (Delayed Release);
56:28.36 – PROTON-PUMP INHIBITORS;
Prescription;
SIVEM PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=89503
RIVA-LANSOPRAZOLE;
02422816;
lansoprazole 30 mg;
2014-06-12;
Oral;
Capsule (Delayed Release);
56:28.36 – PROTON-PUMP INHIBITORS;
Prescription;
LABORATOIRE RIVA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90747
LANSOPRAZOLE;
02433028;
lansoprazole 30 mg;
2015-02-11;
Oral;
Capsule (Delayed Release);
56:28.36 – PROTON-PUMP INHIBITORS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=91739
M-LANSOPRAZOLE;
02489813;
lansoprazole 30 mg;
2019-12-13;
Oral;
Capsule (Delayed Release);
56:28.36 – PROTON-PUMP INHIBITORS;
Prescription;
MANTRA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97989
NAT-LANTHANUM;
02498774;
lanthanum (lanthanum carbonate dihydrate) 1000 mg;
2020-07-21;
Oral;
Tablet (Chewable);
40:18.19 – PHOSPHATE-REMOVING AGENTS;
Prescription;
NATCO PHARMA (CANADA) INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98846
NAT-LANTHANUM;
02498731;
lanthanum (lanthanum carbonate dihydrate) 250 mg;
2020-07-21;
Oral;
Tablet (Chewable);
40:18.19 – PHOSPHATE-REMOVING AGENTS;
Prescription;
NATCO PHARMA (CANADA) INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98843
NAT-LANTHANUM;
02498758;
lanthanum (lanthanum carbonate dihydrate) 500 mg;
2020-07-21;
Oral;
Tablet (Chewable);
40:18.19 – PHOSPHATE-REMOVING AGENTS;
Prescription;
NATCO PHARMA (CANADA) INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98844
NAT-LANTHANUM;
02498766;
lanthanum (lanthanum carbonate dihydrate) 750 mg;
2020-07-21;
Oral;
Tablet (Chewable);
40:18.19 – PHOSPHATE-REMOVING AGENTS;
Prescription;
NATCO PHARMA (CANADA) INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98845
FOSRENOL;
02287188;
lanthanum (lanthanum carbonate hydrate) 1000 mg;
2006-12-06;
Oral;
Tablet (Chewable);
40:18.19 – PHOSPHATE-REMOVING AGENTS;
Prescription;
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=77261
FOSRENOL;
02287145;
lanthanum (lanthanum carbonate hydrate) 250 mg;
2006-12-06;
Oral;
Tablet (Chewable);
40:18.19 – PHOSPHATE-REMOVING AGENTS;
Prescription;
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=77258
FOSRENOL;
02287153;
lanthanum (lanthanum carbonate hydrate) 500 mg;
2006-12-06;
Oral;
Tablet (Chewable);
40:18.19 – PHOSPHATE-REMOVING AGENTS;
Prescription;
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=77259
FOSRENOL;
02287161;
lanthanum (lanthanum carbonate hydrate) 750 mg;
2006-12-06;
Oral;
Tablet (Chewable);
40:18.19 – PHOSPHATE-REMOVING AGENTS;
Prescription;
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=77260
TYKERB;
02326442;
lapatinib (lapatinib ditosylate monohydrate) 250 mg;
2009-06-05;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
NOVARTIS PHARMACEUTICALS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=81179
ALDURAZYME;
02254506;
laronidase 0.58 mg / ml;
2004-08-12;
Intravenous;
Solution;
44:00.00 – ENZYMES;
Prescription , Schedule D;
SANOFI GENZYME, A DIVISION OF SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=73940
VITRAKVI;
02490323;
larotrectinib (larotrectinib sulfate) 100 mg;
2020-11-13;
Oral;
Capsule;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
BAYER INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98038
VITRAKVI;
02490331;
larotrectinib (larotrectinib sulfate) 20 mg / ml;
2019-09-04;
Oral;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
BAYER INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98039
VITRAKVI;
02490315;
larotrectinib (larotrectinib sulfate) 25 mg;
2020-11-13;
Oral;
Capsule;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
BAYER INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98037
XALATAN;
02231493;
latanoprost 50 mcg / ml;
1997-07-28;
Ophthalmic;
Solution;
52:40.28 – PROSTAGLANDIN ANALOGS;
Prescription;
UPJOHN CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=50823
TEVA-LATANOPROST;
02254786;
latanoprost 50 mcg / ml;
2011-10-13;
Ophthalmic;
Solution;
52:40.28 – PROSTAGLANDIN ANALOGS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=73994
APO-LATANOPROST;
02296527;
latanoprost 50 mcg / ml;
2011-10-03;
Ophthalmic;
Solution;
52:40.28 – PROSTAGLANDIN ANALOGS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78185
RIVA-LATANOPROST;
02341085;
latanoprost 50 mcg / ml;
2015-05-11;
Ophthalmic;
Solution;
52:40.28 – PROSTAGLANDIN ANALOGS;
Prescription;
LABORATOIRE RIVA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=82663
SANDOZ LATANOPROST;
02367335;
latanoprost 50 mcg / ml;
2011-12-06;
Ophthalmic;
Solution;
52:40.28 – PROSTAGLANDIN ANALOGS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85213
GD-LATANOPROST;
02373041;
latanoprost 50 mcg / ml;
2011-10-03;
Ophthalmic;
Solution;
52:40.28 – PROSTAGLANDIN ANALOGS;
Prescription;
UPJOHN CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85817
MED-LATANOPROST;
02426935;
latanoprost 50 mcg / ml;
2015-01-09;
Ophthalmic;
Solution;
52:40.28 – PROSTAGLANDIN ANALOGS;
Prescription;
GENERIC MEDICAL PARTNERS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=91148
JAMP LATANOPROST;
02453355;
latanoprost 50 mcg / ml;
2020-02-07;
Ophthalmic;
Solution;
52:40.28 – PROSTAGLANDIN ANALOGS;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93988
MONOPROST;
02456230;
latanoprost 50 mcg / ml;
2018-01-03;
Ophthalmic;
Solution;
52:40.28 – PROSTAGLANDIN ANALOGS;
Prescription;
LABORATOIRES THEA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94312
LATANOPROST OPHTHALMIC SOLUTION;
02489570;
latanoprost 50 mcg / ml;
2020-06-26;
Ophthalmic;
Solution;
52:40.28 – PROSTAGLANDIN ANALOGS;
Prescription;
TELIGENT CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97965
VYZULTA;
02484218;
latanoprostene bunod 0.024 % / w/v;
2019-05-17;
Ophthalmic;
Solution;
52:40.28 – PROSTAGLANDIN ANALOGS;
Prescription;
BAUSCH & LOMB INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97453
ARAVA 10MG;
02241888;
leflunomide 10 mg;
2000-03-29;
Oral;
Tablet;
92:36.00 – DISEASE-MODIFYING ANTIRHEUMATIC AGENTS;
Prescription;
SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=65558
APO-LEFLUNOMIDE;
02256495;
leflunomide 10 mg;
2004-09-14;
Oral;
Tablet;
92:36.00 – DISEASE-MODIFYING ANTIRHEUMATIC AGENTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=74173
TEVA-LEFLUNOMIDE;
02261251;
leflunomide 10 mg;
2004-12-21;
Oral;
Tablet;
92:36.00 – DISEASE-MODIFYING ANTIRHEUMATIC AGENTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=74665
SANDOZ LEFLUNOMIDE;
02283964;
leflunomide 10 mg;
2006-08-15;
Oral;
Tablet;
92:36.00 – DISEASE-MODIFYING ANTIRHEUMATIC AGENTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=76953
LEFLUNOMIDE;
02351668;
leflunomide 10 mg;
2010-06-15;
Oral;
Tablet;
92:36.00 – DISEASE-MODIFYING ANTIRHEUMATIC AGENTS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83692
LEFLUNOMIDE;
02415828;
leflunomide 10 mg;
2013-11-28;
Oral;
Tablet;
92:36.00 – DISEASE-MODIFYING ANTIRHEUMATIC AGENTS;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90041
ACCEL-LEFLUNOMIDE;
02478862;
leflunomide 10 mg;
2019-09-19;
Oral;
Tablet;
92:36.00 – DISEASE-MODIFYING ANTIRHEUMATIC AGENTS;
Prescription;
ACCEL PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96957
ARAVA 100 MG;
02241890;
leflunomide 100 mg;
2000-03-29;
Oral;
Tablet;
92:36.00 – DISEASE-MODIFYING ANTIRHEUMATIC AGENTS;
Prescription;
SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=65560
ARAVA 20 MG;
02241889;
leflunomide 20 mg;
2000-03-29;
Oral;
Tablet;
92:36.00 – DISEASE-MODIFYING ANTIRHEUMATIC AGENTS;
Prescription;
SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=65559
APO-LEFLUNOMIDE;
02256509;
leflunomide 20 mg;
2004-09-14;
Oral;
Tablet;
92:36.00 – DISEASE-MODIFYING ANTIRHEUMATIC AGENTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=74174
TEVA-LEFLUNOMIDE;
02261278;
leflunomide 20 mg;
2004-12-21;
Oral;
Tablet;
92:36.00 – DISEASE-MODIFYING ANTIRHEUMATIC AGENTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=74666
SANDOZ LEFLUNOMIDE;
02283972;
leflunomide 20 mg;
2006-08-15;
Oral;
Tablet;
92:36.00 – DISEASE-MODIFYING ANTIRHEUMATIC AGENTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=76954
LEFLUNOMIDE;
02351676;
leflunomide 20 mg;
2010-06-15;
Oral;
Tablet;
92:36.00 – DISEASE-MODIFYING ANTIRHEUMATIC AGENTS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83693
LEFLUNOMIDE;
02415836;
leflunomide 20 mg;
2013-11-28;
Oral;
Tablet;
92:36.00 – DISEASE-MODIFYING ANTIRHEUMATIC AGENTS;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90042
ACCEL-LEFLUNOMIDE;
02478870;
leflunomide 20 mg;
2019-09-19;
Oral;
Tablet;
92:36.00 – DISEASE-MODIFYING ANTIRHEUMATIC AGENTS;
Prescription;
ACCEL PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96958
DAYVIGO;
02507374;
lemborexant 10 mg;
2020-11-06;
Oral;
Tablet;
28:24.92 – MISCELLANEOUS ANXIOLYTICS SEDATIVES AND HYPNOTICS;
Prescription;
EISAI LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=99676
DAYVIGO;
02507366;
lemborexant 5 mg;
2020-11-06;
Oral;
Tablet;
28:24.92 – MISCELLANEOUS ANXIOLYTICS SEDATIVES AND HYPNOTICS;
Prescription;
EISAI LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=99675
REVLIMID;
02304902;
lenalidomide 10 mg;
2008-02-19;
Oral;
Capsule;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
CELGENE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=79017
REVLIMID;
02317699;
lenalidomide 15 mg;
2008-10-10;
Oral;
Capsule;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
CELGENE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80322
REVLIMID;
02459418;
lenalidomide 2.5 mg;
2016-12-20;
Oral;
Capsule;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
CELGENE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94664
REVLIMID;
02440601;
lenalidomide 20 mg;
2015-09-28;
Oral;
Capsule;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
CELGENE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92497
REVLIMID;
02317710;
lenalidomide 25 mg;
2008-10-10;
Oral;
Capsule;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
CELGENE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80324
REVLIMID;
02304899;
lenalidomide 5 mg;
2008-02-19;
Oral;
Capsule;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
CELGENE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=79016
LENVIMA;
02450321;
lenvatinib (lenvatinib mesylate) 10 mg / dose;
2016-03-31;
Oral;
Capsule;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
EISAI LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93646
LENVIMA;
02484129;
lenvatinib (lenvatinib mesylate) 12 mg / dose;
2019-10-21;
Oral;
Capsule;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
EISAI LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97445
LENVIMA;
02450313;
lenvatinib (lenvatinib mesylate) 14 mg / dose;
2016-03-31;
Oral;
Capsule;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
EISAI LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93645
LENVIMA;
02468239;
lenvatinib (lenvatinib mesylate) 18 mg / dose;
2018-05-08;
Oral;
Capsule;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
EISAI LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95664
LENVIMA;
02450305;
lenvatinib (lenvatinib mesylate) 20 mg / dose;
2016-03-31;
Oral;
Capsule;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
EISAI LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93644
LENVIMA;
02450291;
lenvatinib (lenvatinib mesylate) 24 mg / dose;
2016-03-31;
Oral;
Capsule;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
EISAI LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93643
LENVIMA;
02484056;
lenvatinib (lenvatinib mesylate) 4 mg / dose;
2019-10-21;
Oral;
Capsule;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
EISAI LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97438
LENVIMA;
02468220;
lenvatinib (lenvatinib mesylate) 8 mg / dose;
2018-05-08;
Oral;
Capsule;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
EISAI LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95663
PREVYMIS;
02469367;
letermovir 20 mg / ml;
2017-12-20;
Intravenous;
Solution;
08:18.08.08 – HIV PROTEASE INHIBITORS;
Prescription;
MERCK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95815
PREVYMIS;
02469405;
letermovir 20 mg / ml;
2017-12-20;
Intravenous;
Solution;
08:18.08.08 – HIV PROTEASE INHIBITORS;
Prescription;
MERCK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95819
PREVYMIS;
02469375;
letermovir 240 mg;
2017-12-20;
Oral;
Tablet;
08:18.08.08 – HIV PROTEASE INHIBITORS;
Prescription;
MERCK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95816
PREVYMIS;
02469383;
letermovir 480 mg;
2017-12-20;
Oral;
Tablet;
08:18.08.08 – HIV PROTEASE INHIBITORS;
Prescription;
MERCK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95817
FEMARA 2.5MG;
02231384;
letrozole 2.5 mg;
1997-09-02;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
NOVARTIS PHARMACEUTICALS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=50695
PMS-LETROZOLE;
02309114;
letrozole 2.5 mg;
2010-04-28;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=79471
ACH-LETROZOLE;
02338459;
letrozole 2.5 mg;
2010-05-03;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
ACCORD HEALTHCARE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=82411
TEVA-LETROZOLE;
02343657;
letrozole 2.5 mg;
2013-07-08;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=82909
SANDOZ LETROZOLE;
02344815;
letrozole 2.5 mg;
2010-04-27;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83029
APO-LETROZOLE;
02358514;
letrozole 2.5 mg;
2012-06-11;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84356
JAMP-LETROZOLE;
02373009;
letrozole 2.5 mg;
2011-09-30;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85813
MAR-LETROZOLE;
02373424;
letrozole 2.5 mg;
2013-01-08;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
MARCAN PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85857
BIO-LETROZOLE;
02392496;
letrozole 2.5 mg;
2013-02-12;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
BIOMED PHARMA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87776
RIVA-LETROZOLE;
02398656;
letrozole 2.5 mg;
2014-02-11;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
LABORATOIRE RIVA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88359
LETROZOLE;
02402025;
letrozole 2.5 mg;
2013-02-14;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88690
NAT-LETROZOLE;
02421585;
letrozole 2.5 mg;
2015-02-03;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
NATCO PHARMA (CANADA) INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90623
CCP-LETROZOLE;
02459884;
letrozole 2.5 mg;
2017-07-24;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
CELLCHEM PHARMACEUTICALS INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94719
LETROZOLE;
02504472;
letrozole 2.5 mg;
2021-03-19;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=99389
LEUCOVORIN CALCIUM INJECTION;
02087316;
leucovorin (leucovorin calcium) 10 mg / ml;
1994-12-31;
Intramuscular , Intravenous;
Solution;
92:12.00 – ANTIDOTES;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=18209
LEUCOVORIN CALCIUM INJECTION USP;
02182998;
leucovorin (leucovorin calcium) 10 mg / ml;
1997-05-09;
Intravenous;
Solution;
92:12.00 – ANTIDOTES;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=44265
LEUCOVORIN CALCIUM INJECTION USP;
02183005;
leucovorin (leucovorin calcium) 10 mg / ml;
1997-08-07;
Intramuscular , Intravenous;
Solution;
92:12.00 – ANTIDOTES;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=44266
LEUCOVORIN CALCIUM INJECTION;
02480042;
leucovorin (leucovorin calcium) 10 mg / ml;
2019-09-19;
Intramuscular , Intravenous;
Solution;
92:12.00 – ANTIDOTES;
Prescription;
GENERIC MEDICAL PARTNERS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97064
LEDERLE LEUCOVORIN;
02170493;
leucovorin (leucovorin calcium) 5 mg;
1996-10-25;
Oral;
Tablet;
92:12.00 – ANTIDOTES;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=44146
RIVA LEUCOVORIN;
02493357;
leucovorin (leucovorin calcium) 5 mg;
2019-12-02;
Oral;
Tablet;
92:12.00 – ANTIDOTES;
Prescription;
LABORATOIRE RIVA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98337
MINT-LEUCOVORIN;
02496828;
leucovorin (leucovorin calcium) 5 mg;
2021-01-12;
Oral;
Tablet;
92:12.00 – ANTIDOTES;
Prescription;
MINT PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98666
LUPRON DEPOT;
02239834;
leuprolide acetate 11.25 mg / syr;
1999-09-13;
Intramuscular;
Powder For Suspension, Sustained-Release;
68:18.08 – GONADOTROPINS;
Prescription;
ABBVIE CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=63321
LUPRON DEPOT;
02230248;
leuprolide acetate 22.5 mg / syr;
1997-01-29;
Intramuscular;
Powder For Suspension, Sustained-Release;
68:18.08 – GONADOTROPINS;
Prescription;
ABBVIE CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=48922
ELIGARD;
02248240;
leuprolide acetate 22.5 mg / syr;
2003-12-01;
Subcutaneous;
Powder For Suspension, Sustained-Release;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=72577
ZEULIDE DEPOT;
02462699;
leuprolide acetate 22.5 mg / vial;
2019-10-08;
Intramuscular;
Powder For Suspension, Sustained-Release , Kit;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
VERITY PHARMACEUTICALS INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95052
LUPRON DEPOT;
00884502;
leuprolide acetate 3.75 mg / syr;
1992-12-31;
Intramuscular;
Powder For Suspension, Sustained-Release;
68:18.08 – GONADOTROPINS;
Prescription;
ABBVIE CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=13443
ZEULIDE DEPOT;
02429977;
leuprolide acetate 3.75 mg / vial;
2019-10-08;
Intramuscular;
Powder For Suspension, Sustained-Release , Kit;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
VERITY PHARMACEUTICALS INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=91439
LUPRON DEPOT;
02239833;
leuprolide acetate 30 mg / syr;
1999-09-13;
Intramuscular;
Powder For Suspension, Sustained-Release;
68:18.08 – GONADOTROPINS;
Prescription;
ABBVIE CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=63320
ELIGARD;
02248999;
leuprolide acetate 30 mg / syr;
2004-04-29;
Subcutaneous;
Powder For Suspension, Sustained-Release;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=73384
ELIGARD;
02268892;
leuprolide acetate 45 mg / syr;
2005-08-15;
Subcutaneous;
Powder For Suspension, Sustained-Release;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=75428
LUPRON;
00727695;
leuprolide acetate 5 mg / ml;
1985-12-31;
Subcutaneous;
Solution;
68:18.08 – GONADOTROPINS;
Prescription;
ABBVIE CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=7367
LUPRON DEPOT;
00836273;
leuprolide acetate 7.5 mg / syr;
1989-12-31;
Intramuscular;
Powder For Suspension, Sustained-Release;
68:18.08 – GONADOTROPINS;
Prescription;
ABBVIE CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=10318
ELIGARD;
02248239;
leuprolide acetate 7.5 mg / syr;
2003-12-01;
Subcutaneous;
Powder For Suspension, Sustained-Release;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=72576
PDP-LEVETIRACETAM;
02490439;
levetiracetam 100 mg / ml;
2019-10-30;
Intravenous;
Solution;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
PENDOPHARM DIVISION OF PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98048
PDP-LEVETIRACETAM;
02490447;
levetiracetam 100 mg / ml;
2020-05-01;
Oral;
Solution;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
PENDOPHARM DIVISION OF PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98049
SANDOZ LEVETIRACETAM;
02462028;
levetiracetam 1000 mg;
2018-06-01;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94976
KEPPRA;
02247027;
levetiracetam 250 mg;
2003-07-23;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
UCB CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=71262
TEVA-LEVETIRACETAM;
02274183;
levetiracetam 250 mg;
2005-12-07;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=75964
APO-LEVETIRACETAM;
02285924;
levetiracetam 250 mg;
2006-10-20;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=77141
PRO-LEVETIRACETAM – 250;
02311372;
levetiracetam 250 mg;
2013-06-06;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=79695
LEVETIRACETAM;
02353342;
levetiracetam 250 mg;
2010-07-26;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83854
AURO-LEVETIRACETAM;
02375249;
levetiracetam 250 mg;
2012-02-14;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
AURO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86064
LEVETIRACETAM TABLETS;
02399776;
levetiracetam 250 mg;
2013-03-20;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
ACCORD HEALTHCARE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88462
JAMP-LEVETIRACETAM;
02403005;
levetiracetam 250 mg;
2013-04-29;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88784
NAT-LEVETIRACETAM;
02440202;
levetiracetam 250 mg;
2015-07-22;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
NATCO PHARMA (CANADA) INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92458
LEVETIRACETAM;
02442531;
levetiracetam 250 mg;
2015-07-22;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
SIVEM PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92688
LEVETIRACETAM;
02454653;
levetiracetam 250 mg;
2016-11-01;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94136
SANDOZ LEVETIRACETAM;
02461986;
levetiracetam 250 mg;
2017-08-04;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94973
RIVA-LEVETIRACETAM;
02482274;
levetiracetam 250 mg;
2019-04-12;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
LABORATOIRE RIVA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97274
KEPPRA;
02247028;
levetiracetam 500 mg;
2003-07-23;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
UCB CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=71263
TEVA-LEVETIRACETAM;
02274191;
levetiracetam 500 mg;
2005-12-07;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=75965
APO-LEVETIRACETAM;
02285932;
levetiracetam 500 mg;
2006-10-20;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=77142
PRO-LEVETIRACETAM – 500;
02311380;
levetiracetam 500 mg;
2009-06-16;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=79696
LEVETIRACETAM;
02353350;
levetiracetam 500 mg;
2010-07-26;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83855
AURO-LEVETIRACETAM;
02375257;
levetiracetam 500 mg;
2012-03-15;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
AURO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86065
LEVETIRACETAM TABLETS;
02399784;
levetiracetam 500 mg;
2013-03-20;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
ACCORD HEALTHCARE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88463
JAMP-LEVETIRACETAM;
02403021;
levetiracetam 500 mg;
2013-04-29;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88785
NAT-LEVETIRACETAM;
02440210;
levetiracetam 500 mg;
2015-07-22;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
NATCO PHARMA (CANADA) INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92459
LEVETIRACETAM;
02442558;
levetiracetam 500 mg;
2015-07-22;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
SIVEM PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92689
LEVETIRACETAM;
02454661;
levetiracetam 500 mg;
2016-11-01;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94137
SANDOZ LEVETIRACETAM;
02461994;
levetiracetam 500 mg;
2017-08-04;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94974
RIVA-LEVETIRACETAM;
02482282;
levetiracetam 500 mg;
2019-04-12;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
LABORATOIRE RIVA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97275
KEPPRA;
02247029;
levetiracetam 750 mg;
2003-07-23;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
UCB CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=71264
TEVA-LEVETIRACETAM;
02274205;
levetiracetam 750 mg;
2005-12-07;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=75966
APO-LEVETIRACETAM;
02285940;
levetiracetam 750 mg;
2006-10-20;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=77143
PRO-LEVETIRACETAM – 750;
02311399;
levetiracetam 750 mg;
2009-10-08;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=79697
LEVETIRACETAM;
02353369;
levetiracetam 750 mg;
2010-07-26;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83856
AURO-LEVETIRACETAM;
02375265;
levetiracetam 750 mg;
2012-02-14;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
AURO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86066
LEVETIRACETAM TABLETS;
02399792;
levetiracetam 750 mg;
2013-03-20;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
ACCORD HEALTHCARE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88464
JAMP-LEVETIRACETAM;
02403048;
levetiracetam 750 mg;
2013-04-29;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88786
NAT-LEVETIRACETAM;
02440229;
levetiracetam 750 mg;
2015-07-22;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
NATCO PHARMA (CANADA) INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92460
LEVETIRACETAM;
02442566;
levetiracetam 750 mg;
2015-07-22;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
SIVEM PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92690
LEVETIRACETAM;
02454688;
levetiracetam 750 mg;
2016-11-01;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94138
SANDOZ LEVETIRACETAM;
02462001;
levetiracetam 750 mg;
2017-08-04;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94975
RIVA-LEVETIRACETAM;
02482290;
levetiracetam 750 mg;
2019-04-12;
Oral;
Tablet;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS;
Prescription;
LABORATOIRE RIVA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97276
CARNITOR;
02144336;
levocarnitine 100 mg / ml;
1995-12-31;
Oral;
Solution;
40:20.00 – CALORIC AGENTS;
Prescription;
LEADIANT BIOSCIENCES, INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19094
ODAN LEVOCARNITINE;
02492105;
levocarnitine 100 mg / ml;
2019-11-18;
Oral;
Solution;
40:20.00 – CALORIC AGENTS;
Prescription;
ODAN LABORATORIES LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98210
CARNITOR;
02144344;
levocarnitine 200 mg / ml;
1995-12-31;
Intravenous;
Solution;
40:20.00 – CALORIC AGENTS;
Prescription;
LEADIANT BIOSCIENCES, INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=18903
CARNITOR;
02144328;
levocarnitine 330 mg;
1995-12-31;
Oral;
Tablet;
40:20.00 – CALORIC AGENTS;
Prescription;
LEADIANT BIOSCIENCES, INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=18931
QUINSAIR;
02442302;
levofloxacin (levofloxacin hemihydrate) 240 mg / 2.4 ml;
2016-12-12;
Inhalation;
Solution;
08:12.18 – QUINOLONES;
Prescription;
HORIZON THERAPEUTICS IRELAND DAC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92667
APO-LEVOFLOXACIN;
02284707;
levofloxacin (levofloxacin hemihydrate) 250 mg;
2009-06-24;
Oral;
Tablet;
08:12.18 – QUINOLONES;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=77026
SANDOZ LEVOFLOXACIN;
02298635;
levofloxacin (levofloxacin hemihydrate) 250 mg;
2009-06-24;
Oral;
Tablet;
08:12.18 – QUINOLONES;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78395
ACT LEVOFLOXACIN;
02315424;
levofloxacin (levofloxacin hemihydrate) 250 mg;
2009-06-24;
Oral;
Tablet;
08:12.18 – QUINOLONES;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80096
RIVA-LEVOFLOXACIN;
02492725;
levofloxacin (levofloxacin hemihydrate) 250 mg;
2020-04-06;
Oral;
Tablet;
08:12.18 – QUINOLONES;
Prescription;
LABORATOIRE RIVA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98271
APO-LEVOFLOXACIN;
02284715;
levofloxacin (levofloxacin hemihydrate) 500 mg;
2009-06-24;
Oral;
Tablet;
08:12.18 – QUINOLONES;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=77027
SANDOZ LEVOFLOXACIN;
02298643;
levofloxacin (levofloxacin hemihydrate) 500 mg;
2009-06-24;
Oral;
Tablet;
08:12.18 – QUINOLONES;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78396
ACT LEVOFLOXACIN;
02315432;
levofloxacin (levofloxacin hemihydrate) 500 mg;
2009-06-24;
Oral;
Tablet;
08:12.18 – QUINOLONES;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80097
LEVOFLOXACIN;
02415879;
levofloxacin (levofloxacin hemihydrate) 500 mg;
2013-11-28;
Oral;
Tablet;
08:12.18 – QUINOLONES;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90046
RIVA-LEVOFLOXACIN;
02492733;
levofloxacin (levofloxacin hemihydrate) 500 mg;
2020-04-06;
Oral;
Tablet;
08:12.18 – QUINOLONES;
Prescription;
LABORATOIRE RIVA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98272
SANDOZ LEVOFLOXACIN;
02298651;
levofloxacin (levofloxacin hemihydrate) 750 mg;
2009-06-24;
Oral;
Tablet;
08:12.18 – QUINOLONES;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78397
ACT LEVOFLOXACIN;
02315440;
levofloxacin (levofloxacin hemihydrate) 750 mg;
2009-06-24;
Oral;
Tablet;
08:12.18 – QUINOLONES;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80098
APO-LEVOFLOXACIN;
02325942;
levofloxacin (levofloxacin hemihydrate) 750 mg;
2009-06-24;
Oral;
Tablet;
08:12.18 – QUINOLONES;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=81129
RIVA-LEVOFLOXACIN;
02492741;
levofloxacin (levofloxacin hemihydrate) 750 mg;
2020-04-06;
Oral;
Tablet;
08:12.18 – QUINOLONES;
Prescription;
LABORATOIRE RIVA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98273
LEVOFLOXACIN IN 5% DEXTROSE INJECTION;
02314932;
levofloxacin 5 mg / ml;
2011-12-23;
Intravenous;
Solution;
08:12.18 – QUINOLONES;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80046
FETZIMA;
02441004;
levomilnacipran (levomilnacipran hydrochloride) 120 mg;
2016-04-22;
Oral;
Capsule (Extended Release);
28:16.04.92 – MISCELLANEOUS ANTIDEPRESSANTS;
Prescription;
ALLERGAN INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92536
FETZIMA;
02440970;
levomilnacipran (levomilnacipran hydrochloride) 20 mg;
2015-11-19;
Oral;
Capsule (Extended Release);
28:16.04.92 – MISCELLANEOUS ANTIDEPRESSANTS;
Prescription;
ALLERGAN INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92533
FETZIMA;
02440989;
levomilnacipran (levomilnacipran hydrochloride) 40 mg;
2015-11-19;
Oral;
Capsule (Extended Release);
28:16.04.92 – MISCELLANEOUS ANTIDEPRESSANTS;
Prescription;
ALLERGAN INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92534
FETZIMA;
02440997;
levomilnacipran (levomilnacipran hydrochloride) 80 mg;
2016-04-22;
Oral;
Capsule (Extended Release);
28:16.04.92 – MISCELLANEOUS ANTIDEPRESSANTS;
Prescription;
ALLERGAN INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92535
PLAN B;
02293854;
levonorgestrel 1.5 mg;
2015-07-23;
Oral;
Tablet;
68:12.00 – CONTRACEPTIVES;
Otc;
FOUNDATION CONSUMER HEALTHCARE, LLC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=77922
CONTINGENCY ONE;
02425009;
levonorgestrel 1.5 mg;
2015-08-31;
Oral;
Tablet;
68:12.00 – CONTRACEPTIVES;
Otc;
MYLAN PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90967
BACKUP PLAN ONESTEP;
02433532;
levonorgestrel 1.5 mg;
2016-06-07;
Oral;
Tablet;
68:12.00 – CONTRACEPTIVES;
Otc;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=91790
KYLEENA;
02459523;
levonorgestrel 19.5 mg;
2017-01-10;
Intrauterine;
Insert (Extended-Release);
68:12.00 – CONTRACEPTIVES;
Prescription;
BAYER INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94684
MIRENA;
02243005;
levonorgestrel 52 mg;
2001-02-22;
Intrauterine;
Insert (Extended-Release);
68:12.00 – CONTRACEPTIVES;
Prescription;
BAYER INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=66845
SYNTHROID;
02172100;
levothyroxine sodium 100 mcg;
1996-12-31;
Oral;
Tablet;
68:36.04 – THYROID AGENTS;
Prescription;
BGP PHARMA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19601
ELTROXIN;
02213206;
levothyroxine sodium 100 mcg;
1998-11-27;
Oral;
Tablet;
68:36.04 – THYROID AGENTS;
Prescription;
ASPEN PHARMACARE CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=36946
SYNTHROID;
02171228;
levothyroxine sodium 112 mcg;
1996-12-31;
Oral;
Tablet;
68:36.04 – THYROID AGENTS;
Prescription;
BGP PHARMA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19589
SYNTHROID;
02172119;
levothyroxine sodium 125 mcg;
1996-12-31;
Oral;
Tablet;
68:36.04 – THYROID AGENTS;
Prescription;
BGP PHARMA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19594
SYNTHROID;
02233852;
levothyroxine sodium 137 mcg;
2003-11-01;
Oral;
Tablet;
68:36.04 – THYROID AGENTS;
Prescription;
BGP PHARMA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=53868
SYNTHROID;
02172127;
levothyroxine sodium 150 mcg;
1996-12-31;
Oral;
Tablet;
68:36.04 – THYROID AGENTS;
Prescription;
BGP PHARMA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19598
ELTROXIN;
02213214;
levothyroxine sodium 150 mcg;
1974-12-31;
Oral;
Tablet;
68:36.04 – THYROID AGENTS;
Prescription;
ASPEN PHARMACARE CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=36947
SYNTHROID;
02172135;
levothyroxine sodium 175 mcg;
1996-12-31;
Oral;
Tablet;
68:36.04 – THYROID AGENTS;
Prescription;
BGP PHARMA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19600
SYNTHROID;
02172143;
levothyroxine sodium 200 mcg;
1996-12-31;
Oral;
Tablet;
68:36.04 – THYROID AGENTS;
Prescription;
BGP PHARMA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19597
ELTROXIN;
02213222;
levothyroxine sodium 200 mcg;
1997-04-02;
Oral;
Tablet;
68:36.04 – THYROID AGENTS;
Prescription;
ASPEN PHARMACARE CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=36948
LEVOTHYROXINE SODIUM FOR INJECTION;
02461714;
levothyroxine sodium 200 mcg / vial;
2019-11-15;
Intramuscular , Intravenous;
Powder For Solution;
68:36.04 – THYROID AGENTS;
Prescription;
AVIR PHARMA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94948
SYNTHROID;
02172062;
levothyroxine sodium 25 mcg;
1996-12-31;
Oral;
Tablet;
68:36.04 – THYROID AGENTS;
Prescription;
BGP PHARMA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19588
SYNTHROID;
02172151;
levothyroxine sodium 300 mcg;
1996-12-31;
Oral;
Tablet;
68:36.04 – THYROID AGENTS;
Prescription;
BGP PHARMA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19596
SYNTHROID;
02172070;
levothyroxine sodium 50 mcg;
1996-12-31;
Oral;
Tablet;
68:36.04 – THYROID AGENTS;
Prescription;
BGP PHARMA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19587
ELTROXIN;
02213192;
levothyroxine sodium 50 mcg;
1951-12-30;
Oral;
Tablet;
68:36.04 – THYROID AGENTS;
Prescription;
ASPEN PHARMACARE CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=36945
LEVOTHYROXINE SODIUM FOR INJECTION;
02245948;
levothyroxine sodium 500 mcg / vial;
2002-08-27;
Intramuscular , Intravenous;
Powder For Solution;
68:36.04 – THYROID AGENTS;
Prescription;
FRESENIUS KABI CANADA LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=70072
LEVOTHYROXINE SODIUM FOR INJECTION;
02461722;
levothyroxine sodium 500 mcg / vial;
2018-09-26;
Intramuscular , Intravenous;
Powder For Solution;
68:36.04 – THYROID AGENTS;
Prescription;
AVIR PHARMA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94949
SYNTHROID;
02172089;
levothyroxine sodium 75 mcg;
1996-12-31;
Oral;
Tablet;
68:36.04 – THYROID AGENTS;
Prescription;
BGP PHARMA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19595
SYNTHROID;
02172097;
levothyroxine sodium 88 mcg;
1996-12-31;
Oral;
Tablet;
68:36.04 – THYROID AGENTS;
Prescription;
BGP PHARMA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19599
LIDODAN ENDOTRACHEAL NON-AEROSOL SPRAY;
02231147;
lidocaine (lidocaine hydrochloride) 10 mg / act;
1998-07-22;
Topical;
Liquid;
72:00.00 – LOCAL ANESTHETICS;
Ethical;
ODAN LABORATORIES LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=50454
SOLARCAINE FIRST AID LIDOCAINE SPRAY;
01923986;
lidocaine 0.5 %;
1990-12-31;
Topical;
Aerosol;
84:08.00 – ANTIPRURITICS AND LOCAL ANESTHETICS;
Otc;
BAYER INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=12266
XYLOCAINE SPRAY;
02003767;
lidocaine 10 mg / act;
1993-12-31;
Oral;
Spray, Metered Dose;
52:16.00 – LOCAL ANESTHETICS;
Ethical;
ASPEN PHARMACARE CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=14240
BIKINI ZONE;
02231578;
lidocaine 2 %;
1997-10-30;
Topical;
Cream;
84:08.00 – ANTIPRURITICS AND LOCAL ANESTHETICS;
Otc;
CCA INDUSTRIES, INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=50944
MAXILENE 4;
02244533;
lidocaine 4 %;
2003-05-15;
Topical;
Cream;
84:08.00 – ANTIPRURITICS AND LOCAL ANESTHETICS;
Otc;
RGR PHARMA LTD.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=68513
LIDOCAINE;
02485311;
lidocaine 4 %;
2019-05-21;
Topical;
Gel;
84:08.00 – ANTIPRURITICS AND LOCAL ANESTHETICS;
Otc;
THE MENTHOLATUM COMPANY OF CANADA LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97557
XYLOCAINE OINTMENT 5%;
00001961;
lidocaine 5 %;
1954-12-31;
Topical;
Ointment;
84:08.00 – ANTIPRURITICS AND LOCAL ANESTHETICS;
Ethical;
ASPEN PHARMACARE CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=211
LIDODAN OINTMENT 5%;
02083795;
lidocaine 5 %;
1994-12-31;
Topical;
Ointment;
84:08.00 – ANTIPRURITICS AND LOCAL ANESTHETICS;
Ethical;
ODAN LABORATORIES LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=17236
MAXILENE 5;
02245939;
lidocaine 5 %;
2003-05-15;
Topical;
Cream;
84:08.00 – ANTIPRURITICS AND LOCAL ANESTHETICS;
Otc;
RGR PHARMA LTD.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=70063
TOPICAINE 5;
02322560;
lidocaine 5 %;
2009-03-01;
Topical;
Gel;
84:08.00 – ANTIPRURITICS AND LOCAL ANESTHETICS;
Otc;
ESBA LABORATORIES INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80801
NANONUMB;
02439670;
lidocaine 5 %;
2020-01-20;
Topical;
Cream;
84:08.00 – ANTIPRURITICS AND LOCAL ANESTHETICS;
Otc;
ALERA SKIN CARE PRODUCTS INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92407
DR. NUMB;
02354527;
lidocaine 5 % / w/w;
2013-10-08;
Topical;
Cream;
84:08.00 – ANTIPRURITICS AND LOCAL ANESTHETICS;
Otc;
SHINPHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83969
JAMPOCAINE 5%;
02386836;
lidocaine 5 % / w/w;
2014-05-14;
Topical;
Ointment;
84:08.00 – ANTIPRURITICS AND LOCAL ANESTHETICS;
Otc;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87241
LYRACAINE GEL;
02431025;
lidocaine 5 % / w/w;
2014-09-04;
Topical;
Gel;
84:08.00 – ANTIPRURITICS AND LOCAL ANESTHETICS;
Otc;
PROLLENIUM MEDICAL TECHNOLOGIES INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=91547
ZENSA;
02449684;
lidocaine 5 % / w/w;
2016-05-20;
Topical;
Cream;
84:08.00 – ANTIPRURITICS AND LOCAL ANESTHETICS;
Otc;
ALERA SKIN CARE PRODUCTS INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93551
STUD 100;
01901532;
lidocaine 9.6 % / w/w;
1997-07-15;
Topical;
Spray, Metered Dose;
84:08.00 – ANTIPRURITICS AND LOCAL ANESTHETICS;
Otc;
POUND INTERNATIONAL LTD.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=46020
AFTERBURN;
02122286;
lidocaine hydrochloride 0.5 %;
1995-12-31;
Topical;
Gel;
84:08.00 – ANTIPRURITICS AND LOCAL ANESTHETICS;
Otc;
TENDER CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=18014
SOLARCAINE MEDICATED FIRST AID LOTION;
02229827;
lidocaine hydrochloride 0.5 %;
1997-05-12;
Topical;
Lotion;
84:08.00 – ANTIPRURITICS AND LOCAL ANESTHETICS;
Otc;
BAYER INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=48182
SOLARCAINE MEDICATED LIDOCAINE GEL;
02268361;
lidocaine hydrochloride 0.5 %;
2006-02-01;
Topical;
Gel;
84:08.00 – ANTIPRURITICS AND LOCAL ANESTHETICS;
Otc;
BAYER INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=75376
BURN RELIEF GEL WITH LIDOCAINE;
02262215;
lidocaine hydrochloride 0.72 %;
2005-06-15;
Topical;
Gel;
84:08.00 – ANTIPRURITICS AND LOCAL ANESTHETICS;
Otc;
PRIME ENTERPRISES INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=74760
EQUATE AFTER SUN GEL WITH LIDOCAINE;
02471833;
lidocaine hydrochloride 0.8 %;
2018-03-05;
Topical;
Gel;
84:08.00 – ANTIPRURITICS AND LOCAL ANESTHETICS;
Otc;
FRUIT OF THE EARTH, INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96104
XYLOCAINE 1%;
00001732;
lidocaine hydrochloride 10 mg / ml;
1954-12-31;
Block/Infiltration;
Solution;
72:00.00 – LOCAL ANESTHETICS;
Ethical;
ASPEN PHARMACARE CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=585
LIDOCAINE HYDROCHLORIDE INJECTION USP;
00884154;
lidocaine hydrochloride 10 mg / ml;
1990-12-31;
Block/Infiltration;
Solution;
72:00.00 – LOCAL ANESTHETICS;
Ethical;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=12645
XYLOCAINE 1%;
02302411;
lidocaine hydrochloride 10 mg / ml;
2009-01-23;
Block/Infiltration;
Solution;
72:00.00 – LOCAL ANESTHETICS;
Ethical;
ASPEN PHARMACARE CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78773
LIDOCAINE HYDROCHLORIDE INJECTION USP;
02421984;
lidocaine hydrochloride 10 mg / ml;
2015-06-29;
Block/Infiltration;
Solution;
72:00.00 – LOCAL ANESTHETICS;
Ethical;
TELIGENT OU
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90668
LIDOCAINE HYDROCHLORIDE INJECTION USP;
02422018;
lidocaine hydrochloride 10 mg / ml;
2015-11-25;
Block/Infiltration;
Solution;
72:00.00 – LOCAL ANESTHETICS;
Ethical;
TELIGENT OU
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90670
XYLOCARD;
00001937;
lidocaine hydrochloride 100 mg / 5 ml;
1974-12-31;
Intravenous;
Solution;
24:04.04.08 – CLASS IB ANTIARRYTHMICS;
Ethical;
ASPEN PHARMACARE CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=4478
LIDODAN VISCOUS 2%;
01968823;
lidocaine hydrochloride 2 %;
1994-12-31;
Buccal;
Solution;
72:00.00 – LOCAL ANESTHETICS;
Otc;
ODAN LABORATORIES LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=16823
WATER-JEL BURN JEL-2%;
02144409;
lidocaine hydrochloride 2 %;
1994-12-31;
Topical;
Gel;
84:08.00 – ANTIPRURITICS AND LOCAL ANESTHETICS;
Otc;
ZEE MEDICAL
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=31582
BAND-AID BRAND ANTISEPTIC WASH;
02244468;
lidocaine hydrochloride 2 %;
2002-03-01;
Topical;
Liquid;
84:08.00 – ANTIPRURITICS AND LOCAL ANESTHETICS;
Otc;
JOHNSON & JOHNSON INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=68438
CATHEJELL;
02370840;
lidocaine hydrochloride 20 mg / g;
2012-05-25;
Topical;
Gel;
84:08.00 – ANTIPRURITICS AND LOCAL ANESTHETICS;
Ethical;
PHARMAZEUTISCHE FABRIK MONTAVIT GES M.B.H.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85604
XYLOCAINE JELLY 2%;
00001694;
lidocaine hydrochloride 20 mg / ml;
1951-12-31;
Topical;
Gel;
84:08.00 – ANTIPRURITICS AND LOCAL ANESTHETICS;
Ethical;
ASPEN PHARMACARE CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=212
XYLOCAINE 2%;
00036641;
lidocaine hydrochloride 20 mg / ml;
1954-12-31;
Block/Infiltration;
Solution;
72:00.00 – LOCAL ANESTHETICS;
Ethical;
ASPEN PHARMACARE CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=587
XYLOCAINE JELLY 2%;
00385484;
lidocaine hydrochloride 20 mg / ml;
1978-12-31;
Topical;
Gel;
84:08.00 – ANTIPRURITICS AND LOCAL ANESTHETICS;
Ethical;
ASPEN PHARMACARE CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=2935
LIDOCAINE HYDROCHLORIDE INJECTION USP;
00436208;
lidocaine hydrochloride 20 mg / ml;
1987-12-31;
Intravenous;
Solution;
24:04.04.08 – CLASS IB ANTIARRYTHMICS;
Ethical;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=8351
LIDOCAINE HYDROCHLORIDE INJECTION USP;
01901982;
lidocaine hydrochloride 20 mg / ml;
1994-12-31;
Block/Infiltration;
Solution;
72:00.00 – LOCAL ANESTHETICS;
Ethical;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=18012
LIDODAN JELLY 2%;
02143879;
lidocaine hydrochloride 20 mg / ml;
2002-03-27;
Topical;
Jelly;
84:08.00 – ANTIPRURITICS AND LOCAL ANESTHETICS;
Otc;
ODAN LABORATORIES LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=31563
XYLOCAINE 2%;
02302438;
lidocaine hydrochloride 20 mg / ml;
2009-01-29;
Block/Infiltration;
Solution;
72:00.00 – LOCAL ANESTHETICS;
Ethical;
ASPEN PHARMACARE CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78774
LIDOCAINE HYDROCHLORIDE INJECTION USP;
02421992;
lidocaine hydrochloride 20 mg / ml;
2015-08-19;
Block/Infiltration;
Solution;
72:00.00 – LOCAL ANESTHETICS;
Ethical;
TELIGENT OU
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90671
LIDOCAINE HYDROCHLORIDE INJECTION USP;
02422026;
lidocaine hydrochloride 20 mg / ml;
2016-01-12;
Block/Infiltration;
Solution;
72:00.00 – LOCAL ANESTHETICS;
Ethical;
TELIGENT OU
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90672
JELIDO;
02469146;
lidocaine hydrochloride 20 mg / ml;
2018-05-28;
Topical;
Gel;
84:08.00 – ANTIPRURITICS AND LOCAL ANESTHETICS;
Ethical;
PENDOPHARM DIVISION OF PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95780
LIDODAN 4% TOPICAL SOLUTION;
02419505;
lidocaine hydrochloride 4 %;
2014-02-20;
Topical;
Solution;
84:08.00 – ANTIPRURITICS AND LOCAL ANESTHETICS;
Ethical;
ODAN LABORATORIES LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90413
LIDOCAINE HYDROCHLORIDE TOPICAL SOLUTION USP;
02458128;
lidocaine hydrochloride 4 %;
2020-03-02;
Topical;
Solution;
84:08.00 – ANTIPRURITICS AND LOCAL ANESTHETICS;
Otc;
TELIGENT PHARMA, INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94517
XYLOCAINE 0.5%;
02372983;
lidocaine hydrochloride 5 mg / ml;
2012-10-29;
Block/Infiltration;
Solution;
72:00.00 – LOCAL ANESTHETICS;
Ethical;
ASPEN PHARMACARE CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85810
XIIDRA;
02471027;
lifitegrast 5 % / w/v;
2018-02-12;
Ophthalmic;
Solution;
52:08.92 – ANTI-INFLAMMATORY AGENTS, MISCELLANEOUS;
Prescription;
NOVARTIS PHARMACEUTICALS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96012
CONSTELLA;
02417162;
linaclotide 145 mcg;
2014-04-29;
Oral;
Capsule;
56:92.00 – MISCELLANEOUS GI DRUGS;
Prescription;
ALLERGAN INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90180
CONSTELLA;
02417170;
linaclotide 290 mcg;
2014-12-17;
Oral;
Capsule;
56:92.00 – MISCELLANEOUS GI DRUGS;
Prescription;
ALLERGAN INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90181
CONSTELLA;
02469510;
linaclotide 72 mcg;
2018-04-02;
Oral;
Capsule;
56:92.00 – MISCELLANEOUS GI DRUGS;
Prescription;
ALLERGAN INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95831
TRAJENTA;
02370921;
linagliptin 5 mg;
2011-09-13;
Oral;
Tablet;
68:20.05 – DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS;
Prescription;
BOEHRINGER INGELHEIM (CANADA) LTD LTEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85612
ZYVOXAM;
02243686;
linezolid 100 mg / 5 ml;
2010-08-04;
Oral;
Powder For Suspension;
08:12.28.24 – OXAZOLIDINONES;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=67616
ZYVOXAM 2 MG/ML;
02243685;
linezolid 2 mg / ml;
2001-06-07;
Intravenous;
Solution;
08:12.28.24 – OXAZOLIDINONES;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=67615
LINEZOLID INJECTION;
02430827;
linezolid 2 mg / ml;
2015-06-12;
Intravenous;
Solution;
08:12.28.24 – OXAZOLIDINONES;
Prescription;
FRESENIUS KABI CANADA LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=91526
LINEZOLID INJECTION;
02481278;
linezolid 2 mg / ml;
2019-12-30;
Intravenous;
Solution;
08:12.28.24 – OXAZOLIDINONES;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97176
SANDOZ LINEZOLID;
02422689;
linezolid 600 mg;
2014-08-25;
Oral;
Tablet;
08:12.28.24 – OXAZOLIDINONES;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90735
APO-LINEZOLID;
02426552;
linezolid 600 mg;
2014-08-19;
Oral;
Tablet;
08:12.28.24 – OXAZOLIDINONES;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=91113
CYTOMEL;
01919466;
liothyronine (liothyronine sodium) 25 mcg;
1993-12-31;
Oral;
Tablet;
68:36.04 – THYROID AGENTS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=15908
TEVA-LIOTHYRONINE;
02494345;
liothyronine (liothyronine sodium) 25 mcg;
2020-07-10;
Oral;
Tablet;
68:36.04 – THYROID AGENTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98437
CYTOMEL;
01919458;
liothyronine (liothyronine sodium) 5 mcg;
1993-12-31;
Oral;
Tablet;
68:36.04 – THYROID AGENTS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=15909
TEVA-LIOTHYRONINE;
02494337;
liothyronine (liothyronine sodium) 5 mcg;
2020-07-10;
Oral;
Tablet;
68:36.04 – THYROID AGENTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98436
VICTOZA;
02351064;
liraglutide 6 mg / ml;
2010-05-27;
Subcutaneous;
Solution;
68:20.06 – INCRETIN MIMETICS;
Prescription , Schedule D;
NOVO NORDISK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83627
SAXENDA;
02437899;
liraglutide 6 mg / ml;
2015-05-27;
Subcutaneous;
Solution;
68:20.06 – INCRETIN MIMETICS;
Prescription , Schedule D;
NOVO NORDISK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92226
VYVANSE;
02439603;
lisdexamfetamine dimesylate 10 mg;
2015-06-26;
Oral;
Capsule;
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92401
VYVANSE;
02490226;
lisdexamfetamine dimesylate 10 mg;
2019-08-06;
Oral;
Tablet (Chewable);
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98028
VYVANSE;
02347156;
lisdexamfetamine dimesylate 20 mg;
2010-04-13;
Oral;
Capsule;
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83254
VYVANSE;
02490234;
lisdexamfetamine dimesylate 20 mg;
2019-08-06;
Oral;
Tablet (Chewable);
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98029
VYVANSE;
02322951;
lisdexamfetamine dimesylate 30 mg;
2009-08-04;
Oral;
Capsule;
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80843
VYVANSE;
02490242;
lisdexamfetamine dimesylate 30 mg;
2019-08-06;
Oral;
Tablet (Chewable);
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98030
VYVANSE;
02347164;
lisdexamfetamine dimesylate 40 mg;
2010-04-14;
Oral;
Capsule;
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83255
VYVANSE;
02490250;
lisdexamfetamine dimesylate 40 mg;
2019-08-06;
Oral;
Tablet (Chewable);
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98031
VYVANSE;
02322978;
lisdexamfetamine dimesylate 50 mg;
2009-08-04;
Oral;
Capsule;
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80844
VYVANSE;
02490269;
lisdexamfetamine dimesylate 50 mg;
2019-08-06;
Oral;
Tablet (Chewable);
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98032
VYVANSE;
02347172;
lisdexamfetamine dimesylate 60 mg;
2010-04-14;
Oral;
Capsule;
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83256
VYVANSE;
02490277;
lisdexamfetamine dimesylate 60 mg;
2019-08-06;
Oral;
Tablet (Chewable);
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98033
VYVANSE;
02458071;
lisdexamfetamine dimesylate 70 mg;
2017-01-05;
Oral;
Capsule;
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94514
RAN-LISINOPRIL;
02294249;
lisinopril (lisinopril dihydrate) 10 mg;
2007-10-17;
Oral;
Tablet;
24:32.04 – ANGIOTENSIN-CONVERTING ENZYME INHIBITORS;
Prescription;
RANBAXY PHARMACEUTICALS CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=77959
AURO-LISINOPRIL;
02394480;
lisinopril (lisinopril dihydrate) 10 mg;
2013-02-12;
Oral;
Tablet;
24:32.04 – ANGIOTENSIN-CONVERTING ENZYME INHIBITORS;
Prescription;
AURO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87964
RAN-LISINOPRIL;
02294257;
lisinopril (lisinopril dihydrate) 20 mg;
2007-10-17;
Oral;
Tablet;
24:32.04 – ANGIOTENSIN-CONVERTING ENZYME INHIBITORS;
Prescription;
RANBAXY PHARMACEUTICALS CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=77960
AURO-LISINOPRIL;
02394499;
lisinopril (lisinopril dihydrate) 20 mg;
2013-02-12;
Oral;
Tablet;
24:32.04 – ANGIOTENSIN-CONVERTING ENZYME INHIBITORS;
Prescription;
AURO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87965
SANDOZ LISINOPRIL;
02289199;
lisinopril (lisinopril dihydrate) 5 mg;
2007-10-17;
Oral;
Tablet;
24:32.04 – ANGIOTENSIN-CONVERTING ENZYME INHIBITORS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=77458
RAN-LISINOPRIL;
02294230;
lisinopril (lisinopril dihydrate) 5 mg;
2007-10-17;
Oral;
Tablet;
24:32.04 – ANGIOTENSIN-CONVERTING ENZYME INHIBITORS;
Prescription;
RANBAXY PHARMACEUTICALS CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=77958
AURO-LISINOPRIL;
02394472;
lisinopril (lisinopril dihydrate) 5 mg;
2013-02-12;
Oral;
Tablet;
24:32.04 – ANGIOTENSIN-CONVERTING ENZYME INHIBITORS;
Prescription;
AURO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87963
ZESTRIL;
02049376;
lisinopril 10 mg;
1994-12-31;
Oral;
Tablet;
24:32.04 – ANGIOTENSIN-CONVERTING ENZYME INHIBITORS;
Prescription;
ASTRAZENECA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=17215
APO-LISINOPRIL TABLET 10 MG;
02217503;
lisinopril 10 mg;
1996-10-30;
Oral;
Tablet;
24:32.04 – ANGIOTENSIN-CONVERTING ENZYME INHIBITORS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=43222
TEVA-LISINOPRIL (TYPE P);
02285088;
lisinopril 10 mg;
2007-10-17;
Oral;
Tablet;
24:32.04 – ANGIOTENSIN-CONVERTING ENZYME INHIBITORS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=77060
TEVA-LISINOPRIL (TYPE Z);
02285126;
lisinopril 10 mg;
2007-10-17;
Oral;
Tablet;
24:32.04 – ANGIOTENSIN-CONVERTING ENZYME INHIBITORS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=77063
PRO-LISINOPRIL – 10;
02310988;
lisinopril 10 mg;
2008-07-03;
Oral;
Tablet;
24:32.04 – ANGIOTENSIN-CONVERTING ENZYME INHIBITORS;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=79659
LISINOPRIL;
02386240;
lisinopril 10 mg;
2012-06-11;
Oral;
Tablet;
24:32.04 – ANGIOTENSIN-CONVERTING ENZYME INHIBITORS;
Prescription;
SIVEM PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87182
ZESTRIL;
02049384;
lisinopril 20 mg;
1994-12-31;
Oral;
Tablet;
24:32.04 – ANGIOTENSIN-CONVERTING ENZYME INHIBITORS;
Prescription;
ASTRAZENECA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=17123
APO-LISINOPRIL TABLET 20 MG;
02217511;
lisinopril 20 mg;
1996-10-30;
Oral;
Tablet;
24:32.04 – ANGIOTENSIN-CONVERTING ENZYME INHIBITORS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=43223
TEVA-LISINOPRIL (TYPE P);
02285096;
lisinopril 20 mg;
2007-10-17;
Oral;
Tablet;
24:32.04 – ANGIOTENSIN-CONVERTING ENZYME INHIBITORS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=77061
TEVA-LISINOPRIL (TYPE Z);
02285134;
lisinopril 20 mg;
2007-10-17;
Oral;
Tablet;
24:32.04 – ANGIOTENSIN-CONVERTING ENZYME INHIBITORS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=77064
PRO-LISINOPRIL – 20;
02310996;
lisinopril 20 mg;
2008-07-03;
Oral;
Tablet;
24:32.04 – ANGIOTENSIN-CONVERTING ENZYME INHIBITORS;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=79660
LISINOPRIL;
02386259;
lisinopril 20 mg;
2012-06-11;
Oral;
Tablet;
24:32.04 – ANGIOTENSIN-CONVERTING ENZYME INHIBITORS;
Prescription;
SIVEM PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87183
ZESTRIL;
02049333;
lisinopril 5 mg;
1994-12-31;
Oral;
Tablet;
24:32.04 – ANGIOTENSIN-CONVERTING ENZYME INHIBITORS;
Prescription;
ASTRAZENECA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=17126
APO-LISINOPRIL TABLET 5 MG;
02217481;
lisinopril 5 mg;
1996-10-30;
Oral;
Tablet;
24:32.04 – ANGIOTENSIN-CONVERTING ENZYME INHIBITORS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=43221
TEVA-LISINOPRIL (TYPE P);
02285061;
lisinopril 5 mg;
2007-10-17;
Oral;
Tablet;
24:32.04 – ANGIOTENSIN-CONVERTING ENZYME INHIBITORS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=77059
TEVA-LISINOPRIL (TYPE Z);
02285118;
lisinopril 5 mg;
2007-10-17;
Oral;
Tablet;
24:32.04 – ANGIOTENSIN-CONVERTING ENZYME INHIBITORS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=77062
PRO-LISINOPRIL – 5;
02310961;
lisinopril 5 mg;
2008-07-03;
Oral;
Tablet;
24:32.04 – ANGIOTENSIN-CONVERTING ENZYME INHIBITORS;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=79658
LISINOPRIL;
02386232;
lisinopril 5 mg;
2012-06-11;
Oral;
Tablet;
24:32.04 – ANGIOTENSIN-CONVERTING ENZYME INHIBITORS;
Prescription;
SIVEM PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87181
CARBOLITH;
00461733;
lithium carbonate 150 mg;
1979-12-31;
Oral;
Capsule;
28:28.00 – ANTIMANIC AGENTS;
Prescription;
BAUSCH HEALTH, CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=3414
LITHANE;
02013231;
lithium carbonate 150 mg;
1993-12-31;
Oral;
Capsule;
28:28.00 – ANTIMANIC AGENTS;
Prescription;
ERFA CANADA 2012 INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=13626
PMS-LITHIUM CARBONATE – CAP 150MG;
02216132;
lithium carbonate 150 mg;
1996-12-31;
Oral;
Capsule;
28:28.00 – ANTIMANIC AGENTS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19894
APO-LITHIUM CARBONATE;
02242837;
lithium carbonate 150 mg;
2001-02-12;
Oral;
Capsule;
28:28.00 – ANTIMANIC AGENTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=66667
CARBOLITH;
00236683;
lithium carbonate 300 mg;
1971-12-31;
Oral;
Capsule;
28:28.00 – ANTIMANIC AGENTS;
Prescription;
BAUSCH HEALTH, CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=1327
LITHANE;
00406775;
lithium carbonate 300 mg;
1979-12-31;
Oral;
Capsule;
28:28.00 – ANTIMANIC AGENTS;
Prescription;
ERFA CANADA 2012 INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=3192
PMS-LITHIUM CARBONATE – CAP 300MG;
02216140;
lithium carbonate 300 mg;
1996-12-31;
Oral;
Capsule;
28:28.00 – ANTIMANIC AGENTS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19933
APO-LITHIUM CARBONATE;
02242838;
lithium carbonate 300 mg;
2001-02-12;
Oral;
Capsule;
28:28.00 – ANTIMANIC AGENTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=66668
LITHMAX;
02266695;
lithium carbonate 300 mg;
2005-04-06;
Oral;
Tablet (Extended-Release);
28:28.00 – ANTIMANIC AGENTS;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=75210
CARBOLITH;
02011239;
lithium carbonate 600 mg;
1992-12-31;
Oral;
Capsule;
28:28.00 – ANTIMANIC AGENTS;
Prescription;
BAUSCH HEALTH, CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=13429
PMS-LITHIUM CARBONATE – CAP 600MG;
02216159;
lithium carbonate 600 mg;
1996-12-31;
Oral;
Capsule;
28:28.00 – ANTIMANIC AGENTS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19893
ADLYXINE;
02464276;
lixisenatide 10 mcg / act;
2017-09-12;
Subcutaneous;
Solution;
68:20.06 – INCRETIN MIMETICS;
Prescription;
SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95243
ADLYXINE;
02464284;
lixisenatide 20 mcg / act;
2017-09-12;
Subcutaneous;
Solution;
68:20.06 – INCRETIN MIMETICS;
Prescription;
SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95244
ALOMIDE;
00893560;
lodoxamide (lodoxamide tromethamine) 0.1 % / w/v;
1992-12-31;
Ophthalmic;
Solution;
52:02.00 – ANTIALLERGIC AGENTS;
Prescription;
NOVARTIS PHARMACEUTICALS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=13591
JUXTAPID;
02420376;
lomitapide (lomitapide mesylate) 10 mg;
2014-05-06;
Oral;
Capsule;
24:06.92 – MISCELLANEOUS ANTILIPEMIC AGENTS;
Prescription;
AEGERION PHARMACEUTICALS CANADA LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90496
JUXTAPID;
02420384;
lomitapide (lomitapide mesylate) 20 mg;
2014-05-06;
Oral;
Capsule;
24:06.92 – MISCELLANEOUS ANTILIPEMIC AGENTS;
Prescription;
AEGERION PHARMACEUTICALS CANADA LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90498
JUXTAPID;
02420341;
lomitapide (lomitapide mesylate) 5 mg;
2014-05-06;
Oral;
Capsule;
24:06.92 – MISCELLANEOUS ANTILIPEMIC AGENTS;
Prescription;
AEGERION PHARMACEUTICALS CANADA LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90495
CEENU;
00360430;
lomustine 10 mg;
1976-12-31;
Oral;
Capsule;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
BRISTOL-MYERS SQUIBB CANADA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=2531
CEENU;
00360422;
lomustine 40 mg;
1976-12-31;
Oral;
Capsule;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
BRISTOL-MYERS SQUIBB CANADA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=2530
PMS-LOPERAMIDE HYDROCHLORIDE SOLUTION.2MG/ML;
02016095;
loperamide hydrochloride 0.2 mg / ml;
1993-12-31;
Oral;
Solution;
56:08.00 – ANTIDIARRHEA AGENTS;
Otc;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=14567
TEVA-LOPERAMIDE;
02132591;
loperamide hydrochloride 2 mg;
1995-12-31;
Oral;
Tablet;
56:08.00 – ANTIDIARRHEA AGENTS;
Otc;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=18071
LOPERAMIDE-2;
02225182;
loperamide hydrochloride 2 mg;
1997-11-05;
Oral;
Tablet;
56:08.00 – ANTIDIARRHEA AGENTS;
Otc;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=43419
PMS-LOPERAMIDE – CAPLET 2MG;
02228351;
loperamide hydrochloride 2 mg;
1996-09-12;
Oral;
Tablet;
56:08.00 – ANTIDIARRHEA AGENTS;
Otc;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=43486
IMODIUM QUICK DISSOLVE;
02230542;
loperamide hydrochloride 2 mg;
1997-09-24;
Oral;
Tablet (Orally Disintegrating);
56:08.00 – ANTIDIARRHEA AGENTS;
Otc;
MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=49614
RIVA-LOPERAMIDE;
02238211;
loperamide hydrochloride 2 mg;
1998-08-27;
Oral;
Tablet;
56:08.00 – ANTIDIARRHEA AGENTS;
Otc;
LABORATOIRE RIVA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=61604
DIARRHEA RELIEF;
02248994;
loperamide hydrochloride 2 mg;
2004-06-11;
Oral;
Tablet;
56:08.00 – ANTIDIARRHEA AGENTS;
Otc;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=73379
DIARRHEA RELIEF;
02256452;
loperamide hydrochloride 2 mg;
2004-12-19;
Oral;
Tablet;
56:08.00 – ANTIDIARRHEA AGENTS;
Otc;
VITA HEALTH PRODUCTS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=74169
IMODIUM LIQUI-GELS;
02376016;
loperamide hydrochloride 2 mg;
2013-07-02;
Oral;
Capsule;
56:08.00 – ANTIDIARRHEA AGENTS;
Otc;
MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86147
DIARRHEA RELIEF;
02453517;
loperamide hydrochloride 2 mg;
2016-09-20;
Oral;
Tablet;
56:08.00 – ANTIDIARRHEA AGENTS;
Otc;
LABORATOIRE RIVA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94007
IMODIUM CALMING LIQUID;
02291800;
loperamide hydrochloride 2 mg / 15 ml;
2007-07-11;
Oral;
Solution;
56:08.00 – ANTIDIARRHEA AGENTS;
Otc;
MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=77716
CLARITIN ALLERGY;
00782696;
loratadine 10 mg;
1988-12-18;
Oral;
Tablet;
04:08.00 – SECOND GENERATION ANTIHISTAMINES;
Otc;
BAYER INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=10533
CLARITIN RAPID DISSOLVE;
02237734;
loratadine 10 mg;
1998-05-05;
Oral;
Tablet (Orally Disintegrating);
04:08.00 – SECOND GENERATION ANTIHISTAMINES;
Otc;
BAYER INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=61088
APO-LORATADINE;
02243880;
loratadine 10 mg;
2001-06-27;
Oral;
Tablet;
04:08.00 – SECOND GENERATION ANTIHISTAMINES;
Otc;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=67821
24 HOUR ALLERGY REMEDY;
02280159;
loratadine 10 mg;
2006-07-28;
Oral;
Tablet;
04:08.00 – SECOND GENERATION ANTIHISTAMINES;
Otc;
VITA HEALTH PRODUCTS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=76583
LORATADINE;
02366444;
loratadine 10 mg;
2013-04-18;
Oral;
Tablet;
04:08.00 – SECOND GENERATION ANTIHISTAMINES;
Otc;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85127
ALLERGY REMEDY;
02375990;
loratadine 10 mg;
2013-05-23;
Oral;
Tablet;
04:08.00 – SECOND GENERATION ANTIHISTAMINES;
Otc;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86145
LORATADINE SOFT GEL CAPSULES;
02379481;
loratadine 10 mg;
2012-09-07;
Oral;
Capsule;
04:08.00 – SECOND GENERATION ANTIHISTAMINES;
Otc;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86538
ALLERTIN;
02390388;
loratadine 10 mg;
2013-10-31;
Oral;
Capsule;
04:08.00 – SECOND GENERATION ANTIHISTAMINES;
Otc;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87582
CLARITIN LIQUID CAPSULES;
02404494;
loratadine 10 mg;
2013-07-01;
Oral;
Capsule;
04:08.00 – SECOND GENERATION ANTIHISTAMINES;
Otc;
BAYER INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88925
ALLERTIN;
02418959;
loratadine 10 mg;
2018-10-09;
Oral;
Tablet;
04:08.00 – SECOND GENERATION ANTIHISTAMINES;
Otc;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90350
CLARITIN KIDS;
02241523;
loratadine 5 mg / 5 ml;
2000-04-06;
Oral;
Syrup;
04:08.00 – SECOND GENERATION ANTIHISTAMINES;
Otc;
BAYER INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=65175
APO-LORAZEPAM TAB 0.5MG;
00655740;
lorazepam 0.5 mg;
1985-12-31;
Oral;
Tablet;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=6295
PRO-LORAZEPAM;
00655643;
lorazepam 0.5 mg;
1986-12-31;
Oral;
Tablet;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=6656
TEVA-LORAZEPAM;
00711101;
lorazepam 0.5 mg;
1987-12-31;
Oral;
Tablet;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=7314
PMS-LORAZEPAM TAB 0.5MG;
00728187;
lorazepam 0.5 mg;
1988-12-31;
Oral;
Tablet;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=9349
ATIVAN;
02041413;
lorazepam 0.5 mg;
1994-12-31;
Oral;
Tablet;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=16589
ATIVAN;
02041456;
lorazepam 0.5 mg;
1995-12-31;
Sublingual;
Tablet;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=17817
LORAZEPAM SUBLINGUAL;
02410745;
lorazepam 0.5 mg;
2013-10-16;
Sublingual;
Tablet;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=89541
TEVA-LORAZEPAM;
00637742;
lorazepam 1 mg;
1985-12-31;
Oral;
Tablet;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=6135
APO-LORAZEPAM TAB 1MG;
00655759;
lorazepam 1 mg;
1985-12-31;
Oral;
Tablet;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=6296
PRO-LORAZEPAM TAB 1.0MG;
00655651;
lorazepam 1 mg;
1986-12-31;
Oral;
Tablet;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=6657
PMS-LORAZEPAM TAB 1MG;
00728195;
lorazepam 1 mg;
1988-12-31;
Oral;
Tablet;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=9423
ATIVAN;
02041464;
lorazepam 1 mg;
1994-12-31;
Sublingual;
Tablet;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=16118
ATIVAN;
02041421;
lorazepam 1 mg;
1994-12-31;
Oral;
Tablet;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=16588
LORAZEPAM SUBLINGUAL;
02410753;
lorazepam 1 mg;
2013-10-16;
Sublingual;
Tablet;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=89542
LORAZEPAM;
02351080;
lorazepam 1.0 mg;
2010-06-15;
Oral;
Tablet;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83629
TEVA-LORAZEPAM;
00637750;
lorazepam 2 mg;
1985-12-31;
Oral;
Tablet;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=6136
APO-LORAZEPAM TAB 2MG;
00655767;
lorazepam 2 mg;
1985-12-31;
Oral;
Tablet;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=6297
PRO-LORAZEPAM TAB 2MG;
00655678;
lorazepam 2 mg;
1986-12-31;
Oral;
Tablet;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=6658
PMS-LORAZEPAM TAB 2MG;
00728209;
lorazepam 2 mg;
1988-12-31;
Oral;
Tablet;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=9424
ATIVAN;
02041472;
lorazepam 2 mg;
1994-12-31;
Sublingual;
Tablet;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=16586
ATIVAN;
02041448;
lorazepam 2 mg;
1994-12-31;
Oral;
Tablet;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=16587
LORAZEPAM SUBLINGUAL;
02410761;
lorazepam 2 mg;
2013-10-16;
Sublingual;
Tablet;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=89543
LORAZEPAM INJECTION USP;
02438704;
lorazepam 2 mg / 1 ml;
2015-11-12;
Intramuscular , Intravenous;
Solution;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92310
LORAZEPAM;
02351099;
lorazepam 2.0 mg;
2010-06-15;
Oral;
Tablet;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83630
LORAZEPAM INJECTION USP;
02243278;
lorazepam 4 mg / 1 ml;
2001-06-06;
Intramuscular , Intravenous;
Liquid;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=67176
LORAZEPAM INJECTION USP;
02388669;
lorazepam 4 mg / 1 ml;
2014-06-10;
Intramuscular , Intravenous;
Solution;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87417
LORBRENA;
02485974;
lorlatinib 100 mg;
2019-04-22;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97620
LORBRENA;
02485966;
lorlatinib 25 mg;
2019-04-22;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97619
COZAAR;
02182882;
losartan potassium 100 mg;
1998-01-16;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
ORGANON CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=44255
PMS-LOSARTAN;
02309777;
losartan potassium 100 mg;
2012-01-25;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=79544
SANDOZ LOSARTAN;
02313359;
losartan potassium 100 mg;
2012-01-25;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=79888
TEVA-LOSARTAN;
02357976;
losartan potassium 100 mg;
2012-01-25;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84305
LOSARTAN;
02388812;
losartan potassium 100 mg;
2012-07-05;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
SIVEM PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87433
LOSARTAN;
02388898;
losartan potassium 100 mg;
2012-07-20;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87443
JAMP-LOSARTAN;
02398850;
losartan potassium 100 mg;
2013-06-11;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88377
AURO-LOSARTAN;
02403358;
losartan potassium 100.0 mg;
2013-03-26;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
AURO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88816
COZAAR;
02182815;
losartan potassium 25 mg;
1995-12-31;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
ORGANON CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19167
PMS-LOSARTAN;
02309750;
losartan potassium 25 mg;
2012-01-25;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=79542
SANDOZ LOSARTAN;
02313332;
losartan potassium 25 mg;
2012-01-25;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=79886
TEVA-LOSARTAN;
02380838;
losartan potassium 25 mg;
2012-02-28;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86659
LOSARTAN;
02388790;
losartan potassium 25 mg;
2012-07-05;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
SIVEM PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87431
LOSARTAN;
02388863;
losartan potassium 25 mg;
2012-07-20;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87441
JAMP-LOSARTAN;
02398834;
losartan potassium 25 mg;
2013-06-11;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88375
AURO-LOSARTAN;
02403323;
losartan potassium 25.0 mg;
2013-03-26;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
AURO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88814
COZAAR;
02182874;
losartan potassium 50 mg;
1995-12-31;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
ORGANON CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19168
PMS-LOSARTAN;
02309769;
losartan potassium 50 mg;
2012-01-25;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=79543
SANDOZ LOSARTAN;
02313340;
losartan potassium 50 mg;
2012-01-25;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=79887
TEVA-LOSARTAN;
02357968;
losartan potassium 50 mg;
2012-01-25;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84304
LOSARTAN;
02388804;
losartan potassium 50 mg;
2012-07-05;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
SIVEM PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87432
LOSARTAN;
02388871;
losartan potassium 50 mg;
2012-07-20;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87442
JAMP-LOSARTAN;
02398842;
losartan potassium 50 mg;
2013-06-11;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88376
PRIVA-LOSARTAN;
02446707;
losartan potassium 50 mg;
2016-05-09;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
PHARMAPAR INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93214
AURO-LOSARTAN;
02403331;
losartan potassium 50.0 mg;
2013-03-26;
Oral;
Tablet;
24:32.08 – ANGIOTENSIN II RECEPTOR ANTAGONISTS;
Prescription;
AURO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88815
ALREX;
02320924;
loteprednol etabonate 0.2 % / w/v;
2009-06-24;
Ophthalmic;
Suspension;
52:08.08 – CORTICOSTEROIDS;
Prescription;
BAUSCH & LOMB INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80634
LOTEMAX;
02321114;
loteprednol etabonate 0.5 % / w/v;
2009-06-24;
Ophthalmic;
Suspension;
52:08.08 – CORTICOSTEROIDS;
Prescription;
BAUSCH & LOMB INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80652
LOTEMAX OINTMENT;
02421941;
loteprednol etabonate 0.5 % / w/w;
2014-10-29;
Ophthalmic;
Ointment;
52:08.08 – CORTICOSTEROIDS;
Prescription;
BAUSCH & LOMB INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90664
LOTEMAX GEL;
02435853;
loteprednol etabonate 0.5 % / w/w;
2015-06-25;
Ophthalmic;
Gel;
52:08.08 – CORTICOSTEROIDS;
Prescription;
BAUSCH & LOMB INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92020
LOVASTATIN;
02220172;
lovastatin 20 mg;
1997-03-27;
Oral;
Tablet;
24:06.08 – HMG-COA REDUCTASE INHIBITORS;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=43279
LOVASTATIN;
02353229;
lovastatin 20 mg;
2010-07-26;
Oral;
Tablet;
24:06.08 – HMG-COA REDUCTASE INHIBITORS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83844
LOVASTATIN;
02220180;
lovastatin 40 mg;
1997-03-27;
Oral;
Tablet;
24:06.08 – HMG-COA REDUCTASE INHIBITORS;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=43280
LOVASTATIN;
02353237;
lovastatin 40 mg;
2010-07-26;
Oral;
Tablet;
24:06.08 – HMG-COA REDUCTASE INHIBITORS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83845
LOXAPAC IM;
02169991;
loxapine (loxapine hydrochloride) 50 mg / ml;
1997-06-13;
Intramuscular;
Liquid;
28:16.08.92 – MISCELLANEOUS ANTIPSYCHOTICS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=34560
XYLAC;
02230838;
loxapine (loxapine succinate) 10 mg;
1998-04-16;
Oral;
Tablet;
28:16.08.92 – MISCELLANEOUS ANTIPSYCHOTICS;
Prescription;
PENDOPHARM DIVISION OF PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=50116
XYLAC;
02242868;
loxapine (loxapine succinate) 2.5 mg;
2000-10-05;
Oral;
Tablet;
28:16.08.92 – MISCELLANEOUS ANTIPSYCHOTICS;
Prescription;
PENDOPHARM DIVISION OF PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=66699
XYLAC;
02230839;
loxapine (loxapine succinate) 25 mg;
1997-07-08;
Oral;
Tablet;
28:16.08.92 – MISCELLANEOUS ANTIPSYCHOTICS;
Prescription;
PENDOPHARM DIVISION OF PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=50117
LATUDA;
02387786;
lurasidone hydrochloride 120 mg;
2012-09-06;
Oral;
Tablet;
28:16.08.04 – ATYPICAL ANTIPSYCHOTICS;
Prescription;
SUNOVION PHARMACEUTICALS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87336
LATUDA;
02422050;
lurasidone hydrochloride 20 mg;
2014-04-09;
Oral;
Tablet;
28:16.08.04 – ATYPICAL ANTIPSYCHOTICS;
Prescription;
SUNOVION PHARMACEUTICALS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90675
LATUDA;
02387751;
lurasidone hydrochloride 40 mg;
2012-09-06;
Oral;
Tablet;
28:16.08.04 – ATYPICAL ANTIPSYCHOTICS;
Prescription;
SUNOVION PHARMACEUTICALS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87334
LATUDA;
02413361;
lurasidone hydrochloride 60 mg;
2014-03-14;
Oral;
Tablet;
28:16.08.04 – ATYPICAL ANTIPSYCHOTICS;
Prescription;
SUNOVION PHARMACEUTICALS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=89804
LATUDA;
02387778;
lurasidone hydrochloride 80 mg;
2012-09-05;
Oral;
Tablet;
28:16.08.04 – ATYPICAL ANTIPSYCHOTICS;
Prescription;
SUNOVION PHARMACEUTICALS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87335
REBLOZYL;
02505541;
luspatercept 25 mg / vial;
2020-11-23;
Subcutaneous;
Powder For Solution;
20:16.00 – HEMATOPOIETIC AGENTS;
Prescription , Schedule D;
CELGENE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=99492
REBLOZYL;
02505568;
luspatercept 75 mg / vial;
2020-11-23;
Subcutaneous;
Powder For Solution;
20:04.00 – ANTIANEMIA DRUGS;
Prescription , Schedule D;
CELGENE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=99493
LUVERIS;
02269066;
lutropin alfa 75 unit / vial;
2005-06-28;
Subcutaneous;
Powder For Solution;
68:18.00 – GONADOTROPINS AND ANTIGONADOTROPINS;
Prescription , Schedule D;
EMD SERONO, A DIVISION OF EMD INC., CANADA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=75446
ATGAM;
02234470;
lymphocyte immunoglobulin anti-thymocyte globulin (equine) 50 mg / ml;
1998-12-04;
Intravenous;
Solution;
92:00.00 – MISCELLANEOUS THERAPEUTIC AGENTS;
Schedule D;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=55838
OPSUMIT;
02415690;
macitentan 10 mg;
2014-01-15;
Oral;
Tablet;
48:48.00 – VASODILATING AGENTS;
Prescription;
JANSSEN INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90029
MAGNESIUM-45 0.5-4.5;
02219301;
magnesium chloride 20.5 g / 4.5 l;
1996-12-31;
Dialysis;
Powder For Solution;
40:34.00* – HEMODIALYSIS SOLUTION;
Ethical;
BAXTER CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=20112
MAGNESIUM SULFATE INJ 20% USP;
00392618;
magnesium sulfate 200 mg / ml;
1978-12-31;
Intramuscular , Intravenous;
Liquid;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS , 40:12.00 – REPLACEMENT PREPARATIONS;
Ethical;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=3088
MAGNESIUM SULFATE INJECTION;
02139499;
magnesium sulfate 500 mg / ml;
1992-12-31;
Intramuscular , Intravenous;
Solution;
28:12.92 – MISCELLANEOUS ANTICONVULSANTS , 40:12.00 – REPLACEMENT PREPARATIONS;
Ethical;
FRESENIUS KABI CANADA LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19701
MICRO MN;
00786942;
manganese (manganese sulfate) 0.1 mg / ml;
1992-12-31;
Intravenous;
Solution;
40:12.00 – REPLACEMENT PREPARATIONS;
Ethical;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=13486
OSMITROL INJECTION 10%;
00060410;
mannitol 10 %;
1989-12-31;
Intravenous;
Solution;
40:28.12 – OSMOTIC DIURETICS;
Ethical;
BAXTER CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=10517
MANNITOL INJECTION USP;
00038016;
mannitol 20 %;
1963-12-31;
Intravenous;
Solution;
40:28.12 – OSMOTIC DIURETICS;
Ethical;
ICU MEDICAL CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=1740
OSMITROL INJECTION 20%;
00060437;
mannitol 20 %;
1989-12-31;
Intravenous;
Solution;
36:40.00 – KIDNEY FUNCTION;
Ethical;
BAXTER CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=10516
MANNITOL INJECTION USP;
00038024;
mannitol 25 %;
1970-12-31;
Intravenous;
Solution;
40:28.12 – OSMOTIC DIURETICS;
Ethical;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=1181
MANNITOL INJECTION;
02243176;
mannitol 25 %;
2002-04-09;
Intravenous;
Solution;
40:28.12 – OSMOTIC DIURETICS;
Ethical;
FRESENIUS KABI CANADA LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=67055
CELSENTRI;
02299844;
maraviroc 150 mg;
2007-09-26;
Oral;
Tablet;
08:18.08.04 – HIV FUSION INHIBITORS;
Prescription;
VIIV HEALTHCARE ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78519
CELSENTRI;
02299852;
maraviroc 300 mg;
2007-09-26;
Oral;
Tablet;
08:18.08.04 – HIV FUSION INHIBITORS;
Prescription;
VIIV HEALTHCARE ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78520
VERMOX;
00556734;
mebendazole 100 mg;
1982-12-31;
Oral;
Tablet;
08:08.00 – ANTHELMINTICS;
Prescription;
JANSSEN INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=4743
INCRELEX;
02509733;
mecasermin 40 mg / 4 ml;
2021-03-01;
Subcutaneous;
Solution;
68:30.04 – SOMATOTROPIN AGONISTS*;
Prescription Recommended , Schedule D;
IPSEN BIOPHARMACEUTICALS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=99902
PROVERA 10MG TABLETS;
00729973;
medroxyprogesterone acetate 10 mg;
1987-12-31;
Oral;
Tablet;
68:32.00 – PROGESTINS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=7480
TEVA-MEDROXYPROGESTERONE;
02221306;
medroxyprogesterone acetate 10 mg;
1997-01-07;
Oral;
Tablet;
68:32.00 – PROGESTINS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=43301
APO-MEDROXY;
02277298;
medroxyprogesterone acetate 10 mg;
2007-01-10;
Oral;
Tablet;
68:32.00 – PROGESTINS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=76294
APO-MEDROXY;
02267640;
medroxyprogesterone acetate 100 mg;
2005-08-04;
Oral;
Tablet;
68:32.00 – PROGESTINS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=75305
DEPO-PROVERA;
00585092;
medroxyprogesterone acetate 150 mg / ml;
1995-12-31;
Intramuscular;
Suspension;
68:32.00 – PROGESTINS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19667
PROVERA 2.5MG TABLETS;
00708917;
medroxyprogesterone acetate 2.5 mg;
1992-12-31;
Oral;
Tablet;
68:32.00 – PROGESTINS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=13037
TEVA-MEDROXYPROGESTERONE;
02221284;
medroxyprogesterone acetate 2.5 mg;
1997-01-07;
Oral;
Tablet;
68:32.00 – PROGESTINS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=43299
APO-MEDROXY TABLETS;
02244726;
medroxyprogesterone acetate 2.5 mg;
2002-04-22;
Oral;
Tablet;
68:32.00 – PROGESTINS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=68715
PROVERA 5MG TABLETS;
00030937;
medroxyprogesterone acetate 5 mg;
1961-12-31;
Oral;
Tablet;
68:32.00 – PROGESTINS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=430
TEVA-MEDROXYPROGESTERONE;
02221292;
medroxyprogesterone acetate 5 mg;
1997-01-07;
Oral;
Tablet;
68:32.00 – PROGESTINS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=43300
APO-MEDROXY TABLETS;
02244727;
medroxyprogesterone acetate 5 mg;
2002-04-22;
Oral;
Tablet;
68:32.00 – PROGESTINS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=68716
MEFENAMIC;
02229452;
mefenamic acid 250 mg;
1996-11-06;
Oral;
Capsule;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=47338
MEFLOQUINE;
02244366;
mefloquine (mefloquine hydrochloride) 250 mg;
2002-07-23;
Oral;
Tablet;
08:30.08 – ANTIMALARIALS;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=68334
MEGESTROL;
02195925;
megestrol acetate 160 mg;
1995-12-31;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=20026
MEGESTROL;
02195917;
megestrol acetate 40 mg;
1995-12-31;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=20029
PMS-MELOXICAM;
02248268;
meloxicam 15 mg;
2003-11-07;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=72607
APO-MELOXICAM;
02248974;
meloxicam 15 mg;
2004-02-13;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=73356
ACT MELOXICAM;
02250020;
meloxicam 15 mg;
2004-08-12;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=73484
TEVA-MELOXICAM;
02258323;
meloxicam 15 mg;
2004-10-22;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=74354
MELOXICAM;
02353156;
meloxicam 15 mg;
2010-07-26;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83837
AURO-MELOXICAM;
02390892;
meloxicam 15 mg;
2012-10-18;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
AURO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87628
PMS-MELOXICAM;
02248267;
meloxicam 7.5 mg;
2003-11-07;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=72606
APO-MELOXICAM;
02248973;
meloxicam 7.5 mg;
2004-02-13;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=73355
ACT MELOXICAM;
02250012;
meloxicam 7.5 mg;
2004-08-12;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=73483
TEVA-MELOXICAM;
02258315;
meloxicam 7.5 mg;
2004-10-22;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=74353
MELOXICAM;
02353148;
meloxicam 7.5 mg;
2010-07-26;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83836
AURO-MELOXICAM;
02390884;
meloxicam 7.5 mg;
2012-10-19;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
AURO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87627
ALKERAN;
00004715;
melphalan 2 mg;
1964-12-31;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
ASPEN PHARMACARE CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=1195
EBIXA;
02260638;
memantine hydrochloride 10 mg;
2004-12-16;
Oral;
Tablet;
28:92.00 – MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS;
Prescription;
LUNDBECK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=74607
PMS-MEMANTINE;
02321130;
memantine hydrochloride 10 mg;
2009-11-04;
Oral;
Tablet;
28:92.00 – MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80653
ACT MEMANTINE;
02324067;
memantine hydrochloride 10 mg;
2010-02-18;
Oral;
Tablet;
28:92.00 – MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80955
RIVA-MEMANTINE;
02348950;
memantine hydrochloride 10 mg;
2010-06-14;
Oral;
Tablet;
28:92.00 – MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS;
Prescription;
LABORATOIRE RIVA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83428
APO-MEMANTINE;
02366487;
memantine hydrochloride 10 mg;
2011-06-17;
Oral;
Tablet;
28:92.00 – MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85130
SANDOZ MEMANTINE FCT;
02375532;
memantine hydrochloride 10 mg;
2014-07-17;
Oral;
Tablet;
28:92.00 – MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86095
MEMANTINE;
02443082;
memantine hydrochloride 10 mg;
2015-07-22;
Oral;
Tablet;
28:92.00 – MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92762
MEMANTINE;
02446049;
memantine hydrochloride 10 mg;
2015-10-07;
Oral;
Tablet;
28:92.00 – MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS;
Prescription;
SIVEM PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93131
PMS-MEMANTINE;
02382830;
memantine hydrochloride 5.0 mg;
2015-03-02;
Oral;
Tablet;
28:92.00 – MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86864
MENOPUR;
02283093;
menotropins 75 unit / vial;
2006-09-19;
Subcutaneous;
Powder For Solution;
68:18.00 – GONADOTROPINS AND ANTIGONADOTROPINS;
Prescription , Schedule D;
FERRING INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=76872
MEPERIDINE HYDROCHLORIDE INJECTION USP;
00725765;
meperidine hydrochloride 50 mg / ml;
1987-12-31;
Intramuscular , Intravenous , Subcutaneous;
Solution;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=8121
CARBOCAINE 1%;
02241999;
mepivacaine hydrochloride 10 mg / ml;
2001-06-01;
Intracaudal , Epidural;
Solution;
72:00.00 – LOCAL ANESTHETICS;
Ethical;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=65669
CARBOCAINE 1%;
02242000;
mepivacaine hydrochloride 10 mg / ml;
2001-07-15;
Block/Infiltration;
Solution;
72:00.00 – LOCAL ANESTHETICS;
Ethical;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=65670
CARBOCAINE 2%;
02242001;
mepivacaine hydrochloride 20 mg / ml;
2001-07-15;
Intracaudal , Epidural;
Solution;
72:00.00 – LOCAL ANESTHETICS;
Ethical;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=65671
ISOCAINE HCL INJ 3%;
00364304;
mepivacaine hydrochloride 30 mg / ml;
1977-12-31;
Subcutaneous;
Solution;
72:00.00 – LOCAL ANESTHETICS;
Ethical;
NOVOCOL PHARMACEUTICAL OF CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=2743
SCANDONEST 3% PLAIN INJ;
00479934;
mepivacaine hydrochloride 30 mg / ml;
1980-12-31;
Block/Infiltration;
Liquid;
72:00.00 – LOCAL ANESTHETICS;
Ethical;
SEPTODONT
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=3804
3% POLOCAINE DENTAL;
02330733;
mepivacaine hydrochloride 30 mg / ml;
2009-10-19;
Block/Infiltration;
Liquid;
72:00.00 – LOCAL ANESTHETICS;
Ethical;
DENTSPLY CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=81649
CARBOCAINE 3%;
02474174;
mepivacaine hydrochloride 30 mg / ml;
2019-05-07;
Block/Infiltration;
Solution;
72:00.00 – LOCAL ANESTHETICS;
Ethical;
SEPTODONT
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96420
NUCALA;
02492989;
mepolizumab 100 mg / ml;
2019-12-10;
Subcutaneous;
Solution;
92:44.00 – IMMUNOSUPPRESSIVE AGENTS;
Prescription , Schedule D;
GLAXOSMITHKLINE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98296
NUCALA;
02492997;
mepolizumab 100 mg / ml;
2019-12-10;
Subcutaneous;
Solution;
92:44.00 – IMMUNOSUPPRESSIVE AGENTS;
Prescription , Schedule D;
GLAXOSMITHKLINE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98297
NUCALA;
02449781;
mepolizumab 100 mg / vial;
2016-03-14;
Subcutaneous;
Powder For Solution;
92:44.00 – IMMUNOSUPPRESSIVE AGENTS;
Prescription , Schedule D;
GLAXOSMITHKLINE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93562
PURINETHOL;
00004723;
mercaptopurine 50 mg;
1954-12-31;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=960
MERCAPTOPURINE TABLETS USP;
02415275;
mercaptopurine 50 mg;
2013-11-27;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
STERIMAX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=89989
MEROPENEM FOR INJECTION;
02378795;
meropenem (meropenem trihydrate) 1 g / vial;
2012-01-26;
Intravenous;
Powder For Solution;
08:12.07.08 – CARBAPENEMS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86467
MEROPENEM FOR INJECTION USP;
02436507;
meropenem (meropenem trihydrate) 1 g / vial;
2015-06-11;
Intravenous;
Powder For Solution;
08:12.07.08 – CARBAPENEMS;
Prescription;
STERIMAX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92084
MEROPENEM FOR INJECTION;
02462893;
meropenem (meropenem trihydrate) 1 g / vial;
2017-10-20;
Intravenous;
Powder For Solution;
08:12.07.08 – CARBAPENEMS;
Prescription;
AURO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95076
MEROPENEM FOR INJECTION;
02493349;
meropenem (meropenem trihydrate) 1 g / vial;
2021-02-22;
Intravenous;
Powder For Solution;
08:12.07.08 – CARBAPENEMS;
Prescription;
STERIMAX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98336
MEROPENEM FOR INJECTION;
02378787;
meropenem (meropenem trihydrate) 500 mg / vial;
2012-01-26;
Intravenous;
Powder For Solution;
08:12.07.08 – CARBAPENEMS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86463
MEROPENEM FOR INJECTION;
02462885;
meropenem (meropenem trihydrate) 500 mg / vial;
2017-10-20;
Intravenous;
Powder For Solution;
08:12.07.08 – CARBAPENEMS;
Prescription;
AURO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95075
MEROPENEM FOR INJECTION, USP;
02415224;
meropenem 1 g / vial;
2014-06-05;
Intravenous;
Powder For Solution;
08:12.07.08 – CARBAPENEMS;
Prescription;
FRESENIUS KABI CANADA LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=89984
MEROPENEM FOR INJECTION, USP;
02415216;
meropenem 500 mg / vial;
2014-10-20;
Intravenous;
Powder For Solution;
08:12.07.08 – CARBAPENEMS;
Prescription;
FRESENIUS KABI CANADA LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=89983
PENTASA;
02153564;
mesalazine 1 g;
1995-12-31;
Rectal;
Suppository;
56:36.00 – ANTI-INFLAMMATORY AGENTS;
Prescription;
FERRING INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=18493
SALOFALK;
02242146;
mesalazine 1 g;
2000-06-01;
Rectal;
Suppository;
56:36.00 – ANTI-INFLAMMATORY AGENTS;
Prescription;
APTALIS PHARMA CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=65824
PENTASA;
02399466;
mesalazine 1 g;
2013-03-12;
Oral;
Tablet (Extended-Release);
56:36.00 – ANTI-INFLAMMATORY AGENTS;
Prescription;
FERRING INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88434
MEZERA;
02474018;
mesalazine 1 g;
2018-07-13;
Rectal;
Suppository;
56:36.00 – ANTI-INFLAMMATORY AGENTS;
Prescription;
AVIR PHARMA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96402
MEZERA;
02474026;
mesalazine 1 g / act;
2018-07-13;
Rectal;
Foam;
56:36.00 – ANTI-INFLAMMATORY AGENTS;
Prescription;
AVIR PHARMA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96403
PENTASA;
02153521;
mesalazine 1 g / 100 ml;
1995-12-31;
Rectal;
Suspension;
56:36.00 – ANTI-INFLAMMATORY AGENTS;
Prescription;
FERRING INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=18496
MEZAVANT;
02297558;
mesalazine 1.2 g;
2007-07-27;
Oral;
Tablet (Delayed And Extended Release);
56:36.00 – ANTI-INFLAMMATORY AGENTS;
Prescription;
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78289
SALOFALK;
02112795;
mesalazine 2 g / 60 ml;
1995-12-31;
Rectal;
Suspension;
56:36.00 – ANTI-INFLAMMATORY AGENTS;
Prescription;
APTALIS PHARMA CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=18510
PENTASA;
02153556;
mesalazine 4 g / 100 ml;
1995-12-31;
Rectal;
Suspension;
56:36.00 – ANTI-INFLAMMATORY AGENTS;
Prescription;
FERRING INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=18494
SALOFALK;
02112809;
mesalazine 4 g / 60 ml;
1995-12-31;
Rectal;
Suspension;
56:36.00 – ANTI-INFLAMMATORY AGENTS;
Prescription;
APTALIS PHARMA CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=18509
TEVA-5 ASA;
02171929;
mesalazine 400 mg;
1995-12-31;
Oral;
Tablet (Enteric-Coated);
56:36.00 – ANTI-INFLAMMATORY AGENTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19524
PENTASA;
02099683;
mesalazine 500 mg;
1994-12-31;
Oral;
Tablet (Extended-Release);
56:36.00 – ANTI-INFLAMMATORY AGENTS;
Prescription;
FERRING INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=16855
SALOFALK;
02112760;
mesalazine 500 mg;
1995-12-31;
Rectal;
Suppository;
56:36.00 – ANTI-INFLAMMATORY AGENTS;
Prescription;
APTALIS PHARMA CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=18212
SALOFALK;
02112787;
mesalazine 500 mg;
1995-12-31;
Oral;
Tablet (Delayed-Release);
56:36.00 – ANTI-INFLAMMATORY AGENTS;
Prescription;
APTALIS PHARMA CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=18214
UROMITEXAN;
02241411;
mesna 100 mg / ml;
2001-03-06;
Intravenous , Oral;
Solution;
92:56.00 – PROTECTIVE AGENTS;
Prescription;
BAXTER CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=65047
MESNA FOR INJECTION;
02244931;
mesna 100 mg / ml;
2002-08-22;
Intravenous;
Solution;
92:56.00 – PROTECTIVE AGENTS;
Prescription;
FRESENIUS KABI CANADA LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=68929
UROMITEXAN;
02371839;
mesna 100 mg / ml;
2012-04-13;
Intravenous;
Solution;
92:56.00 – PROTECTIVE AGENTS;
Prescription;
BAXTER CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85696
GLUMETZA;
02300451;
metformin hydrochloride 1000 mg;
2008-01-08;
Oral;
Tablet (Extended-Release);
68:20.04 – BIGUANIDES;
Prescription;
BAUSCH HEALTH, CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78575
APO-METFORMIN ER;
02460653;
metformin hydrochloride 1000 mg;
2017-10-02;
Oral;
Tablet (Extended-Release);
68:20.04 – BIGUANIDES;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94808
GLUCOPHAGE;
02099233;
metformin hydrochloride 500 mg;
1995-12-31;
Oral;
Tablet;
68:20.04 – BIGUANIDES;
Prescription;
SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=17104
PMS-METFORMIN – TAB 500MG;
02223562;
metformin hydrochloride 500 mg;
1996-09-05;
Oral;
Tablet;
68:20.04 – BIGUANIDES;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=43371
RIVA-METFORMIN;
02239081;
metformin hydrochloride 500 mg;
1999-05-31;
Oral;
Tablet;
68:20.04 – BIGUANIDES;
Prescription;
LABORATOIRE RIVA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=62536
RATIO-METFORMIN;
02242974;
metformin hydrochloride 500 mg;
2001-01-04;
Oral;
Tablet;
68:20.04 – BIGUANIDES;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=66814
SANDOZ METFORMIN FC;
02246820;
metformin hydrochloride 500 mg;
2002-12-20;
Oral;
Tablet;
68:20.04 – BIGUANIDES;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=71020
ACT METFORMIN;
02257726;
metformin hydrochloride 500 mg;
2004-11-05;
Oral;
Tablet;
68:20.04 – BIGUANIDES;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=74296
GLUMETZA;
02268493;
metformin hydrochloride 500 mg;
2005-11-03;
Oral;
Tablet (Extended-Release);
68:20.04 – BIGUANIDES;
Prescription;
BAUSCH HEALTH, CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=75387
RAN-METFORMIN;
02269031;
metformin hydrochloride 500 mg;
2005-07-12;
Oral;
Tablet;
68:20.04 – BIGUANIDES;
Prescription;
RANBAXY PHARMACEUTICALS CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=75444
PRO-METFORMIN;
02314908;
metformin hydrochloride 500 mg;
2008-10-27;
Oral;
Tablet;
68:20.04 – BIGUANIDES;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80043
METFORMIN;
02353377;
metformin hydrochloride 500 mg;
2010-07-26;
Oral;
Tablet;
68:20.04 – BIGUANIDES;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83857
JAMP-METFORMIN;
02380196;
metformin hydrochloride 500 mg;
2012-03-22;
Oral;
Tablet;
68:20.04 – BIGUANIDES;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86602
METFORMIN FC;
02385341;
metformin hydrochloride 500 mg;
2012-06-10;
Oral;
Tablet;
68:20.04 – BIGUANIDES;
Prescription;
SIVEM PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87098
AURO-METFORMIN;
02438275;
metformin hydrochloride 500 mg;
2015-04-08;
Oral;
Tablet;
68:20.04 – BIGUANIDES;
Prescription;
AURO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92264
GLUCOPHAGE;
02162849;
metformin hydrochloride 850 mg;
1995-12-31;
Oral;
Tablet;
68:20.04 – BIGUANIDES;
Prescription;
SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=18835
PMS-METFORMIN;
02242589;
metformin hydrochloride 850 mg;
2000-07-28;
Oral;
Tablet;
68:20.04 – BIGUANIDES;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=66363
RIVA-METFORMIN;
02242783;
metformin hydrochloride 850 mg;
2001-10-18;
Oral;
Tablet;
68:20.04 – BIGUANIDES;
Prescription;
LABORATOIRE RIVA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=66606
RATIO-METFORMIN;
02242931;
metformin hydrochloride 850 mg;
2001-01-04;
Oral;
Tablet;
68:20.04 – BIGUANIDES;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=66769
SANDOZ METFORMIN FC;
02246821;
metformin hydrochloride 850 mg;
2002-12-20;
Oral;
Tablet;
68:20.04 – BIGUANIDES;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=71021
ACT METFORMIN;
02257734;
metformin hydrochloride 850 mg;
2004-11-05;
Oral;
Tablet;
68:20.04 – BIGUANIDES;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=74297
RAN-METFORMIN;
02269058;
metformin hydrochloride 850 mg;
2005-07-12;
Oral;
Tablet;
68:20.04 – BIGUANIDES;
Prescription;
RANBAXY PHARMACEUTICALS CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=75445
PRO-METFORMIN;
02314894;
metformin hydrochloride 850 mg;
2008-10-27;
Oral;
Tablet;
68:20.04 – BIGUANIDES;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80042
METFORMIN;
02353385;
metformin hydrochloride 850 mg;
2010-07-26;
Oral;
Tablet;
68:20.04 – BIGUANIDES;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83858
JAMP-METFORMIN;
02380218;
metformin hydrochloride 850 mg;
2012-03-22;
Oral;
Tablet;
68:20.04 – BIGUANIDES;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86603
METFORMIN FC;
02385368;
metformin hydrochloride 850 mg;
2012-06-10;
Oral;
Tablet;
68:20.04 – BIGUANIDES;
Prescription;
SIVEM PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87099
AURO-METFORMIN;
02438283;
metformin hydrochloride 850 mg;
2015-04-08;
Oral;
Tablet;
68:20.04 – BIGUANIDES;
Prescription;
AURO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92265
PROVOCHOLINE;
02239656;
methacholine chloride 100 mg / vial;
1999-04-01;
Inhalation;
Powder For Solution;
36:89.00* – OTHER DIAGNOSTIC AGENTS;
Prescription;
METHAPHARM INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=63128
METHACHOLINE OMEGA;
02263890;
methacholine chloride 100 mg / vial;
2006-03-27;
Inhalation;
Powder For Solution;
36:89.00* – OTHER DIAGNOSTIC AGENTS;
Prescription;
OMEGA LABORATORIES LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=74930
PROVOCHOLINE;
02243834;
methacholine chloride 1280 mg / vial;
2001-09-24;
Inhalation;
Powder For Solution;
36:89.00* – OTHER DIAGNOSTIC AGENTS;
Prescription;
METHAPHARM INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=67775
PROVOCHOLINE;
02246492;
methacholine chloride 160 mg / vial;
2003-03-12;
Inhalation;
Powder For Solution;
36:89.00* – OTHER DIAGNOSTIC AGENTS;
Prescription;
METHAPHARM INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=70667
METHACHOLINE OMEGA;
02263912;
methacholine chloride 1600 mg / vial;
2006-07-03;
Inhalation;
Powder For Solution;
36:89.00* – OTHER DIAGNOSTIC AGENTS;
Prescription;
OMEGA LABORATORIES LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=74932
PROVOCHOLINE;
02288826;
methacholine chloride 1600 mg / vial;
2008-02-28;
Inhalation;
Powder For Solution;
36:89.00* – OTHER DIAGNOSTIC AGENTS;
Prescription;
METHAPHARM INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=77421
PROVOCHOLINE;
02246493;
methacholine chloride 320 mg / vial;
2003-03-12;
Inhalation;
Powder For Solution;
36:89.00* – OTHER DIAGNOSTIC AGENTS;
Prescription;
METHAPHARM INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=70668
METADOL;
02247698;
methadone hydrochloride 1 mg;
2003-07-29;
Oral;
Tablet;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PALADIN LABS INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=71959
METADOL-D;
02247374;
methadone hydrochloride 1 mg / ml;
2014-08-18;
Oral;
Solution;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PALADIN LABS INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=71619
METADOL;
02247694;
methadone hydrochloride 1 mg / ml;
2003-07-11;
Oral;
Solution;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PALADIN LABS INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=71958
METADOL;
02247700;
methadone hydrochloride 10 mg;
2003-07-29;
Oral;
Tablet;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PALADIN LABS INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=71964
METADOL;
02241377;
methadone hydrochloride 10 mg / ml;
2000-05-05;
Oral;
Solution;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PALADIN LABS INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=65010
METADOL-D;
02244290;
methadone hydrochloride 10 mg / ml;
2001-08-03;
Oral;
Solution;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PALADIN LABS INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=68257
METHADOSE;
02394596;
methadone hydrochloride 10 mg / ml;
2013-01-03;
Oral;
Solution;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
MALLINCKRODT CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87974
METHADOSE;
02394618;
methadone hydrochloride 10 mg / ml;
2013-01-03;
Oral;
Solution;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
MALLINCKRODT CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87975
SANDOZ METHADONE;
02481979;
methadone hydrochloride 10 mg / ml;
2019-07-30;
Oral;
Solution;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97248
JAMP METHADONE ORAL CONCENTRATE;
02495783;
methadone hydrochloride 10 mg / ml;
2020-10-30;
Oral;
Solution;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98568
ODAN-METHADONE;
02495872;
methadone hydrochloride 10 mg / ml;
2020-06-17;
Oral;
Solution;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
ODAN LABORATORIES LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98577
ODAN-METHADONE;
02495880;
methadone hydrochloride 10 mg / ml;
2020-06-17;
Oral;
Solution;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
ODAN LABORATORIES LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98578
METADOL;
02247701;
methadone hydrochloride 25 mg;
2003-07-29;
Oral;
Tablet;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PALADIN LABS INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=71965
METADOL;
02247699;
methadone hydrochloride 5 mg;
2003-07-29;
Oral;
Tablet;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PALADIN LABS INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=71963
METHAZOLAMIDE;
02245882;
methazolamide 50 mg;
2002-07-25;
Oral;
Tablet;
52:40.12 – CARBONIC ANHYDRASE INHIBITORS;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=69999
TAPAZOLE;
02296039;
methimazole 10 mg;
2008-01-07;
Oral;
Tablet;
68:36.08 – ANTITHYROID AGENTS;
Prescription;
PALADIN LABS INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78139
MAR-METHIMAZOLE;
02480115;
methimazole 10 mg;
2018-10-19;
Oral;
Tablet;
68:36.08 – ANTITHYROID AGENTS;
Prescription;
MARCAN PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97067
TAPAZOLE;
00015741;
methimazole 5 mg;
1951-12-31;
Oral;
Tablet;
68:36.08 – ANTITHYROID AGENTS;
Prescription;
PALADIN LABS INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=9
MAR-METHIMAZOLE;
02480107;
methimazole 5 mg;
2018-10-19;
Oral;
Tablet;
68:36.08 – ANTITHYROID AGENTS;
Prescription;
MARCAN PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97066
ROBAXIN;
01930990;
methocarbamol 500 mg;
1958-12-31;
Oral;
Tablet;
12:20.04 – CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS;
Otc;
GLAXOSMITHKLINE CONSUMER HEALTHCARE ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=13297
ROBAXIN 750;
01932187;
methocarbamol 750 mg;
1993-12-31;
Oral;
Tablet;
12:20.04 – CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS;
Otc;
GLAXOSMITHKLINE CONSUMER HEALTHCARE ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=13624
PMS-METHOTREXATE;
02170698;
methotrexate (methotrexate disodium) 2.5 mg;
1996-11-15;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=44161
METHOTREXATE INJECTION USP;
02182947;
methotrexate (methotrexate sodium) 10 mg / ml;
1997-07-30;
Intracerebroventricular , Intra-Arterial , Intramuscular , Intrathecal , Intravenous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=44261
METOJECT SUBCUTANEOUS;
02454831;
methotrexate (methotrexate sodium) 10 mg / 0.2 ml;
2019-09-16;
Subcutaneous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
MEDEXUS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94161
METHOTREXATE INJECTION, BP;
02422174;
methotrexate (methotrexate sodium) 10 mg / 0.4 ml;
2014-05-08;
Intra-Arterial , Intramuscular , Intrathecal , Intravenous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90688
METOJECT SUBCUTANEOUS;
02454750;
methotrexate (methotrexate sodium) 12.5 mg / 0.25 ml;
2019-09-16;
Subcutaneous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
MEDEXUS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94144
METOJECT SUBCUTANEOUS;
02454858;
methotrexate (methotrexate sodium) 15 mg / 0.3 ml;
2018-11-30;
Subcutaneous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
MEDEXUS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94162
METHOTREXATE SUBCUTANEOUS;
02491311;
methotrexate (methotrexate sodium) 15 mg / 0.3 ml;
2020-06-02;
Subcutaneous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
ACCORD HEALTHCARE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98132
METHOTREXATE INJECTION, BP;
02422182;
methotrexate (methotrexate sodium) 15 mg / 0.6 ml;
2014-05-08;
Intra-Arterial , Intramuscular , Intrathecal , Intravenous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90689
METOJECT SUBCUTANEOUS;
02454769;
methotrexate (methotrexate sodium) 17.5 mg / 0.35 ml;
2016-12-02;
Subcutaneous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
MEDEXUS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94145
METHOTREXATE SUBCUTANEOUS;
02491338;
methotrexate (methotrexate sodium) 17.5 mg / 0.35 ml;
2020-02-28;
Subcutaneous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
ACCORD HEALTHCARE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98133
METOJECT SUBCUTANEOUS;
02454866;
methotrexate (methotrexate sodium) 20 mg / 0.4 ml;
2016-12-02;
Subcutaneous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
MEDEXUS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94163
METHOTREXATE SUBCUTANEOUS;
02491346;
methotrexate (methotrexate sodium) 20 mg / 0.4 ml;
2020-02-28;
Subcutaneous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
ACCORD HEALTHCARE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98134
METHOTREXATE INJECTION, BP;
02422190;
methotrexate (methotrexate sodium) 20 mg / 0.8 ml;
2014-05-08;
Intra-Arterial , Intramuscular , Intrathecal , Intravenous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90690
METOJECT SUBCUTANEOUS;
02454777;
methotrexate (methotrexate sodium) 22.5 mg / 0.45 ml;
2016-12-02;
Subcutaneous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
MEDEXUS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94146
METHOTREXATE SUBCUTANEOUS;
02491354;
methotrexate (methotrexate sodium) 22.5 mg / 0.45 ml;
2020-02-28;
Subcutaneous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
ACCORD HEALTHCARE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98135
METHOTREXATE SODIUM INJECTION;
02099705;
methotrexate (methotrexate sodium) 25 mg / ml;
1995-12-31;
Intracerebroventricular , Intra-Arterial , Intramuscular , Intrathecal , Intravenous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19681
METHOTREXATE INJECTION USP;
02182777;
methotrexate (methotrexate sodium) 25 mg / ml;
1998-04-30;
Intra-Arterial , Intramuscular , Intravenous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=42844
METHOTREXATE INJECTION USP;
02182955;
methotrexate (methotrexate sodium) 25 mg / ml;
1998-07-13;
Intracerebroventricular , Intra-Arterial , Intramuscular , Intrathecal , Intravenous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=44262
METHOTREXATE INJECTION USP;
02182971;
methotrexate (methotrexate sodium) 25 mg / ml;
1997-07-30;
Intravenous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=44264
METHOTREXATE INJECTION BP;
02327236;
methotrexate (methotrexate sodium) 25 mg / ml;
2011-09-30;
Intracerebroventricular , Intra-Arterial , Intramuscular , Intrathecal , Intravenous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
ACCORD HEALTHCARE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=81253
JAMP-METHOTREXATE;
02419173;
methotrexate (methotrexate sodium) 25 mg / ml;
2014-03-12;
Intra-Arterial , Intramuscular , Intrathecal , Intravenous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90372
METHOTREXATE INJECTION, BP;
02422204;
methotrexate (methotrexate sodium) 25 mg / ml;
2014-05-08;
Intra-Arterial , Intramuscular , Intrathecal , Intravenous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90691
METHOTREXATE INJECTION BP;
02464365;
methotrexate (methotrexate sodium) 25 mg / ml;
2020-10-22;
Intra-Arterial , Intramuscular , Intravenous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
ACCORD HEALTHCARE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95252
METHOTREXATE INJECTION BP;
02474735;
methotrexate (methotrexate sodium) 25 mg / ml;
2019-04-23;
Intravenous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
ACCORD HEALTHCARE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96492
METHOTREXATE INJECTION BP;
02474891;
methotrexate (methotrexate sodium) 25 mg / ml;
2019-04-23;
Intravenous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
ACCORD HEALTHCARE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96511
METOJECT SUBCUTANEOUS;
02454874;
methotrexate (methotrexate sodium) 25 mg / 0.5 ml;
2016-12-02;
Subcutaneous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
MEDEXUS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94164
METHOTREXATE SUBCUTANEOUS;
02491362;
methotrexate (methotrexate sodium) 25 mg / 0.5 ml;
2020-02-28;
Subcutaneous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
ACCORD HEALTHCARE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98136
METHOTREXATE INJECTION, BP;
02422166;
methotrexate (methotrexate sodium) 7.5 mg / 0.3 ml;
2014-05-08;
Intra-Arterial , Intramuscular , Intrathecal , Intravenous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90687
METOJECT;
02320029;
methotrexate (methotrexate sodium) 7.5 mg / 0.75 ml;
2009-01-26;
Intra-Arterial , Intramuscular , Intravenous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
MEDEXUS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80549
METHOTREXATE TABLETS, USP;
02182750;
methotrexate 10 mg;
2004-04-12;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=42842
NOZINAN INJ 25MG/ML;
01927698;
methotrimeprazine (methotrimeprazine hydrochloride) 25 mg / ml;
1958-12-31;
Intramuscular , Intravenous;
Solution;
28:16.08.24 – PHENOTHIAZINES;
Prescription;
SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=13163
METHOPRAZINE;
02238403;
methotrimeprazine (methotrimeprazine maleate) 2 mg;
1998-07-20;
Oral;
Tablet;
28:16.08.24 – PHENOTHIAZINES;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=61820
METHOPRAZINE;
02238405;
methotrimeprazine (methotrimeprazine maleate) 25 mg;
1998-07-20;
Oral;
Tablet;
28:16.08.24 – PHENOTHIAZINES;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=61822
METHOPRAZINE;
02238404;
methotrimeprazine (methotrimeprazine maleate) 5 mg;
1998-07-20;
Oral;
Tablet;
28:16.08.24 – PHENOTHIAZINES;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=61821
METHOPRAZINE;
02238406;
methotrimeprazine (methotrimeprazine maleate) 50 mg;
1998-07-20;
Oral;
Tablet;
28:16.08.24 – PHENOTHIAZINES;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=61823
UVADEX;
02406233;
methoxsalen 20 mcg / ml;
2013-12-09;
Extracorporeal;
Solution;
84:50.06 – PIGMENTING AGENTS;
Prescription;
THERAKOS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=89096
PENTHROX;
02474719;
methoxyflurane 99.9 %;
2018-06-13;
Inhalation;
Solution;
28:08.92 – MISCELLANEOUS ANALGESICS AND ANTIPYRETICS;
Prescription;
PURDUE PHARMA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96490
PENTHROX;
02474727;
methoxyflurane 99.9 %;
2018-06-12;
Inhalation;
Solution , Kit;
28:08.92 – MISCELLANEOUS ANALGESICS AND ANTIPYRETICS;
Prescription;
PURDUE PHARMA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96491
METVIX;
02323273;
methyl aminolevulinate (methyl aminolevulinate hydrochloride) 168 mg / g;
2009-06-16;
Topical;
Cream;
84:92.00 – MISC. SKIN AND MUCOUS MEMBRANE AGENTS;
Prescription;
GALDERMA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80876
METHYLDOPA;
00360252;
methyldopa 125 mg;
1980-04-02;
Oral;
Tablet;
24:08.16 – CENTRAL ALPHA-AGONISTS;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=2470
METHYLDOPA;
00360260;
methyldopa 250 mg;
1976-12-31;
Oral;
Tablet;
24:08.16 – CENTRAL ALPHA-AGONISTS;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=2471
METHYLDOPA;
00426830;
methyldopa 500 mg;
1978-12-31;
Oral;
Tablet;
24:08.16 – CENTRAL ALPHA-AGONISTS;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=2909
METHYLENE BLEU LIQ 1%;
00050466;
methylene blue 1 %;
1951-12-31;
Oral;
Liquid;
92:00.00 – MISCELLANEOUS THERAPEUTIC AGENTS;
Otc;
LABORATOIRE ATLAS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=68
METHYLENE BLUE INJECTION USP;
02230770;
methylene blue 10 mg / ml;
2001-03-11;
Intravenous;
Liquid;
92:12.00 – ANTIDOTES;
Ethical;
OMEGA LABORATORIES LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=50032
METHYLENE BLUE INJECTION USP;
02431548;
methylene blue 10 mg / ml;
2016-02-19;
Intravenous;
Solution;
92:12.00 – ANTIDOTES;
Ethical;
TELIGENT OU
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=91597
METHYLENE BLUE INJECTION;
02487993;
methylene blue 10 mg / ml;
2020-09-22;
Intravenous;
Solution;
92:12.00 – ANTIDOTES;
Ethical;
PHEBRA PTY LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97817
METHYLENE BLEU LIQ 2%;
00050474;
methylene blue 2 %;
1951-12-31;
Oral;
Liquid;
92:12.00 – ANTIDOTES;
Otc;
LABORATOIRE ATLAS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=69
RELISTOR;
02308215;
methylnaltrexone bromide 20 mg / ml;
2008-05-07;
Subcutaneous;
Solution;
56:92.00 – MISCELLANEOUS GI DRUGS;
Prescription;
SALIX PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=79388
RITALIN 10MG;
00005606;
methylphenidate hydrochloride 10 mg;
1956-12-31;
Oral;
Tablet;
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
NOVARTIS PHARMACEUTICALS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=800
PMS-METHYLPHENIDATE;
00584991;
methylphenidate hydrochloride 10 mg;
1990-12-31;
Oral;
Tablet;
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=10398
APO-METHYLPHENIDATE;
02249324;
methylphenidate hydrochloride 10 mg;
2004-11-02;
Oral;
Tablet;
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=73416
BIPHENTIN;
02277166;
methylphenidate hydrochloride 10 mg;
2006-08-01;
Oral;
Capsule (Extended Release);
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
ELVIUM LIFE SCIENCES
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=76281
FOQUEST;
02470357;
methylphenidate hydrochloride 100 mg;
2018-01-11;
Oral;
Capsule (Controlled Release);
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
ELVIUM LIFE SCIENCES
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95933
BIPHENTIN;
02277131;
methylphenidate hydrochloride 15 mg;
2006-08-01;
Oral;
Capsule (Extended Release);
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
ELVIUM LIFE SCIENCES
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=76279
CONCERTA;
02247732;
methylphenidate hydrochloride 18 mg;
2003-07-23;
Oral;
Tablet (Extended-Release);
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
JANSSEN INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=72012
ACT METHYLPHENIDATE ER;
02441934;
methylphenidate hydrochloride 18 mg;
2017-10-26;
Oral;
Tablet (Extended-Release);
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92630
APO-METHYLPHENIDATE ER;
02452731;
methylphenidate hydrochloride 18 mg;
2016-07-22;
Oral;
Tablet (Extended-Release);
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93914
RITALIN-SR TAB 20MG;
00632775;
methylphenidate hydrochloride 20 mg;
1984-12-31;
Oral;
Tablet (Extended-Release);
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
NOVARTIS PHARMACEUTICALS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=6067
PMS-METHYLPHENIDATE;
00585009;
methylphenidate hydrochloride 20 mg;
1990-12-31;
Oral;
Tablet;
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=10399
APO-METHYLPHENIDATE;
02249332;
methylphenidate hydrochloride 20 mg;
2004-11-02;
Oral;
Tablet;
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=73417
APO-METHYLPHENIDATE SR;
02266687;
methylphenidate hydrochloride 20 mg;
2005-04-27;
Oral;
Tablet (Extended-Release);
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=75209
BIPHENTIN;
02277158;
methylphenidate hydrochloride 20 mg;
2006-08-01;
Oral;
Capsule (Extended Release);
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
ELVIUM LIFE SCIENCES
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=76280
SANDOZ METHYLPHENIDATE SR;
02320312;
methylphenidate hydrochloride 20 mg;
2008-12-23;
Oral;
Tablet (Extended-Release);
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80575
FOQUEST;
02470292;
methylphenidate hydrochloride 25 mg;
2017-12-14;
Oral;
Capsule (Controlled Release);
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
ELVIUM LIFE SCIENCES
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95927
CONCERTA;
02250241;
methylphenidate hydrochloride 27 mg;
2005-01-06;
Oral;
Tablet (Extended-Release);
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
JANSSEN INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=73505
ACT METHYLPHENIDATE ER;
02441942;
methylphenidate hydrochloride 27 mg;
2017-10-26;
Oral;
Tablet (Extended-Release);
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92631
APO-METHYLPHENIDATE ER;
02452758;
methylphenidate hydrochloride 27 mg;
2016-07-22;
Oral;
Tablet (Extended-Release);
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93915
BIPHENTIN;
02277174;
methylphenidate hydrochloride 30 mg;
2006-08-01;
Oral;
Capsule (Extended Release);
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
ELVIUM LIFE SCIENCES
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=76282
FOQUEST;
02470306;
methylphenidate hydrochloride 35 mg;
2017-12-14;
Oral;
Capsule (Controlled Release);
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
ELVIUM LIFE SCIENCES
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95928
CONCERTA;
02247733;
methylphenidate hydrochloride 36 mg;
2003-07-23;
Oral;
Tablet (Extended-Release);
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
JANSSEN INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=72013
ACT METHYLPHENIDATE ER;
02441950;
methylphenidate hydrochloride 36 mg;
2017-10-26;
Oral;
Tablet (Extended-Release);
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92632
APO-METHYLPHENIDATE ER;
02452766;
methylphenidate hydrochloride 36 mg;
2016-07-22;
Oral;
Tablet (Extended-Release);
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93916
BIPHENTIN;
02277182;
methylphenidate hydrochloride 40 mg;
2006-08-01;
Oral;
Capsule (Extended Release);
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
ELVIUM LIFE SCIENCES
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=76283
FOQUEST;
02470314;
methylphenidate hydrochloride 45 mg;
2017-12-14;
Oral;
Capsule (Controlled Release);
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
ELVIUM LIFE SCIENCES
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95929
PMS-METHYLPHENIDATE;
02234749;
methylphenidate hydrochloride 5 mg;
1997-10-24;
Oral;
Tablet;
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=55866
APO-METHYLPHENIDATE;
02273950;
methylphenidate hydrochloride 5 mg;
2006-02-01;
Oral;
Tablet;
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=75941
BIPHENTIN;
02277190;
methylphenidate hydrochloride 50 mg;
2006-08-01;
Oral;
Capsule (Extended Release);
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
ELVIUM LIFE SCIENCES
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=76284
CONCERTA;
02247734;
methylphenidate hydrochloride 54 mg;
2003-07-23;
Oral;
Tablet (Extended-Release);
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
JANSSEN INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=72014
APO-METHYLPHENIDATE ER;
02330377;
methylphenidate hydrochloride 54 mg;
2016-07-22;
Oral;
Tablet (Extended-Release);
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=81611
ACT METHYLPHENIDATE ER;
02441969;
methylphenidate hydrochloride 54 mg;
2017-10-26;
Oral;
Tablet (Extended-Release);
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92633
FOQUEST;
02470322;
methylphenidate hydrochloride 55 mg;
2017-12-14;
Oral;
Capsule (Controlled Release);
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
ELVIUM LIFE SCIENCES
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95930
BIPHENTIN;
02277204;
methylphenidate hydrochloride 60 mg;
2006-08-01;
Oral;
Capsule (Extended Release);
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
ELVIUM LIFE SCIENCES
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=76285
FOQUEST;
02470330;
methylphenidate hydrochloride 70 mg;
2017-12-14;
Oral;
Capsule (Controlled Release);
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
ELVIUM LIFE SCIENCES
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95931
BIPHENTIN;
02277212;
methylphenidate hydrochloride 80 mg;
2007-03-09;
Oral;
Capsule (Extended Release);
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
ELVIUM LIFE SCIENCES
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=76286
FOQUEST;
02470349;
methylphenidate hydrochloride 85 mg;
2017-12-14;
Oral;
Capsule (Controlled Release);
28:20.32 – Respiratory and CNS Stimulants;
Schedule G (Cdsa Iii);
ELVIUM LIFE SCIENCES
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95932
SOLU-MEDROL;
00036137;
methylprednisolone (methylprednisolone sodium succinate) 1 g / vial;
1971-12-31;
Intramuscular , Intravenous;
Kit , Powder For Solution;
68:04.00 – ADRENALS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=1130
METHYLPREDNISOLONE SODIUM SUCCINATE FOR INJECTION;
02241229;
methylprednisolone (methylprednisolone sodium succinate) 1 g / vial;
2000-03-01;
Intramuscular , Intravenous;
Powder For Solution;
68:04.00 – ADRENALS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=64837
SOLU-MEDROL;
02367971;
methylprednisolone (methylprednisolone sodium succinate) 1 g / vial;
2012-02-07;
Intramuscular , Intravenous;
Kit , Powder For Solution;
68:04.00 – ADRENALS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85280
SOLU-MEDROL;
02367955;
methylprednisolone (methylprednisolone sodium succinate) 125 mg / vial;
2012-01-18;
Intramuscular , Intravenous;
Kit , Powder For Solution;
68:04.00 – ADRENALS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85278
METHYLPREDNISOLONE SODIUM SUCCINATE FOR INJECTION;
02231893;
methylprednisolone (methylprednisolone sodium succinate) 40 mg / vial;
2000-03-01;
Intramuscular , Intravenous;
Powder For Solution;
68:04.00 – ADRENALS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=51346
SOLU-MEDROL;
02367947;
methylprednisolone (methylprednisolone sodium succinate) 40 mg / vial;
2012-01-11;
Intramuscular , Intravenous;
Kit , Powder For Solution;
68:04.00 – ADRENALS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85277
SOLU-MEDROL;
00030678;
methylprednisolone (methylprednisolone sodium succinate) 500 mg / vial;
1970-12-31;
Intramuscular , Intravenous;
Kit , Powder For Solution;
68:04.00 – ADRENALS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=1132
METHYLPREDNISOLONE SODIUM SUCCINATE FOR INJECTION;
02231895;
methylprednisolone (methylprednisolone sodium succinate) 500 mg / vial;
2000-03-01;
Intramuscular , Intravenous;
Powder For Solution;
68:04.00 – ADRENALS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=51348
SOLU-MEDROL;
02367963;
methylprednisolone (methylprednisolone sodium succinate) 500 mg / vial;
2012-01-18;
Intramuscular , Intravenous;
Kit , Powder For Solution;
68:04.00 – ADRENALS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85279
MEDROL 16 MG;
00036129;
methylprednisolone 16 mg;
1968-12-31;
Oral;
Tablet;
68:04.00 – ADRENALS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=1396
MEDROL 4 MG;
00030988;
methylprednisolone 4 mg;
1960-12-31;
Oral;
Tablet;
68:04.00 – ADRENALS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=1397
DEPO-MEDROL (WITH PRESERVATIVE) 20 MG/ML;
01934325;
methylprednisolone acetate 20 mg / ml;
1995-12-31;
Intra-Articular , Intralesional , Intramuscular , Intrasynovial;
Suspension;
68:04.00 – ADRENALS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=18988
DEPO-MEDROL 40 MG/ML;
00030759;
methylprednisolone acetate 40 mg / ml;
1960-12-31;
Intra-Articular , Intralesional , Intramuscular , Intrasynovial;
Suspension;
68:04.00 – ADRENALS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=1134
DEPO-MEDROL (WITH PRESERVATIVE) 40 MG/ML;
01934333;
methylprednisolone acetate 40 mg / ml;
1994-12-31;
Intra-Articular , Intralesional , Intramuscular , Intrasynovial;
Suspension;
68:04.00 – ADRENALS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=16275
DEPO-MEDROL 80 MG/ML;
00030767;
methylprednisolone acetate 80 mg / ml;
1969-12-31;
Intra-Articular , Intralesional , Intramuscular , Intrasynovial;
Suspension;
68:04.00 – ADRENALS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=789
DEPO-MEDROL (WITH PRESERVATIVE) 80 MG/ML;
01934341;
methylprednisolone acetate 80 mg / ml;
1994-12-31;
Intra-Articular , Intralesional , Intramuscular , Intrasynovial;
Suspension;
68:04.00 – ADRENALS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=16276
METONIA;
02230431;
metoclopramide hydrochloride 5 mg;
1998-04-16;
Oral;
Tablet;
56:32.00 – PROKINETIC AGENTS;
Prescription;
PENDOPHARM DIVISION OF PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=49332
METOCLOPRAMIDE HYDROCHLORIDE INJECTION;
02185431;
metoclopramide hydrochloride 5 mg / ml;
1995-12-31;
Intramuscular , Intravenous;
Liquid;
56:32.00 – PROKINETIC AGENTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19409
METOCLOPRAMIDE OMEGA;
02243563;
metoclopramide hydrochloride 5 mg / ml;
2001-04-30;
Intramuscular , Intravenous;
Liquid;
56:32.00 – PROKINETIC AGENTS;
Prescription;
OMEGA LABORATORIES LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=67481
METONIA;
02230433;
metoclopramide hydrochloride 5 mg / 5 ml;
1997-02-25;
Oral;
Solution;
56:32.00 – PROKINETIC AGENTS;
Prescription;
PENDOPHARM DIVISION OF PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=49340
ZAROXOLYN;
00888400;
metolazone 2.5 mg;
1974-12-31;
Oral;
Tablet;
40:28.24 – THIAZIDE-LIKE DIURETICS;
Prescription;
SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=13126
METOPROLOL TARTRATE INJECTION USP;
02474271;
metoprolol tartrate 1 mg / ml;
2019-07-08;
Intravenous;
Solution;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
JUNO PHARMACEUTICALS CORP.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96432
METOPROLOL TARTRATE INJECTION USP;
02267853;
metoprolol tartrate 1 mg / 1 ml;
2005-07-20;
Intravenous;
Solution;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=75326
APO-METOPROLOL;
00618640;
metoprolol tartrate 100 mg;
1984-12-31;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=5819
LOPRESOR SR 100MG;
00658855;
metoprolol tartrate 100 mg;
1985-12-31;
Oral;
Tablet (Extended-Release);
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
NOVARTIS PHARMACEUTICALS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=6311
METOPROLOL-100;
00648027;
metoprolol tartrate 100 mg;
1985-12-31;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=6513
TEVA-METOPROLOL;
00648043;
metoprolol tartrate 100 mg;
1986-12-31;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=6612
APO-METOPROLOL (TYPE L);
00751170;
metoprolol tartrate 100 mg;
1988-12-31;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=8602
TEVA-METOPROLOL;
00842656;
metoprolol tartrate 100 mg;
1989-12-31;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=9887
PMS-METOPROLOL-L;
02230804;
metoprolol tartrate 100 mg;
1998-04-16;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=50068
APO-METOPROLOL SR;
02285169;
metoprolol tartrate 100 mg;
2007-07-30;
Oral;
Tablet (Extended-Release);
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=77067
SANDOZ METOPROLOL SR;
02303396;
metoprolol tartrate 100 mg;
2007-12-13;
Oral;
Tablet (Extended-Release);
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78871
RIVA-METOPROLOL-L;
02315327;
metoprolol tartrate 100 mg;
2008-09-10;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
LABORATOIRE RIVA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80087
METOPROLOL;
02350408;
metoprolol tartrate 100 mg;
2010-05-31;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83561
METOPROLOL SR;
02351404;
metoprolol tartrate 100 mg;
2010-10-15;
Oral;
Tablet (Extended-Release);
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83667
JAMP-METOPROLOL-L;
02356848;
metoprolol tartrate 100 mg;
2010-10-21;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84196
METOPROLOL-L;
02442132;
metoprolol tartrate 100 mg;
2015-07-09;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
SIVEM PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92649
AG-METOPROLOL-L;
02481324;
metoprolol tartrate 100 mg;
2018-12-27;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
ANGITA PHARMA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97181
LOPRESOR SR 200 MG;
00534560;
metoprolol tartrate 200 mg;
1983-12-31;
Oral;
Tablet (Extended-Release);
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
NOVARTIS PHARMACEUTICALS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=5091
SANDOZ METOPROLOL SR;
02303418;
metoprolol tartrate 200 mg;
2007-12-13;
Oral;
Tablet (Extended-Release);
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78872
APO-METOPROLOL;
02246010;
metoprolol tartrate 25 mg;
2002-10-08;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=70136
PMS-METOPROLOL-L;
02248855;
metoprolol tartrate 25 mg;
2004-03-19;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=73226
TEVA-METOPROLOL;
02261898;
metoprolol tartrate 25 mg;
2012-02-15;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=74725
METOPROLOL – 25;
02296713;
metoprolol tartrate 25 mg;
2007-10-26;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78208
RIVA-METOPROLOL-L;
02315300;
metoprolol tartrate 25 mg;
2008-09-10;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
LABORATOIRE RIVA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80085
JAMP-METOPROLOL-L;
02356813;
metoprolol tartrate 25 mg;
2010-10-21;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84194
AG-METOPROLOL-L;
02481308;
metoprolol tartrate 25 mg;
2018-12-27;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
ANGITA PHARMA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97179
APO-METOPROLOL;
00618632;
metoprolol tartrate 50 mg;
1984-12-31;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=5818
METOPROLOL-50;
00648019;
metoprolol tartrate 50 mg;
1985-12-31;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=6512
TEVA-METOPROLOL;
00648035;
metoprolol tartrate 50 mg;
1986-12-31;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=6611
APO-METOPROLOL (TYPE L);
00749354;
metoprolol tartrate 50 mg;
1988-12-31;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=8603
TEVA-METOPROLOL;
00842648;
metoprolol tartrate 50 mg;
1989-12-31;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=9886
PMS-METOPROLOL-L;
02230803;
metoprolol tartrate 50 mg;
1998-04-16;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=50067
RIVA-METOPROLOL-L;
02315319;
metoprolol tartrate 50 mg;
2008-09-10;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
LABORATOIRE RIVA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80086
METOPROLOL;
02350394;
metoprolol tartrate 50 mg;
2010-05-31;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83560
JAMP-METOPROLOL-L;
02356821;
metoprolol tartrate 50 mg;
2010-10-21;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84195
METOPROLOL-L;
02442124;
metoprolol tartrate 50 mg;
2015-07-09;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
SIVEM PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92648
AG-METOPROLOL-L;
02481316;
metoprolol tartrate 50 mg;
2018-12-27;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
ANGITA PHARMA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97180
METROGEL 0.75%;
02092832;
metronidazole 0.75 %;
1994-12-31;
Topical;
Gel;
84:04.04 – ANTIBIOTICS;
Prescription;
GALDERMA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=17824
NIDAGEL VAGINAL GEL 0.75%;
02125226;
metronidazole 0.75 % / w/w;
1994-12-31;
Vaginal;
Gel;
84:04.04 – ANTIBIOTICS;
Prescription;
VALEANT CANADA LP/VALEANT CANADA S.E.C.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=16852
METROGEL 1%;
02297809;
metronidazole 1 %;
2007-12-20;
Topical;
Gel;
84:04.04 – ANTIBIOTICS;
Prescription;
GALDERMA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78314
NORITATE;
02156091;
metronidazole 1 % / w/w;
1995-12-31;
Topical;
Cream;
84:04.04 – ANTIBIOTICS;
Prescription;
BAUSCH HEALTH, CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19257
FLAGYL;
01926861;
metronidazole 10 %;
1970-12-31;
Vaginal;
Cream;
84:04.92 – MISCELLANEOUS LOCAL ANTI-INFECTIVES;
Prescription;
SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=12997
METRONIDAZOLE;
00545066;
metronidazole 250 mg;
1982-12-31;
Oral;
Tablet;
08:30.92 – MISCELLANEOUS ANTIPROTOZOALS;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=4902
METRONIDAZOLE INJECTION USP;
00649074;
metronidazole 5 mg / ml;
1987-12-31;
Intravenous;
Solution;
08:30.92 – MISCELLANEOUS ANTIPROTOZOALS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=7425
METRONIDAZOLE INJECTION, USP;
00870420;
metronidazole 5 mg / ml;
1990-12-31;
Intravenous;
Solution;
08:30.92 – MISCELLANEOUS ANTIPROTOZOALS;
Prescription;
BAXTER CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=10871
FLAGYL;
01926853;
metronidazole 500 mg;
1979-12-31;
Oral;
Capsule;
08:30.92 – MISCELLANEOUS ANTIPROTOZOALS;
Prescription;
ODAN LABORATORIES LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=12221
APO-METRONIDAZOLE;
02248562;
metronidazole 500 mg;
2003-11-27;
Oral;
Capsule;
08:30.92 – MISCELLANEOUS ANTIPROTOZOALS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=72917
AURO-METRONIDAZOLE;
02470284;
metronidazole 500 mg;
2018-04-03;
Oral;
Capsule;
08:30.92 – MISCELLANEOUS ANTIPROTOZOALS;
Prescription;
AURO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95926
TEVA-MEXILETINE;
02230359;
mexiletine hydrochloride 100 mg;
1997-03-17;
Oral;
Capsule;
24:04.04.08 – CLASS IB ANTIARRYTHMICS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=49155
TEVA-MEXILETINE;
02230360;
mexiletine hydrochloride 200 mg;
1997-02-17;
Oral;
Capsule;
24:04.04.08 – CLASS IB ANTIARRYTHMICS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=49157
MYCAMINE;
02311054;
micafungin sodium 100 mg / vial;
2009-12-17;
Intravenous;
Powder For Solution;
08:14.16 – ECHINOCANDINS;
Prescription;
ASTELLAS PHARMA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=79665
MYCAMINE;
02294222;
micafungin sodium 50 mg / vial;
2007-09-18;
Intravenous;
Powder For Solution;
08:14.16 – ECHINOCANDINS;
Prescription;
ASTELLAS PHARMA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=77957
MONISTAT 1 VAGINAL OVULE;
02239601;
miconazole nitrate 1200 mg;
1999-02-26;
Vaginal;
Suppository;
84:04.08.08 – AZOLES;
Otc;
INSIGHT PHARMACEUTICALS, LLC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=63071
MONISTAT 7 VAGINAL CREAM;
02084309;
miconazole nitrate 2 %;
1978-12-31;
Vaginal;
Cream;
84:04.08.08 – AZOLES;
Otc;
INSIGHT PHARMACEUTICALS, LLC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=16608
MONISTAT DERM CREAM;
02126567;
miconazole nitrate 2 %;
1980-12-31;
Topical;
Cream;
84:04.08.08 – AZOLES;
Otc;
INSIGHT PHARMACEUTICALS, LLC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=17832
MICATIN POWDER SPRAY – UNSCENTED 2%;
02230304;
miconazole nitrate 2 %;
1997-06-16;
Topical;
Aerosol;
84:04.08.08 – AZOLES;
Otc;
WELLSPRING PHARMACEUTICAL CANADA CORP
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=49064
MICOZOLE;
02231106;
miconazole nitrate 2 %;
1997-08-11;
Vaginal;
Cream;
84:04.08.08 – AZOLES;
Otc;
TARO PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=50390
MICONAZOLE NITRATE VAGINAL CREAM USP, 2%;
02231533;
miconazole nitrate 2 %;
1997-08-12;
Vaginal;
Cream;
84:04.08.08 – AZOLES;
Otc;
TARO PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=50876
MICONAZOLE NITRATE VAGINAL CREAM 2%;
02245546;
miconazole nitrate 2 %;
2003-03-13;
Vaginal;
Cream;
84:04.08.08 – AZOLES;
Otc;
VITA HEALTH PRODUCTS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=69637
MICATIN MICONAZOLE NITRATE CREAM 2% USP;
02085852;
miconazole nitrate 2 % / w/w;
1974-12-31;
Topical;
Cream;
84:04.08.08 – AZOLES;
Otc;
WELLSPRING PHARMACEUTICAL CANADA CORP
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=16609
MONISTAT 3 VAGINAL CREAM;
02244005;
miconazole nitrate 4 %;
2001-10-10;
Vaginal;
Cream;
84:04.08.08 – AZOLES;
Otc;
INSIGHT PHARMACEUTICALS, LLC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=67948
MONISTAT 3 VAGINAL OVULES;
02126605;
miconazole nitrate 400 mg;
1981-12-31;
Vaginal;
Ovule;
84:04.08.08 – AZOLES;
Otc;
INSIGHT PHARMACEUTICALS, LLC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=16612
MICONAZOLE 3 DAY OVULE TREATMENT 400MG;
02171775;
miconazole nitrate 400 mg;
1996-12-31;
Vaginal;
Suppository;
84:04.08.08 – AZOLES;
Otc;
VITA HEALTH PRODUCTS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19677
MIDAZOLAM INJECTION;
02240285;
midazolam 1 mg / ml;
1999-07-21;
Intramuscular , Intravenous;
Solution;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=63823
MIDAZOLAM INJECTION;
02242904;
midazolam 1 mg / ml;
2001-03-26;
Intramuscular , Intravenous;
Solution;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
FRESENIUS KABI CANADA LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=66736
MIDAZOLAM INJECTION USP;
02382342;
midazolam 1 mg / ml;
2015-03-30;
Intramuscular , Intravenous;
Solution;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86819
MIDAZOLAM INJECTION USP;
02382377;
midazolam 1 mg / ml;
2016-06-15;
Intramuscular , Intravenous;
Solution;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86822
MIDAZOLAM INJECTION;
02423758;
midazolam 1 mg / ml;
2015-03-31;
Intramuscular , Intravenous;
Solution;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90845
MIDAZOLAM INJECTION USP;
02498022;
midazolam 1 mg / ml;
2020-10-26;
Intravenous;
Solution;
-;
Targeted (Cdsa Iv);
STERINOVA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98782
MIDAZOLAM INJECTION;
02240286;
midazolam 5 mg / ml;
1999-07-21;
Intramuscular , Intravenous;
Solution;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=63824
MIDAZOLAM INJECTION;
02242905;
midazolam 5 mg / ml;
2001-03-26;
Intramuscular , Intravenous;
Liquid;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
FRESENIUS KABI CANADA LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=66737
MIDAZOLAM INJECTION USP;
02382350;
midazolam 5 mg / ml;
2016-02-09;
Intramuscular , Intravenous;
Solution;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86821
MIDAZOLAM INJECTION USP;
02382385;
midazolam 5 mg / ml;
2016-02-16;
Intramuscular , Intravenous;
Solution;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86823
MIDAZOLAM INJECTION;
02423766;
midazolam 5 mg / ml;
2015-03-31;
Intramuscular , Intravenous;
Solution;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90846
APO-MIDODRINE;
02278677;
midodrine hydrochloride 2.5 mg;
2006-06-13;
Oral;
Tablet;
12:12.04 – ALPHA-ADRENERGIC AGONISTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=76425
MAR-MIDODRINE;
02473984;
midodrine hydrochloride 2.5 mg;
2018-08-03;
Oral;
Tablet;
12:12.04 – ALPHA-ADRENERGIC AGONISTS;
Prescription;
MARCAN PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96400
APO-MIDODRINE;
02278685;
midodrine hydrochloride 5 mg;
2006-06-13;
Oral;
Tablet;
12:12.04 – ALPHA-ADRENERGIC AGONISTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=76426
MAR-MIDODRINE;
02473992;
midodrine hydrochloride 5 mg;
2018-08-03;
Oral;
Tablet;
12:12.04 – ALPHA-ADRENERGIC AGONISTS;
Prescription;
MARCAN PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96401
GALAFOLD;
02468042;
migalastat (migalastat hydrochloride) 123 mg;
2018-01-15;
Oral;
Capsule;
92:92.00 – OTHER MISCELLANEOUS THERAPEUTIC AGENTS;
Prescription;
AMICUS THERAPEUTICS UK LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95640
ZAVESCA;
02250519;
miglustat 100 mg;
2004-05-26;
Oral;
Capsule;
92:92.00 – OTHER MISCELLANEOUS THERAPEUTIC AGENTS;
Prescription;
JANSSEN INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=73533
SANDOZ MIGLUSTAT;
02456257;
miglustat 100 mg;
2020-04-20;
Oral;
Capsule;
92:92.00 – OTHER MISCELLANEOUS THERAPEUTIC AGENTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94314
MILRINONE LACTATE INJECTION, USP;
02244622;
milrinone (milrinone lactate) 1 mg / ml;
2003-07-03;
Intravenous;
Solution;
24:04.08 – CARDIOTONIC AGENTS;
Prescription;
FRESENIUS KABI CANADA LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=68609
MILRINONE LACTATE INJECTION;
02470047;
milrinone (milrinone lactate) 1 mg / ml;
2018-12-24;
Intravenous;
Solution;
24:04.08 – CARDIOTONIC AGENTS;
Prescription;
AURO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95899
MILRINONE LACTATE INJECTION;
02244854;
milrinone (milrinone lactate) 1.0 mg / ml;
2003-06-25;
Intravenous;
Solution;
24:04.08 – CARDIOTONIC AGENTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=68844
FLEET ENEMA MINERAL OIL;
00107875;
mineral oil 100 %;
1969-12-31;
Rectal;
Enema;
56:12.00 – CATHARTICS AND LAXATIVES;
Otc;
C B FLEET COMPANY INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=721
MINERAL OIL (HEAVY);
01935348;
mineral oil 100 %;
1991-12-31;
Oral;
Liquid;
56:12.00 – CATHARTICS AND LAXATIVES;
Otc;
RW CONSUMER PRODUCTS LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=11629
MINERAL OIL;
00485802;
mineral oil 100 %;
1981-12-31;
Oral;
Liquid;
56:12.00 – CATHARTICS AND LAXATIVES;
Otc;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=41536
HUILE MINERALE LOURDE LIQ 100% USP;
00704172;
mineral oil 100 %;
1951-12-31;
Oral;
Liquid;
56:12.00 – CATHARTICS AND LAXATIVES;
Otc;
LABORATOIRE ATLAS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=41698
EUCERIN AQUAPHOR HEALING OINTMENT;
02446189;
mineral oil 52.74 % / w/w;
2020-09-18;
Topical;
Ointment;
84:24.12 – BASIC OINTMENTS AND PROTECTANTS;
Otc;
BEIERSDORF CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93145
LANSOYL GEL 78%;
00608734;
mineral oil 78 %;
1975-12-31;
Oral;
Gel;
56:12.00 – CATHARTICS AND LAXATIVES;
Otc;
AURIUM PHARMA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=5792
LANSOYL SUGAR FREE – JELLY – 78%;
02186926;
mineral oil 78 %;
1996-12-31;
Oral;
Gel;
56:12.00 – CATHARTICS AND LAXATIVES;
Otc;
AURIUM PHARMA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=20312
MINERAL OIL USP;
02381834;
mineral oil 99.9 % / w/w;
2013-02-07;
Oral;
Solution;
56:12.00 – CATHARTICS AND LAXATIVES;
Otc;
VI-JON, LLC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86767
MINERALE LEGERE HUILE;
00050520;
mineral oil light 100 %;
1951-12-31;
Topical;
Liquid;
84:24.12 – BASIC OINTMENTS AND PROTECTANTS;
Otc;
LABORATOIRE ATLAS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=57
LIGHT MINERAL OIL 100% NF;
01935321;
mineral oil light 100 %;
1993-12-31;
Topical;
Liquid;
84:24.12 – BASIC OINTMENTS AND PROTECTANTS;
Otc;
RW CONSUMER PRODUCTS LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=14042
STERILE LIGHT MINERAL OIL 100%;
02203375;
mineral oil light 100 % / v/v;
2001-07-27;
Topical;
Oil;
84:24.12 – BASIC OINTMENTS AND PROTECTANTS;
Otc;
OMEGA LABORATORIES LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=36404
ARESTIN MICROSPHERES;
02278219;
minocycline (minocycline hydrochloride) 1 mg / 4 mg;
2008-07-27;
Subgingival;
Powder (Extended Release);
52:04.04 – ANTIBACTERIALS;
Prescription;
ORAPHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=76380
MINOCYCLINE;
02084104;
minocycline (minocycline hydrochloride) 100 mg;
1994-12-31;
Oral;
Capsule;
08:12.24 – TETRACYCLINES;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=15925
MINOCYCLINE;
02084090;
minocycline (minocycline hydrochloride) 50 mg;
1994-12-31;
Oral;
Capsule;
08:12.24 – TETRACYCLINES;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=15927
LONITEN 10MG;
00514500;
minoxidil 10 mg;
1980-12-31;
Oral;
Tablet;
24:08.20 – DIRECT VASODILATORS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=4010
LONITEN 2.5MG;
00514497;
minoxidil 2.5 mg;
1980-12-31;
Oral;
Tablet;
24:08.20 – DIRECT VASODILATORS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=4011
MEN’S ROGAINE;
00708925;
minoxidil 20 mg / ml;
1986-12-31;
Topical;
Solution;
84:92.00 – MISC. SKIN AND MUCOUS MEMBRANE AGENTS;
Otc;
JOHNSON & JOHNSON INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=7084
HAIR REGROWTH FORMULA;
02356597;
minoxidil 20 mg / ml;
2011-04-15;
Topical;
Solution;
84:92.00 – MISC. SKIN AND MUCOUS MEMBRANE AGENTS;
Otc;
VITA HEALTH PRODUCTS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84173
MEN’S ROGAINE FOAM 5%;
02368684;
minoxidil 5 % / w/w;
2012-11-19;
Topical;
Aerosol, Foam;
84:92.00 – MISC. SKIN AND MUCOUS MEMBRANE AGENTS;
Otc;
JOHNSON & JOHNSON INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85367
WOMEN’S ROGAINE FOAM 5%;
02424703;
minoxidil 5 % / w/w;
2015-03-16;
Topical;
Aerosol, Foam;
84:92.00 – MISC. SKIN AND MUCOUS MEMBRANE AGENTS;
Otc;
JOHNSON & JOHNSON INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90937
MYRBETRIQ;
02402874;
mirabegron 25 mg;
2013-03-28;
Oral;
Tablet (Extended-Release);
86:12.08.12 – Selective Beta 3-Adrenergic Agonists;
Prescription;
ASTELLAS PHARMA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88770
MYRBETRIQ;
02402882;
mirabegron 50 mg;
2013-03-28;
Oral;
Tablet (Extended-Release);
86:12.08.12 – Selective Beta 3-Adrenergic Agonists;
Prescription;
ASTELLAS PHARMA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88771
REMERON RD;
02248542;
mirtazapine 15 mg;
2003-12-22;
Oral;
Tablet (Orally Disintegrating);
28:16.04.92 – MISCELLANEOUS ANTIDEPRESSANTS;
Prescription;
MERCK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=72897
SANDOZ MIRTAZAPINE;
02250594;
mirtazapine 15 mg;
2004-03-31;
Oral;
Tablet;
28:16.04.92 – MISCELLANEOUS ANTIDEPRESSANTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=73540
MYLAN-MIRTAZAPINE;
02256096;
mirtazapine 15 mg;
2004-08-17;
Oral;
Tablet;
28:16.04.92 – MISCELLANEOUS ANTIDEPRESSANTS;
Prescription;
MYLAN PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=74133
PMS-MIRTAZAPINE;
02273942;
mirtazapine 15 mg;
2005-11-30;
Oral;
Tablet;
28:16.04.92 – MISCELLANEOUS ANTIDEPRESSANTS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=75940
APO-MIRTAZAPINE;
02286610;
mirtazapine 15 mg;
2006-10-04;
Oral;
Tablet;
28:16.04.92 – MISCELLANEOUS ANTIDEPRESSANTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=77206
AURO-MIRTAZAPINE OD;
02299801;
mirtazapine 15 mg;
2010-12-20;
Oral;
Tablet (Orally Disintegrating);
28:16.04.92 – MISCELLANEOUS ANTIDEPRESSANTS;
Prescription;
AURO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78516
PRO-MIRTAZAPINE;
02312778;
mirtazapine 15 mg;
2008-07-10;
Oral;
Tablet;
28:16.04.92 – MISCELLANEOUS ANTIDEPRESSANTS;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=79829
AURO-MIRTAZAPINE;
02411695;
mirtazapine 15 mg;
2013-10-16;
Oral;
Tablet;
28:16.04.92 – MISCELLANEOUS ANTIDEPRESSANTS;
Prescription;
AURO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=89629
MIRTAZAPINE;
02496666;
mirtazapine 15 mg;
2020-10-22;
Oral;
Tablet;
28:16.04.92 – MISCELLANEOUS ANTIDEPRESSANTS;
Prescription;
SIVEM PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98652
REMERON;
02243910;
mirtazapine 30 mg;
2001-05-24;
Oral;
Tablet;
28:16.04.92 – MISCELLANEOUS ANTIDEPRESSANTS;
Prescription;
MERCK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=67852
REMERON RD;
02248543;
mirtazapine 30 mg;
2003-12-22;
Oral;
Tablet (Orally Disintegrating);
28:16.04.92 – MISCELLANEOUS ANTIDEPRESSANTS;
Prescription;
MERCK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=72898
PMS-MIRTAZAPINE;
02248762;
mirtazapine 30 mg;
2004-01-14;
Oral;
Tablet;
28:16.04.92 – MISCELLANEOUS ANTIDEPRESSANTS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=73130
SANDOZ MIRTAZAPINE;
02250608;
mirtazapine 30 mg;
2004-03-31;
Oral;
Tablet;
28:16.04.92 – MISCELLANEOUS ANTIDEPRESSANTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=73541
MYLAN-MIRTAZAPINE;
02256118;
mirtazapine 30 mg;
2004-08-17;
Oral;
Tablet;
28:16.04.92 – MISCELLANEOUS ANTIDEPRESSANTS;
Prescription;
MYLAN PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=74134
TEVA-MIRTAZAPINE;
02259354;
mirtazapine 30 mg;
2005-10-22;
Oral;
Tablet;
28:16.04.92 – MISCELLANEOUS ANTIDEPRESSANTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=74461
APO-MIRTAZAPINE;
02286629;
mirtazapine 30 mg;
2006-10-04;
Oral;
Tablet;
28:16.04.92 – MISCELLANEOUS ANTIDEPRESSANTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=77207
AURO-MIRTAZAPINE OD;
02299828;
mirtazapine 30 mg;
2010-12-20;
Oral;
Tablet (Orally Disintegrating);
28:16.04.92 – MISCELLANEOUS ANTIDEPRESSANTS;
Prescription;
AURO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78517
PRO-MIRTAZAPINE;
02312786;
mirtazapine 30 mg;
2008-07-10;
Oral;
Tablet;
28:16.04.92 – MISCELLANEOUS ANTIDEPRESSANTS;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=79830
MIRTAZAPINE;
02370689;
mirtazapine 30 mg;
2011-09-21;
Oral;
Tablet;
28:16.04.92 – MISCELLANEOUS ANTIDEPRESSANTS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85581
AURO-MIRTAZAPINE;
02411709;
mirtazapine 30 mg;
2013-10-16;
Oral;
Tablet;
28:16.04.92 – MISCELLANEOUS ANTIDEPRESSANTS;
Prescription;
AURO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=89630
MIRTAZAPINE;
02496674;
mirtazapine 30 mg;
2020-10-22;
Oral;
Tablet;
28:16.04.92 – MISCELLANEOUS ANTIDEPRESSANTS;
Prescription;
SIVEM PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98653
REMERON RD;
02248544;
mirtazapine 45 mg;
2003-12-22;
Oral;
Tablet (Orally Disintegrating);
28:16.04.92 – MISCELLANEOUS ANTIDEPRESSANTS;
Prescription;
MERCK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=72899
MYLAN-MIRTAZAPINE;
02256126;
mirtazapine 45 mg;
2004-08-17;
Oral;
Tablet;
28:16.04.92 – MISCELLANEOUS ANTIDEPRESSANTS;
Prescription;
MYLAN PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=74135
APO-MIRTAZAPINE;
02286637;
mirtazapine 45 mg;
2006-10-04;
Oral;
Tablet;
28:16.04.92 – MISCELLANEOUS ANTIDEPRESSANTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=77208
AURO-MIRTAZAPINE OD;
02299836;
mirtazapine 45 mg;
2010-12-20;
Oral;
Tablet (Orally Disintegrating);
28:16.04.92 – MISCELLANEOUS ANTIDEPRESSANTS;
Prescription;
AURO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78518
AURO-MIRTAZAPINE;
02411717;
mirtazapine 45 mg;
2013-10-16;
Oral;
Tablet;
28:16.04.92 – MISCELLANEOUS ANTIDEPRESSANTS;
Prescription;
AURO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=89632
MIRTAZAPINE;
02496682;
mirtazapine 45 mg;
2020-10-22;
Oral;
Tablet;
28:16.04.92 – MISCELLANEOUS ANTIDEPRESSANTS;
Prescription;
SIVEM PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98654
MISOPROSTOL;
02244022;
misoprostol 100 mcg;
2001-06-18;
Oral;
Tablet;
56:28.28 – PROSTAGLANDINS;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=67965
MISOPROSTOL;
02244023;
misoprostol 200 mcg;
2001-06-18;
Oral;
Tablet;
56:28.28 – PROSTAGLANDINS;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=67966
MITOMYCIN FOR INJECTION;
02230451;
mitomycin 20 mg / vial;
1997-10-22;
Intravenous , Intravesical;
Powder For Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=49400
MITOMYCIN FOR INJECTION USP;
02464691;
mitomycin 20 mg / vial;
2018-04-30;
Intravenous , Intravesical;
Powder For Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
ACCORD HEALTHCARE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95282
LYSODREN;
00463221;
mitotane 500 mg;
1979-12-31;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
HRA PHARMA RARE DISEASES
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=3348
MITOXANTRONE INJECTION;
02286300;
mitoxantrone (mitoxantrone hydrochloride) 2 mg / ml;
2007-12-03;
Intravenous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
FRESENIUS KABI CANADA LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=77176
ADDERALL XR;
02248809;
mixed salts amphetamine 10 mg;
2004-01-30;
Oral;
Capsule (Extended Release);
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=73178
ACT AMPHETAMINE XR;
02439247;
mixed salts amphetamine 10 mg;
2015-10-02;
Oral;
Capsule (Extended Release);
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92363
APO-AMPHETAMINE XR;
02445506;
mixed salts amphetamine 10 mg;
2019-04-15;
Oral;
Capsule (Extended Release);
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93078
SANDOZ AMPHETAMINE XR;
02457296;
mixed salts amphetamine 10 mg;
2016-12-22;
Oral;
Capsule (Extended Release);
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94436
ADDERALL XR;
02248810;
mixed salts amphetamine 15 mg;
2004-01-30;
Oral;
Capsule (Extended Release);
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=73179
ACT AMPHETAMINE XR;
02439255;
mixed salts amphetamine 15 mg;
2015-10-02;
Oral;
Capsule (Extended Release);
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92364
APO-AMPHETAMINE XR;
02445514;
mixed salts amphetamine 15 mg;
2019-04-15;
Oral;
Capsule (Extended Release);
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93079
SANDOZ AMPHETAMINE XR;
02457318;
mixed salts amphetamine 15 mg;
2016-12-22;
Oral;
Capsule (Extended Release);
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94437
ADDERALL XR;
02248811;
mixed salts amphetamine 20 mg;
2004-01-30;
Oral;
Capsule (Extended Release);
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=73180
ACT AMPHETAMINE XR;
02439263;
mixed salts amphetamine 20 mg;
2015-10-02;
Oral;
Capsule (Extended Release);
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92365
APO-AMPHETAMINE XR;
02445522;
mixed salts amphetamine 20 mg;
2019-04-26;
Oral;
Capsule (Extended Release);
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93080
SANDOZ AMPHETAMINE XR;
02457326;
mixed salts amphetamine 20 mg;
2016-12-22;
Oral;
Capsule (Extended Release);
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94438
ADDERALL XR;
02248812;
mixed salts amphetamine 25 mg;
2004-01-30;
Oral;
Capsule (Extended Release);
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=73181
ACT AMPHETAMINE XR;
02439271;
mixed salts amphetamine 25 mg;
2015-10-02;
Oral;
Capsule (Extended Release);
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92366
APO-AMPHETAMINE XR;
02445530;
mixed salts amphetamine 25 mg;
2019-04-15;
Oral;
Capsule (Extended Release);
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93081
SANDOZ AMPHETAMINE XR;
02457334;
mixed salts amphetamine 25 mg;
2016-12-22;
Oral;
Capsule (Extended Release);
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94439
ADDERALL XR;
02248813;
mixed salts amphetamine 30 mg;
2004-01-30;
Oral;
Capsule (Extended Release);
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=73182
ACT AMPHETAMINE XR;
02439298;
mixed salts amphetamine 30 mg;
2015-10-02;
Oral;
Capsule (Extended Release);
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92367
APO-AMPHETAMINE XR;
02445549;
mixed salts amphetamine 30 mg;
2019-04-15;
Oral;
Capsule (Extended Release);
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93082
SANDOZ AMPHETAMINE XR;
02457342;
mixed salts amphetamine 30 mg;
2016-12-22;
Oral;
Capsule (Extended Release);
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94440
ADDERALL XR;
02248808;
mixed salts amphetamine 5 mg;
2004-01-30;
Oral;
Capsule (Extended Release);
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=73177
ACT AMPHETAMINE XR;
02439239;
mixed salts amphetamine 5 mg;
2015-10-02;
Oral;
Capsule (Extended Release);
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92362
APO-AMPHETAMINE XR;
02445492;
mixed salts amphetamine 5 mg;
2019-04-15;
Oral;
Capsule (Extended Release);
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93077
SANDOZ AMPHETAMINE XR;
02457288;
mixed salts amphetamine 5 mg;
2016-12-22;
Oral;
Capsule (Extended Release);
28:20.04 – AMPHETAMINES;
Schedule G (Cdsa I);
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94435
MOCLOBEMIDE;
02232148;
moclobemide 100 mg;
1997-09-18;
Oral;
Tablet;
28:16.04.12 – MONOAMINE OXIDASE INHIBITORS;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=51594
MANERIX;
00899356;
moclobemide 150 mg;
1992-12-31;
Oral;
Tablet;
28:16.04.12 – MONOAMINE OXIDASE INHIBITORS;
Prescription;
VALEANT CANADA LP/VALEANT CANADA S.E.C.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=13256
MOCLOBEMIDE;
02232150;
moclobemide 150 mg;
1997-09-18;
Oral;
Tablet;
28:16.04.12 – MONOAMINE OXIDASE INHIBITORS;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=51595
MANERIX;
02166747;
moclobemide 300 mg;
1995-12-31;
Oral;
Tablet;
28:16.04.12 – MONOAMINE OXIDASE INHIBITORS;
Prescription;
VALEANT CANADA LP/VALEANT CANADA S.E.C.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=18969
MOCLOBEMIDE;
02240456;
moclobemide 300 mg;
1999-07-14;
Oral;
Tablet;
28:16.04.12 – MONOAMINE OXIDASE INHIBITORS;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=64019
ALERTEC;
02239665;
modafinil 100 mg;
1999-03-24;
Oral;
Tablet;
28:20.80 – Wakefulness-Promoting Agents;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=63139
APO-MODAFINIL;
02285398;
modafinil 100 mg;
2008-05-01;
Oral;
Tablet;
28:20.80 – Wakefulness-Promoting Agents;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=77089
TEVA-MODAFINIL;
02420260;
modafinil 100 mg;
2014-07-02;
Oral;
Tablet;
28:20.80 – Wakefulness-Promoting Agents;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90485
AURO-MODAFINIL;
02430487;
modafinil 100 mg;
2014-10-24;
Oral;
Tablet;
28:20.80 – Wakefulness-Promoting Agents;
Prescription;
AURO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=91494
MAR-MODAFINIL;
02432560;
modafinil 100 mg;
2015-01-09;
Oral;
Tablet;
28:20.80 – Wakefulness-Promoting Agents;
Prescription;
MARCAN PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=91701
JAMP MODAFINIL;
02503727;
modafinil 100 mg;
2021-03-11;
Oral;
Tablet;
28:20.80 – Wakefulness-Promoting Agents;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=99317
IMVAMUNE;
02416638;
modified vaccinia virus (ankara-bavarian nordic) 50000000 ccid50 / 0.5 ml;
2015-06-15;
Subcutaneous;
Suspension;
80:12.00 – VACCINES;
Schedule D;
BAVARIAN NORDIC AS
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90121
SANDOZ MOMETASONE;
02449811;
mometasone furoate (mometasone furoate monohydrate) 50 mcg / act;
2016-07-27;
Nasal;
Spray, Metered Dose;
52:08.08 – CORTICOSTEROIDS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93568
ELOCOM;
00851744;
mometasone furoate 0.1 %;
1991-12-31;
Topical;
Cream;
84:06.00 – ANTI-INFLAMMATORY AGENTS;
Prescription;
MERCK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=11196
ELOCOM;
00871095;
mometasone furoate 0.1 %;
1991-12-31;
Topical;
Lotion;
84:06.00 – ANTI-INFLAMMATORY AGENTS;
Prescription;
MERCK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=11443
ELOCOM;
00851736;
mometasone furoate 0.1 %;
1991-12-31;
Topical;
Ointment;
84:06.00 – ANTI-INFLAMMATORY AGENTS;
Prescription;
MERCK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=11444
TEVA-MOMETASONE;
02248130;
mometasone furoate 0.1 %;
2003-11-04;
Topical;
Ointment;
84:06.00 – ANTI-INFLAMMATORY AGENTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=72459
TARO-MOMETASONE LOTION;
02266385;
mometasone furoate 0.1 % / w/w;
2009-12-01;
Topical;
Lotion;
84:06.00 – ANTI-INFLAMMATORY AGENTS;
Prescription;
TARO PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=75180
TARO-MOMETASONE CREAM;
02367157;
mometasone furoate 0.1 % / w/w;
2011-06-08;
Topical;
Cream;
84:06.00 – ANTI-INFLAMMATORY AGENTS;
Prescription;
TARO PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85196
ASMANEX TWISTHALER;
02438690;
mometasone furoate 100 mcg / act;
2015-04-08;
Inhalation;
Powder;
68:04.00 – ADRENALS;
Prescription;
ORGANON CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92309
ASMANEX TWISTHALER;
02243595;
mometasone furoate 200 mcg / act;
2011-12-21;
Inhalation;
Powder;
68:04.00 – ADRENALS;
Prescription;
ORGANON CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=67513
ASMANEX TWISTHALER;
02243596;
mometasone furoate 400 mcg / act;
2011-12-21;
Inhalation;
Powder;
68:04.00 – ADRENALS;
Prescription;
ORGANON CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=67514
NASONEX;
02238465;
mometasone furoate 50 mcg / act;
1998-09-15;
Nasal;
Spray, Metered Dose;
52:08.08 – CORTICOSTEROIDS;
Prescription;
MERCK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=61885
APO-MOMETASONE;
02403587;
mometasone furoate 50 mcg / act;
2013-03-25;
Nasal;
Spray, Metered Dose;
52:08.08 – CORTICOSTEROIDS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88837
TEVA-MOMETASONE;
02475863;
mometasone furoate 50 mcg / act;
2018-10-02;
Nasal;
Spray, Metered Dose;
52:08.08 – CORTICOSTEROIDS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96662
SINGULAIR;
02238217;
montelukast (montelukast sodium) 10 mg;
1998-08-21;
Oral;
Tablet;
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
MERCK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=61610
SANDOZ MONTELUKAST TABLET;
02328593;
montelukast (montelukast sodium) 10 mg;
2011-10-11;
Oral;
Tablet;
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=81411
TEVA-MONTELUKAST;
02355523;
montelukast (montelukast sodium) 10 mg;
2011-10-11;
Oral;
Tablet;
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84075
PMS-MONTELUKAST FC;
02373947;
montelukast (montelukast sodium) 10 mg;
2011-10-11;
Oral;
Tablet;
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85916
APO-MONTELUKAST;
02374609;
montelukast (montelukast sodium) 10 mg;
2012-01-20;
Oral;
Tablet;
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85993
ACH-MONTELUKAST;
02379236;
montelukast (montelukast sodium) 10 mg;
2012-03-28;
Oral;
Tablet;
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
ACCORD HEALTHCARE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86511
MONTELUKAST;
02379333;
montelukast (montelukast sodium) 10 mg;
2012-03-21;
Oral;
Tablet;
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86521
MONTELUKAST;
02379856;
montelukast (montelukast sodium) 10 mg;
2012-03-29;
Oral;
Tablet;
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86571
MONTELUKAST;
02382474;
montelukast (montelukast sodium) 10 mg;
2012-06-10;
Oral;
Tablet;
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
SIVEM PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86831
TARO-MONTELUKAST;
02389517;
montelukast (montelukast sodium) 10 mg;
2013-01-17;
Oral;
Tablet;
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
SUN PHARMA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87502
JAMP-MONTELUKAST;
02391422;
montelukast (montelukast sodium) 10 mg;
2012-09-21;
Oral;
Tablet;
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87677
RIVA-MONTELUKAST FC;
02398826;
montelukast (montelukast sodium) 10 mg;
2013-01-17;
Oral;
Tablet;
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
LABORATOIRE RIVA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88374
MAR-MONTELUKAST;
02399997;
montelukast (montelukast sodium) 10 mg;
2013-12-30;
Oral;
Tablet;
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
MARCAN PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88483
AURO-MONTELUKAST;
02401274;
montelukast (montelukast sodium) 10 mg;
2013-03-04;
Oral;
Tablet;
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
AURO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88618
MINT-MONTELUKAST;
02408643;
montelukast (montelukast sodium) 10 mg;
2013-10-17;
Oral;
Tablet;
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
MINT PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=89338
PRIVA-MONTELUKAST;
02440350;
montelukast (montelukast sodium) 10 mg;
2018-11-07;
Oral;
Tablet;
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
PHARMAPAR INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92471
BIO-MONTELUKAST;
02445735;
montelukast (montelukast sodium) 10 mg;
2018-11-07;
Oral;
Tablet;
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
BIOMED PHARMA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93101
AG-MONTELUKAST;
02482835;
montelukast (montelukast sodium) 10 mg;
2019-12-10;
Oral;
Tablet;
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
ANGITA PHARMA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97324
M-MONTELUKAST;
02488183;
montelukast (montelukast sodium) 10 mg;
2019-12-13;
Oral;
Tablet;
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
MANTRA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97829
NRA-MONTELUKAST;
02489821;
montelukast (montelukast sodium) 10 mg;
2019-12-28;
Oral;
Tablet;
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
NORA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97990
SINGULAIR;
02243602;
montelukast (montelukast sodium) 4 mg;
2001-04-09;
Oral;
Tablet (Chewable);
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
MERCK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=67521
SANDOZ MONTELUKAST;
02330385;
montelukast (montelukast sodium) 4 mg;
2011-10-11;
Oral;
Tablet (Chewable);
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=81612
PMS-MONTELUKAST;
02354977;
montelukast (montelukast sodium) 4 mg;
2011-10-11;
Oral;
Tablet (Chewable);
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84016
TEVA-MONTELUKAST;
02355507;
montelukast (montelukast sodium) 4 mg;
2011-10-11;
Oral;
Tablet (Chewable);
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84073
APO-MONTELUKAST;
02377608;
montelukast (montelukast sodium) 4 mg;
2013-02-15;
Oral;
Tablet (Chewable);
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86341
MONTELUKAST;
02379821;
montelukast (montelukast sodium) 4 mg;
2012-03-29;
Oral;
Tablet (Chewable);
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86569
MONTELUKAST;
02382458;
montelukast (montelukast sodium) 4 mg;
2012-06-10;
Oral;
Tablet (Chewable);
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
SIVEM PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86829
MAR-MONTELUKAST;
02399865;
montelukast (montelukast sodium) 4 mg;
2013-12-30;
Oral;
Tablet (Chewable);
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
MARCAN PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88471
MINT-MONTELUKAST;
02408627;
montelukast (montelukast sodium) 4 mg;
2013-10-17;
Oral;
Tablet (Chewable);
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
MINT PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=89336
JAMP-MONTELUKAST;
02442353;
montelukast (montelukast sodium) 4 mg;
2018-11-09;
Oral;
Tablet (Chewable);
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92672
SINGULAIR;
02247997;
montelukast (montelukast sodium) 4 mg / sachet;
2004-02-20;
Oral;
Granules;
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
MERCK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=72310
SANDOZ MONTELUKAST GRANULES;
02358611;
montelukast (montelukast sodium) 4 mg / sachet;
2011-10-11;
Oral;
Granules;
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84365
SINGULAIR;
02238216;
montelukast (montelukast sodium) 5 mg;
1998-08-21;
Oral;
Tablet (Chewable);
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
MERCK CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=61609
SANDOZ MONTELUKAST;
02330393;
montelukast (montelukast sodium) 5 mg;
2011-10-11;
Oral;
Tablet (Chewable);
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=81613
PMS-MONTELUKAST;
02354985;
montelukast (montelukast sodium) 5 mg;
2011-10-11;
Oral;
Tablet (Chewable);
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84017
TEVA-MONTELUKAST;
02355515;
montelukast (montelukast sodium) 5 mg;
2011-10-11;
Oral;
Tablet (Chewable);
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84074
APO-MONTELUKAST;
02377616;
montelukast (montelukast sodium) 5 mg;
2013-02-15;
Oral;
Tablet (Chewable);
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86342
MONTELUKAST;
02379848;
montelukast (montelukast sodium) 5 mg;
2012-03-29;
Oral;
Tablet (Chewable);
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86570
MONTELUKAST;
02382466;
montelukast (montelukast sodium) 5 mg;
2012-06-10;
Oral;
Tablet (Chewable);
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
SIVEM PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86830
MAR-MONTELUKAST;
02399873;
montelukast (montelukast sodium) 5 mg;
2013-12-30;
Oral;
Tablet (Chewable);
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
MARCAN PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88472
MINT-MONTELUKAST;
02408635;
montelukast (montelukast sodium) 5 mg;
2013-10-17;
Oral;
Tablet (Chewable);
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
MINT PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=89337
JAMP-MONTELUKAST;
02442361;
montelukast (montelukast sodium) 5 mg;
2018-11-09;
Oral;
Tablet (Chewable);
48:10.24 – LEUKOTRIENE MODIFIERS;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92673
XYNTHA SOLOFUSE;
02374072;
moroctocog alfa 1000 unit / syr;
2012-04-13;
Intravenous;
Powder For Solution;
20:28.16 – HEMOSTATICS;
Schedule D;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85927
XYNTHA SOLOFUSE;
02374080;
moroctocog alfa 2000 unit / syr;
2012-05-08;
Intravenous;
Powder For Solution;
20:28.16 – HEMOSTATICS;
Schedule D;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85928
XYNTHA;
02309483;
moroctocog alfa 250 unit / vial;
2009-01-23;
Intravenous;
Kit , Powder For Solution;
20:28.16 – HEMOSTATICS;
Schedule D;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=79508
XYNTHA SOLOFUSE;
02374099;
moroctocog alfa 3000 unit / syr;
2012-05-08;
Intravenous;
Powder For Solution;
20:28.16 – HEMOSTATICS;
Schedule D;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85929
XYNTHA SOLOFUSE;
02374064;
moroctocog alfa 500 unit / syr;
2019-09-27;
Intravenous;
Powder For Solution;
20:28.16 – HEMOSTATICS;
Schedule D;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85926
XYNTHA;
02309491;
moroctocog alfa 500 unit / vial;
2009-01-23;
Intravenous;
Kit , Powder For Solution;
20:28.16 – HEMOSTATICS;
Schedule D;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=79509
DOLORAL 1;
00614491;
morphine hydrochloride 1 mg / ml;
1985-12-31;
Oral;
Syrup;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
LABORATOIRE ATLAS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=6171
DOLORAL 5 SIROP 5MG/ML;
00614505;
morphine hydrochloride 5 mg / ml;
1991-12-31;
Oral;
Syrup;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
LABORATOIRE ATLAS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=11597
MORPHINE LP EPIDURAL;
02021056;
morphine sulfate 0.5 mg / ml;
1993-12-31;
Intravenous , Subcutaneous , Epidural;
Solution;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=13966
MORPHINE LP EPIDURAL;
02021048;
morphine sulfate 1 mg / ml;
1993-12-31;
Intravenous , Subcutaneous , Epidural;
Solution;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=14020
STATEX TAB 10MG;
00594644;
morphine sulfate 10 mg;
1985-12-31;
Oral;
Tablet;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PALADIN LABS INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=6754
MS.IR;
02014211;
morphine sulfate 10 mg;
1993-12-31;
Oral;
Tablet (Immediate Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PURDUE PHARMA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=14144
M-ESLON;
02019930;
morphine sulfate 10 mg;
1993-12-31;
Oral;
Capsule (Extended Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
ETHYPHARM INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=14543
KADIAN;
02242163;
morphine sulfate 10 mg;
2001-12-11;
Oral;
Capsule (Sustained-Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
BGP PHARMA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=65841
MORPHINE SULFATE INJ 10MG/ML USP;
00392588;
morphine sulfate 10 mg / ml;
1978-12-31;
Intramuscular , Intravenous , Subcutaneous;
Liquid;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=3043
MORPHINE SULFATE INJECTION SDZ;
02382997;
morphine sulfate 10 mg / ml;
2012-10-18;
Intramuscular , Intravenous , Subcutaneous;
Solution;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86878
MORPHINE SULFATE INJECTION BP;
02474980;
morphine sulfate 10 mg / ml;
2018-09-21;
Intramuscular , Intravenous , Subcutaneous;
Solution;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
STERIMAX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96526
MORPHINE SULFATE INJECTION, USP;
02482746;
morphine sulfate 10 mg / 1 ml;
2019-12-17;
Intramuscular , Intravenous , Subcutaneous;
Solution;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
FRESENIUS KABI CANADA LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97315
MS CONTIN SRT 100MG;
02014319;
morphine sulfate 100 mg;
1993-12-31;
Oral;
Tablet (Extended-Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PURDUE PHARMA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=14178
M-ESLON;
02019965;
morphine sulfate 100 mg;
1993-12-31;
Oral;
Capsule (Extended Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
ETHYPHARM INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=14541
KADIAN;
02184451;
morphine sulfate 100 mg;
1996-10-25;
Oral;
Capsule (Sustained-Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
BGP PHARMA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=42848
TEVA-MORPHINE SR;
02302799;
morphine sulfate 100 mg;
2008-04-01;
Oral;
Tablet (Extended-Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78811
SANDOZ MORPHINE SR;
02478889;
morphine sulfate 100 mg;
2018-12-19;
Oral;
Tablet (Extended-Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96959
MORPHINE SULFATE INJECTION USP;
02491931;
morphine sulfate 100 mg / 100 ml;
2020-08-25;
Intravenous;
Solution;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
STERINOVA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98194
MS CONTIN SRT 15MG;
02015439;
morphine sulfate 15 mg;
1993-12-31;
Oral;
Tablet (Extended-Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PURDUE PHARMA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=14395
M-ESLON;
02177749;
morphine sulfate 15 mg;
1995-12-31;
Oral;
Capsule (Extended Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
ETHYPHARM INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=18878
SANDOZ MORPHINE SR;
02244790;
morphine sulfate 15 mg;
2001-11-14;
Oral;
Tablet (Extended-Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=68780
TEVA-MORPHINE SR;
02302764;
morphine sulfate 15 mg;
2009-03-25;
Oral;
Tablet (Extended-Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78808
MORPHINE SULFATE INJ 15MG/ML USP;
00392561;
morphine sulfate 15 mg / ml;
1978-12-31;
Intramuscular , Intravenous , Subcutaneous;
Liquid;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=3042
MORPHINE SULFATE INJECTION USP;
02242484;
morphine sulfate 2 mg / ml;
2000-12-12;
Intramuscular , Intravenous , Subcutaneous;
Liquid;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=66221
MORPHINE SULFATE INJECTION, USP;
02482681;
morphine sulfate 2 mg / 1 ml;
2019-12-17;
Intramuscular , Intravenous , Subcutaneous;
Solution;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
FRESENIUS KABI CANADA LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97311
STATEX SUPPOSITORIES 20MG;
00596965;
morphine sulfate 20 mg;
1985-12-31;
Rectal;
Suppository;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PALADIN LABS INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=6129
MS.IR;
02014238;
morphine sulfate 20 mg;
1991-12-31;
Oral;
Tablet (Immediate Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PURDUE PHARMA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=16480
KADIAN;
02184435;
morphine sulfate 20 mg;
1996-10-25;
Oral;
Capsule (Sustained-Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
BGP PHARMA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=42846
MS CONTIN SRT 200MG;
02014327;
morphine sulfate 200 mg;
1993-12-31;
Oral;
Tablet (Extended-Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PURDUE PHARMA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=14142
M-ESLON;
02177757;
morphine sulfate 200 mg;
1995-12-31;
Oral;
Capsule (Extended Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
ETHYPHARM INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=18877
TEVA-MORPHINE SR;
02302802;
morphine sulfate 200 mg;
2008-04-01;
Oral;
Tablet (Extended-Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78812
SANDOZ MORPHINE SR;
02478897;
morphine sulfate 200 mg;
2018-12-19;
Oral;
Tablet (Extended-Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96961
STATEX TABLET 25MG;
00594636;
morphine sulfate 25 mg;
1985-12-31;
Oral;
Tablet;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PALADIN LABS INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=6753
MS CONTIN SRT 30MG;
02014297;
morphine sulfate 30 mg;
1993-12-31;
Oral;
Tablet (Extended-Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PURDUE PHARMA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=14176
M-ESLON;
02019949;
morphine sulfate 30 mg;
1993-12-31;
Oral;
Capsule (Extended Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
ETHYPHARM INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=14502
MS.IR;
02014254;
morphine sulfate 30 mg;
1991-12-31;
Oral;
Tablet (Immediate Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PURDUE PHARMA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=16481
STATEX SUPPOSITORIES 30MG;
00639389;
morphine sulfate 30 mg;
1997-08-04;
Rectal;
Suppository;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PALADIN LABS INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=51392
SANDOZ MORPHINE SR;
02244791;
morphine sulfate 30 mg;
2001-11-14;
Oral;
Tablet (Extended-Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=68781
TEVA-MORPHINE SR;
02302772;
morphine sulfate 30 mg;
2009-03-25;
Oral;
Tablet (Extended-Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78809
STATEX TAB 5MG;
00594652;
morphine sulfate 5 mg;
1985-12-31;
Oral;
Tablet;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PALADIN LABS INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=6755
MS.IR;
02014203;
morphine sulfate 5 mg;
1991-12-31;
Oral;
Tablet (Immediate Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PURDUE PHARMA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=16102
STATEX TABLETS 50MG;
00675962;
morphine sulfate 50 mg;
1986-12-31;
Oral;
Tablet;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PALADIN LABS INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=6757
KADIAN;
02184443;
morphine sulfate 50 mg;
1996-10-23;
Oral;
Capsule (Sustained-Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
BGP PHARMA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=42847
MORPHINE HP 50 – 50MG/ML USP;
00617288;
morphine sulfate 50 mg / ml;
1987-12-31;
Intramuscular , Intravenous , Subcutaneous;
Solution;
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=7421
MS CONTIN SRT 60MG;
02014300;
morphine sulfate 60 mg;
1993-12-31;
Oral;
Tablet (Extended-Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
PURDUE PHARMA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=14394
M-ESLON;
02019957;
morphine sulfate 60 mg;
1993-12-31;
Oral;
Capsule (Extended Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
ETHYPHARM INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=14542
SANDOZ MORPHINE SR;
02244792;
morphine sulfate 60 mg;
2001-11-14;
Oral;
Tablet (Extended-Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=68782
TEVA-MORPHINE SR;
02302780;
morphine sulfate 60 mg;
2008-04-01;
Oral;
Tablet (Extended-Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78810
MORPHINE SR;
02350912;
morphine sulfate 60 mg;
2011-03-02;
Oral;
Tablet (Extended-Release);
28:08.08 – OPIATE AGONISTS;
Narcotic (Cdsa I);
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83610
VIGAMOX;
02252260;
moxifloxacin (moxifloxacin hydrochloride) 0.5 %;
2004-05-12;
Ophthalmic;
Solution;
52:04.04 – ANTIBACTERIALS;
Prescription;
NOVARTIS PHARMACEUTICALS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=73714
SANDOZ MOXIFLOXACIN;
02411520;
moxifloxacin (moxifloxacin hydrochloride) 0.5 %;
2015-10-29;
Ophthalmic;
Solution;
52:04.04 – ANTIBACTERIALS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=89614
PMS-MOXIFLOXACIN;
02432218;
moxifloxacin (moxifloxacin hydrochloride) 0.5 %;
2015-12-21;
Ophthalmic;
Solution;
52:04.04 – ANTIBACTERIALS;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=91667
ACT MOXIFLOXACIN;
02404656;
moxifloxacin (moxifloxacin hydrochloride) 0.5 % / w/v;
2015-11-04;
Ophthalmic;
Solution;
52:04.04 – ANTIBACTERIALS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88945
APO-MOXIFLOXACIN;
02406373;
moxifloxacin (moxifloxacin hydrochloride) 0.5 % / w/v;
2015-11-19;
Ophthalmic;
Solution;
52:04.04 – ANTIBACTERIALS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=89109
JAMP-MOXIFLOXACIN;
02472120;
moxifloxacin (moxifloxacin hydrochloride) 0.5 % / w/v;
2019-02-28;
Ophthalmic;
Solution;
52:04.04 – ANTIBACTERIALS;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96141
AG-MOXIFLOXACIN;
02484757;
moxifloxacin (moxifloxacin hydrochloride) 0.5 % / w/v;
2020-07-09;
Ophthalmic;
Solution;
52:04.04 – ANTIBACTERIALS;
Prescription;
ANGITA PHARMA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97504
TEVA-MOXIFLOXACIN;
02375702;
moxifloxacin (moxifloxacin hydrochloride) 400 mg;
2015-11-04;
Oral;
Tablet;
08:12.18 – QUINOLONES;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86112
SANDOZ MOXIFLOXACIN;
02383381;
moxifloxacin (moxifloxacin hydrochloride) 400 mg;
2017-11-30;
Oral;
Tablet;
08:12.18 – QUINOLONES;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86914
APO-MOXIFLOXACIN;
02404923;
moxifloxacin (moxifloxacin hydrochloride) 400 mg;
2016-01-11;
Oral;
Tablet;
08:12.18 – QUINOLONES;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88976
AURO-MOXIFLOXACIN;
02432242;
moxifloxacin (moxifloxacin hydrochloride) 400 mg;
2015-11-04;
Oral;
Tablet;
08:12.18 – QUINOLONES;
Prescription;
AURO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=91672
JAMP-MOXIFLOXACIN;
02443929;
moxifloxacin (moxifloxacin hydrochloride) 400 mg;
2015-11-04;
Oral;
Tablet;
08:12.18 – QUINOLONES;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92870
MAR-MOXIFLOXACIN;
02447053;
moxifloxacin (moxifloxacin hydrochloride) 400 mg;
2015-12-21;
Oral;
Tablet;
08:12.18 – QUINOLONES;
Prescription;
MARCAN PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93263
BIO-MOXIFLOXACIN;
02447266;
moxifloxacin (moxifloxacin hydrochloride) 400 mg;
2016-01-15;
Oral;
Tablet;
08:12.18 – QUINOLONES;
Prescription;
BIOMED PHARMA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93281
RIVA-MOXIFLOXACIN;
02450976;
moxifloxacin (moxifloxacin hydrochloride) 400 mg;
2016-03-31;
Oral;
Tablet;
08:12.18 – QUINOLONES;
Prescription;
LABORATOIRE RIVA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93722
MOXIFLOXACIN;
02462974;
moxifloxacin (moxifloxacin hydrochloride) 400 mg;
2017-04-20;
Oral;
Tablet;
08:12.18 – QUINOLONES;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95086
M-MOXIFLOXACIN;
02472791;
moxifloxacin (moxifloxacin hydrochloride) 400 mg;
2018-03-07;
Oral;
Tablet;
08:12.18 – QUINOLONES;
Prescription;
MANTRA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96210
AG-MOXIFLOXACIN;
02478137;
moxifloxacin (moxifloxacin hydrochloride) 400 mg;
2018-07-23;
Oral;
Tablet;
08:12.18 – QUINOLONES;
Prescription;
ANGITA PHARMA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96886
MOXIFLOXACIN INJECTION;
02433087;
moxifloxacin (moxifloxacin hydrochloride) 400 mg / 250 ml;
2017-08-16;
Intravenous;
Solution;
52:04.04 – ANTIBACTERIALS;
Prescription;
FRESENIUS KABI CANADA LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=91749
COVID-19 VACCINE MODERNA;
02510014;
mrna-1273 sars-cov-2 100 mcg / 0.5 ml;
2020-12-23;
Intramuscular;
Dispersion;
-;
Covid-19 – Io – Authorization , Schedule D;
MODERNATX, INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=99927
STRAMUCIN;
02483459;
mupirocin (mupirocin calcium) 2 % / w/w;
2019-06-05;
Topical;
Cream;
84:04.04 – ANTIBIOTICS;
Otc;
GLENMARK PHARMACEUTICALS CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97385
TARO-MUPIROCIN;
02279983;
mupirocin 2 %;
2006-07-10;
Topical;
Ointment;
84:04.04 – ANTIBIOTICS;
Otc;
TARO PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=76560
CELLCEPT I.V.;
02240347;
mycophenolate mofetil (mycophenolate mofetil hydrochloride) 500 mg / vial;
1999-12-20;
Intravenous;
Powder For Solution;
92:44.00 – IMMUNOSUPPRESSIVE AGENTS;
Prescription;
HOFFMANN-LA ROCHE LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=63885
MYCOPHENOLATE MOFETIL FOR INJECTION, USP;
02444836;
mycophenolate mofetil (mycophenolate mofetil hydrochloride) 500 mg / vial;
2019-04-23;
Intravenous;
Powder For Solution;
92:44.00 – IMMUNOSUPPRESSIVE AGENTS;
Prescription;
ACCORD HEALTHCARE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93003
MYCOPHENOLATE MOFETIL FOR INJECTION USP;
02479974;
mycophenolate mofetil (mycophenolate mofetil hydrochloride) 500 mg / vial;
2018-11-07;
Intravenous;
Powder For Solution;
92:44.00 – IMMUNOSUPPRESSIVE AGENTS;
Prescription;
STERIMAX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97053
CELLCEPT;
02242145;
mycophenolate mofetil 200 mg / ml;
2002-08-27;
Oral;
Powder For Suspension;
92:44.00 – IMMUNOSUPPRESSIVE AGENTS;
Prescription;
HOFFMANN-LA ROCHE LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=65823
CELLCEPT;
02192748;
mycophenolate mofetil 250 mg;
1995-12-31;
Oral;
Capsule;
92:44.00 – IMMUNOSUPPRESSIVE AGENTS;
Prescription;
HOFFMANN-LA ROCHE LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19525
SANDOZ MYCOPHENOLATE MOFETIL;
02320630;
mycophenolate mofetil 250 mg;
2011-11-30;
Oral;
Capsule;
92:44.00 – IMMUNOSUPPRESSIVE AGENTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80604
APO-MYCOPHENOLATE;
02352559;
mycophenolate mofetil 250 mg;
2011-12-01;
Oral;
Capsule;
92:44.00 – IMMUNOSUPPRESSIVE AGENTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83781
TEVA-MYCOPHENOLATE;
02364883;
mycophenolate mofetil 250 mg;
2011-11-30;
Oral;
Capsule;
92:44.00 – IMMUNOSUPPRESSIVE AGENTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84976
ACH-MYCOPHENOLATE;
02383780;
mycophenolate mofetil 250 mg;
2012-05-01;
Oral;
Capsule;
92:44.00 – IMMUNOSUPPRESSIVE AGENTS;
Prescription;
ACCORD HEALTHCARE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86955
JAMP-MYCOPHENOLATE CAPSULES;
02386399;
mycophenolate mofetil 250 mg;
2012-06-13;
Oral;
Capsule;
92:44.00 – IMMUNOSUPPRESSIVE AGENTS;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87198
MYCOPHENOLATE MOFETIL;
02457369;
mycophenolate mofetil 250 mg;
2016-09-29;
Oral;
Capsule;
92:44.00 – IMMUNOSUPPRESSIVE AGENTS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94442
CELLCEPT;
02237484;
mycophenolate mofetil 500 mg;
1998-11-11;
Oral;
Tablet;
92:44.00 – IMMUNOSUPPRESSIVE AGENTS;
Prescription;
HOFFMANN-LA ROCHE LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=60818
SANDOZ MYCOPHENOLATE MOFETIL;
02313855;
mycophenolate mofetil 500 mg;
2011-11-30;
Oral;
Tablet;
92:44.00 – IMMUNOSUPPRESSIVE AGENTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=79937
TEVA-MYCOPHENOLATE;
02348675;
mycophenolate mofetil 500 mg;
2011-11-30;
Oral;
Tablet;
92:44.00 – IMMUNOSUPPRESSIVE AGENTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83402
APO-MYCOPHENOLATE;
02352567;
mycophenolate mofetil 500 mg;
2011-12-01;
Oral;
Tablet;
92:44.00 – IMMUNOSUPPRESSIVE AGENTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83782
MYCOPHENOLATE MOFETIL TABLETS, USP;
02378574;
mycophenolate mofetil 500 mg;
2012-02-16;
Oral;
Tablet;
92:44.00 – IMMUNOSUPPRESSIVE AGENTS;
Prescription;
ACCORD HEALTHCARE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86436
JAMP-MYCOPHENOLATE;
02380382;
mycophenolate mofetil 500 mg;
2012-03-23;
Oral;
Tablet;
92:44.00 – IMMUNOSUPPRESSIVE AGENTS;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86619
MYCOPHENOLATE MOFETIL;
02457377;
mycophenolate mofetil 500 mg;
2016-09-29;
Oral;
Tablet;
92:44.00 – IMMUNOSUPPRESSIVE AGENTS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94443
MYFORTIC;
02264560;
mycophenolic acid (mycophenolate sodium) 180 mg;
2005-02-11;
Oral;
Tablet (Enteric-Coated);
92:44.00 – IMMUNOSUPPRESSIVE AGENTS;
Prescription;
NOVARTIS PHARMACEUTICALS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=75000
APO-MYCOPHENOLIC ACID;
02372738;
mycophenolic acid (mycophenolate sodium) 180 mg;
2014-07-02;
Oral;
Tablet (Enteric-Coated);
92:44.00 – IMMUNOSUPPRESSIVE AGENTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85782
MAR-MYCOPHENOLIC ACID;
02511673;
mycophenolic acid (mycophenolate sodium) 180 mg;
2021-04-07;
Oral;
Tablet (Enteric-Coated);
92:44.00 – IMMUNOSUPPRESSIVE AGENTS;
Prescription;
MARCAN PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=100086
MYFORTIC;
02264579;
mycophenolic acid (mycophenolate sodium) 360 mg;
2005-02-11;
Oral;
Tablet (Enteric-Coated);
92:44.00 – IMMUNOSUPPRESSIVE AGENTS;
Prescription;
NOVARTIS PHARMACEUTICALS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=75001
APO-MYCOPHENOLIC ACID;
02372746;
mycophenolic acid (mycophenolate sodium) 360 mg;
2014-07-02;
Oral;
Tablet (Enteric-Coated);
92:44.00 – IMMUNOSUPPRESSIVE AGENTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85783
MAR-MYCOPHENOLIC ACID;
02511681;
mycophenolic acid (mycophenolate sodium) 360 mg;
2021-04-07;
Oral;
Tablet (Enteric-Coated);
92:44.00 – IMMUNOSUPPRESSIVE AGENTS;
Prescription;
MARCAN PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=100087
CESAMET;
02312263;
nabilone 0.25 mg;
2008-09-12;
Oral;
Capsule;
56:22.92 – MISCELLANEOUS ANTIEMETICS;
Narcotic (Cdsa Ii);
BAUSCH HEALTH, CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=79778
PMS-NABILONE;
02380897;
nabilone 0.25 mg;
2021-01-22;
Oral;
Capsule;
56:22.92 – MISCELLANEOUS ANTIEMETICS;
Narcotic (Cdsa Ii);
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86665
TEVA-NABILONE;
02392925;
nabilone 0.25 mg;
2013-05-27;
Oral;
Capsule;
56:22.92 – MISCELLANEOUS ANTIEMETICS;
Narcotic (Cdsa Ii);
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87819
CESAMET;
02256193;
nabilone 0.5 mg;
2004-09-16;
Oral;
Capsule;
56:22.92 – MISCELLANEOUS ANTIEMETICS;
Narcotic (Cdsa Ii);
BAUSCH HEALTH, CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=74143
PMS-NABILONE;
02380900;
nabilone 0.5 mg;
2012-03-26;
Oral;
Capsule;
56:22.92 – MISCELLANEOUS ANTIEMETICS;
Narcotic (Cdsa Ii);
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86666
TEVA-NABILONE;
02384884;
nabilone 0.5 mg;
2012-05-23;
Oral;
Capsule;
56:22.92 – MISCELLANEOUS ANTIEMETICS;
Narcotic (Cdsa Ii);
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87056
ACT NABILONE;
02393581;
nabilone 0.5 mg;
2012-10-02;
Oral;
Capsule;
56:22.92 – MISCELLANEOUS ANTIEMETICS;
Narcotic (Cdsa Ii);
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87880
CESAMET;
00548375;
nabilone 1 mg;
1982-12-31;
Oral;
Capsule;
56:22.92 – MISCELLANEOUS ANTIEMETICS;
Narcotic (Cdsa Ii);
BAUSCH HEALTH, CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=4941
ACT NABILONE;
02393603;
nabilone 1 mg;
2012-10-02;
Oral;
Capsule;
56:22.92 – MISCELLANEOUS ANTIEMETICS;
Narcotic (Cdsa Ii);
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87881
PMS-NABILONE;
02380919;
nabilone 1.0 mg;
2012-03-26;
Oral;
Capsule;
56:22.92 – MISCELLANEOUS ANTIEMETICS;
Narcotic (Cdsa Ii);
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86667
TEVA-NABILONE;
02384892;
nabilone 1.0 mg;
2012-05-23;
Oral;
Capsule;
56:22.92 – MISCELLANEOUS ANTIEMETICS;
Narcotic (Cdsa Ii);
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87057
NABUMETONE;
02238639;
nabumetone 500 mg;
1998-08-21;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=62067
APO-NADOLOL;
00782475;
nadolol 160 mg;
1988-12-31;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=9177
APO-NADOLOL;
00782505;
nadolol 40 mg;
1988-12-31;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=9178
MINT-NADOLOL;
02496380;
nadolol 40 mg;
2020-07-21;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
MINT PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98626
APO-NADOLOL;
00782467;
nadolol 80 mg;
1988-12-31;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=9176
MINT-NADOLOL;
02496399;
nadolol 80 mg;
2020-08-19;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
MINT PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98627
FRAXIPARINE FORTE;
02240114;
nadroparin calcium 19000 unit / ml;
1999-06-22;
Intravenous , Subcutaneous;
Solution;
20:12.04.16 – HEPARINS;
Prescription;
ASPEN PHARMACARE CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=63628
FRAXIPARINE FORTE;
02450666;
nadroparin calcium 19000 unit / ml;
1999-06-22;
Intravenous , Subcutaneous;
Solution;
20:12.04.16 – HEPARINS;
Prescription;
ASPEN PHARMACARE CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93681
FRAXIPARINE FORTE;
02450674;
nadroparin calcium 19000 unit / ml;
1999-06-22;
Intravenous , Subcutaneous;
Solution;
20:12.04.16 – HEPARINS;
Prescription;
ASPEN PHARMACARE CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93682
FRAXIPARINE;
02236913;
nadroparin calcium 9500 unit / ml;
1998-02-05;
Intravenous , Subcutaneous;
Solution;
20:12.04.16 – HEPARINS;
Prescription;
ASPEN PHARMACARE CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=60205
FRAXIPARINE;
02450623;
nadroparin calcium 9500 unit / ml;
1998-02-05;
Intravenous , Subcutaneous;
Solution;
20:12.04.16 – HEPARINS;
Prescription;
ASPEN PHARMACARE CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93678
FRAXIPARINE;
02450631;
nadroparin calcium 9500 unit / ml;
1998-02-05;
Intravenous , Subcutaneous;
Solution;
20:12.04.16 – HEPARINS;
Prescription;
ASPEN PHARMACARE CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93679
FRAXIPARINE;
02450658;
nadroparin calcium 9500 unit / ml;
1998-02-05;
Intravenous , Subcutaneous;
Solution;
20:12.04.16 – HEPARINS;
Prescription;
ASPEN PHARMACARE CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93680
SYNAREL;
02188783;
nafarelin (nafarelin acetate) 200 mcg / act;
1996-11-25;
Nasal;
Metered-Dose Aerosol;
68:18.00 – GONADOTROPINS AND ANTIGONADOTROPINS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=42902
NUBAIN INJECTION 10MG/ML;
01913980;
nalbuphine hydrochloride 10 mg / ml;
1993-12-31;
Intramuscular , Intravenous , Subcutaneous;
Solution;
28:08.12 – OPIATE PARTIAL AGONISTS;
Schedule G (Cdsa Iv);
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=13803
MOVANTIK;
02442167;
naloxegol (naloxegol oxalate) 12.5 mg;
2015-08-27;
Oral;
Tablet;
56:92.00 – MISCELLANEOUS GI DRUGS;
Prescription;
KNIGHT THERAPEUTICS INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92652
MOVANTIK;
02442175;
naloxegol (naloxegol oxalate) 25 mg;
2015-08-27;
Oral;
Tablet;
56:92.00 – MISCELLANEOUS GI DRUGS;
Prescription;
KNIGHT THERAPEUTICS INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92653
NALOXONE HYDROCHLORIDE INJECTION USP;
02382482;
naloxone hydrochloride (naloxone hydrochloride dihydrate) 0.4 mg / ml;
2014-01-09;
Intramuscular , Intravenous , Subcutaneous;
Solution;
28:10.00 – OPIATE ANTAGONISTS;
Prescription;
TELIGENT OU
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86832
NALOXONE HYDROCHLORIDE INJECTION;
02393034;
naloxone hydrochloride (naloxone hydrochloride dihydrate) 0.4 mg / ml;
2013-10-03;
Intramuscular , Intravenous , Subcutaneous;
Solution;
28:10.00 – OPIATE ANTAGONISTS;
Prescription;
OMEGA LABORATORIES LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87828
INJECTABLE NALOXONE HYDROCHLORIDE;
02455935;
naloxone hydrochloride (naloxone hydrochloride dihydrate) 0.4 mg / ml;
2016-08-05;
Intramuscular , Intravenous , Subcutaneous;
Solution;
28:10.00 – OPIATE ANTAGONISTS;
Ethical;
OMEGA LABORATORIES LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94280
NALOXONE HYDROCHLORIDE INJECTION;
02393042;
naloxone hydrochloride (naloxone hydrochloride dihydrate) 1 mg / ml;
2013-10-10;
Intramuscular , Intravenous , Subcutaneous;
Solution;
28:10.00 – OPIATE ANTAGONISTS;
Prescription;
OMEGA LABORATORIES LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87829
NALOXONE HCL INJECTION – 0.4MG/ML USP;
02148706;
naloxone hydrochloride 0.4 mg / ml;
1995-12-31;
Intramuscular , Intravenous , Subcutaneous;
Liquid;
28:10.00 – OPIATE ANTAGONISTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=18025
S.O.S. NALOXONE HYDROCHLORIDE INJECTION;
02453258;
naloxone hydrochloride 0.4 mg / ml;
2016-06-21;
Intramuscular , Intravenous , Subcutaneous;
Solution;
28:10.00 – OPIATE ANTAGONISTS;
Ethical;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93978
NALOXONE INJECTABLE;
02458578;
naloxone hydrochloride 0.4 mg / ml;
2018-06-12;
Intramuscular , Intravenous , Subcutaneous;
Solution;
28:10.00 – OPIATE ANTAGONISTS;
Ethical;
TELIGENT OU
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94572
NALOXONE HCL INJECTION – 1MG/ML USP;
02148714;
naloxone hydrochloride 1 mg / ml;
1995-12-31;
Intramuscular , Intravenous , Subcutaneous;
Liquid;
28:10.00 – OPIATE ANTAGONISTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=18024
NARCAN NASAL SPRAY;
02458187;
naloxone hydrochloride 4 mg / 0.1 ml;
2017-07-07;
Nasal;
Spray, Metered Dose;
28:10.00 – OPIATE ANTAGONISTS;
Ethical;
EMERGENT OPERATIONS IRELAND LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94523
REVIA;
02213826;
naltrexone hydrochloride 50 mg;
1997-10-23;
Oral;
Tablet;
28:10.00 – OPIATE ANTAGONISTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=43143
APO-NALTREXONE;
02444275;
naltrexone hydrochloride 50 mg;
2015-11-10;
Oral;
Tablet;
28:10.00 – OPIATE ANTAGONISTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92924
NALTREXONE HYDROCHLORIDE TABLETS USP;
02451883;
naltrexone hydrochloride 50 mg;
2017-05-30;
Oral;
Tablet;
28:10.00 – OPIATE ANTAGONISTS;
Prescription;
STERINOVA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93829
CLEAR EYES;
02248060;
naphazoline hydrochloride .012 %;
2004-03-24;
Ophthalmic;
Liquid;
52:32.00 – VASOCONSTRICTORS;
Otc;
PRESTIGE BRANDS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=72380
ALBALON;
00001147;
naphazoline hydrochloride .1 %;
1970-12-31;
Ophthalmic;
Drops;
52:32.00 – VASOCONSTRICTORS;
Otc;
ALLERGAN INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=934
SOOTHE REDNESS;
00764647;
naphazoline hydrochloride 0.012 % / w/v;
1988-12-31;
Ophthalmic;
Drops;
52:32.00 – VASOCONSTRICTORS;
Otc;
BAUSCH & LOMB INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=8526
REFRESH REDNESS RELIEF;
02315920;
naphazoline hydrochloride 0.1 %;
2009-02-09;
Ophthalmic;
Solution;
52:32.00 – VASOCONSTRICTORS;
Otc;
ALLERGAN INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80143
OPTI-TEARS RED EYE;
02449609;
naphazoline hydrochloride 0.1 % / w/v;
2017-04-04;
Ophthalmic;
Solution;
52:32.00 – VASOCONSTRICTORS;
Otc;
ALCON CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93543
PEDIAPHARM NAPROXEN SUSPENSION;
02162431;
naproxen 25 mg / ml;
1996-12-31;
Oral;
Suspension;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
MEDEXUS PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19661
APO-NAPROXEN;
00522651;
naproxen 250 mg;
1982-12-31;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=4980
TEVA-NAPROXEN;
00565350;
naproxen 250 mg;
1982-12-31;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=5036
NAPROXEN 250;
00590762;
naproxen 250 mg;
1983-12-31;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=5175
TEVA-NAPROXEN EC;
02243312;
naproxen 250 mg;
2001-04-02;
Oral;
Tablet (Enteric-Coated);
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=67215
APO-NAPROXEN EC TABLETS;
02246699;
naproxen 250 mg;
2003-04-23;
Oral;
Tablet (Enteric-Coated);
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=70894
NAPROXEN;
02350750;
naproxen 250 mg;
2010-06-15;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83596
NAPROXEN EC;
02350785;
naproxen 250 mg;
2010-06-15;
Oral;
Tablet (Enteric-Coated);
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83599
APO-NAPROXEN;
00600806;
naproxen 375 mg;
1983-12-31;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=5508
TEVA-NAPROXEN;
00627097;
naproxen 375 mg;
1984-12-31;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=5860
NAPROXEN-375;
00655686;
naproxen 375 mg;
1985-12-31;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=6524
NAPROSYN;
02162415;
naproxen 375 mg;
1995-12-31;
Oral;
Tablet (Enteric-Coated);
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
ATNAHS PHARMA UK LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19316
TEVA-NAPROXEN EC;
02243313;
naproxen 375 mg;
2001-04-02;
Oral;
Tablet (Enteric-Coated);
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=67216
APO-NAPROXEN EC;
02246700;
naproxen 375 mg;
2003-04-23;
Oral;
Tablet (Enteric-Coated);
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=70895
NAPROXEN;
02350769;
naproxen 375 mg;
2010-06-15;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83597
NAPROXEN EC;
02350793;
naproxen 375 mg;
2010-06-15;
Oral;
Tablet (Enteric-Coated);
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83600
TEVA-NAPROXEN;
00589861;
naproxen 500 mg;
1983-12-31;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=5183
APO-NAPROXEN;
00592277;
naproxen 500 mg;
1983-12-31;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=5222
NAPROXEN 500;
00618721;
naproxen 500 mg;
1984-12-31;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=6266
NAPROSYN;
02162423;
naproxen 500 mg;
1995-12-31;
Oral;
Tablet (Enteric-Coated);
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
ATNAHS PHARMA UK LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19315
TEVA-NAPROXEN EC;
02243314;
naproxen 500 mg;
2001-04-02;
Oral;
Tablet (Enteric-Coated);
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=67217
APO-NAPROXEN EC;
02246701;
naproxen 500 mg;
2003-04-23;
Oral;
Tablet (Enteric-Coated);
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=70896
PRO-NAPROXEN EC;
02310953;
naproxen 500 mg;
2008-07-04;
Oral;
Tablet (Enteric-Coated);
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=79657
NAPROXEN;
02350777;
naproxen 500 mg;
2010-06-15;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83598
NAPROXEN EC;
02350807;
naproxen 500 mg;
2010-06-15;
Oral;
Tablet (Enteric-Coated);
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83601
NAPROSYN;
02162466;
naproxen 750 mg;
1995-12-31;
Oral;
Tablet (Extended-Release);
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
ATNAHS PHARMA UK LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19314
ALEVE CAPLETS;
02301733;
naproxen sodium 220 mg;
2009-06-15;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
BAYER INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78704
ALEVE LIQUID GELS;
02361795;
naproxen sodium 220 mg;
2011-09-12;
Oral;
Capsule;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
BAYER INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84684
NAPROXEN;
02362430;
naproxen sodium 220 mg;
2011-03-18;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=84744
MAXIDOL LIQUID GELS;
02372991;
naproxen sodium 220 mg;
2012-05-17;
Oral;
Capsule;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
BAYER INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85812
NAPROXEN;
02378418;
naproxen sodium 220 mg;
2013-09-16;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
PERRIGO INTERNATIONAL
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=86421
NAPROXEN SODIUM TABLETS;
02385007;
naproxen sodium 220 mg;
2014-03-06;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87067
NAPROXEN MENSTRUAL PAIN RELIEF;
02396009;
naproxen sodium 220 mg;
2014-01-24;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88106
ALEVE BACK AND BODY PAIN;
02436337;
naproxen sodium 220 mg;
2015-06-30;
Oral;
Capsule;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Otc;
BAYER INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92069
TEVA-NAPROXEN SODIUM;
00778389;
naproxen sodium 275 mg;
1988-12-31;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=9241
APO-NAPRO-NA;
00784354;
naproxen sodium 275 mg;
1989-12-31;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=10035
NAPROXEN-NA;
00887056;
naproxen sodium 275 mg;
1995-12-31;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=17199
ANAPROX;
02162725;
naproxen sodium 275 mg;
1995-12-31;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
ATNAHS PHARMA UK LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19446
NAPROXEN SODIUM;
02351013;
naproxen sodium 275 mg;
2010-06-15;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83619
TEVA-NAPROXEN SODIUM DS;
02026600;
naproxen sodium 550 mg;
1993-12-31;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=13848
APO-NAPRO-NA DS;
01940309;
naproxen sodium 550 mg;
1993-12-31;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
APOTEX INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=14048
ANAPROX DS;
02162717;
naproxen sodium 550 mg;
1995-12-31;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
ATNAHS PHARMA UK LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19313
NAPROXEN-NA DF;
02153386;
naproxen sodium 550 mg;
1999-09-15;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=44029
NAPROXEN SODIUM DS;
02351021;
naproxen sodium 550 mg;
2010-06-15;
Oral;
Tablet;
28:08.04.92 – OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS;
Prescription;
SANIS HEALTH INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83620
AMERGE;
02237820;
naratriptan (naratriptan hydrochloride) 1 mg;
1998-05-05;
Oral;
Tablet;
28:32.28 – SELECTIVE SEROTONIN AGONISTS;
Prescription;
GLAXOSMITHKLINE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=61179
TEVA-NARATRIPTAN;
02314290;
naratriptan (naratriptan hydrochloride) 1 mg;
2009-12-02;
Oral;
Tablet;
28:32.28 – SELECTIVE SEROTONIN AGONISTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=79985
AMERGE;
02237821;
naratriptan (naratriptan hydrochloride) 2.5 mg;
1998-05-05;
Oral;
Tablet;
28:32.28 – SELECTIVE SEROTONIN AGONISTS;
Prescription;
GLAXOSMITHKLINE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=61180
TEVA-NARATRIPTAN;
02314304;
naratriptan (naratriptan hydrochloride) 2.5 mg;
2009-12-01;
Oral;
Tablet;
28:32.28 – SELECTIVE SEROTONIN AGONISTS;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=79986
SANDOZ NARATRIPTAN;
02322323;
naratriptan (naratriptan hydrochloride) 2.5 mg;
2010-04-08;
Oral;
Tablet;
28:32.28 – SELECTIVE SEROTONIN AGONISTS;
Prescription;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80778
TYSABRI;
02286386;
natalizumab 300 mg / 15 ml;
2006-11-21;
Intravenous;
Solution;
92:20.00 – Immunomodulatory Agents;
Prescription , Schedule D;
BIOGEN CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=77184
BYSTOLIC;
02399016;
nebivolol (nebivolol hydrochloride) 10 mg;
2013-04-02;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
ALLERGAN INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88392
BYSTOLIC;
02398990;
nebivolol (nebivolol hydrochloride) 2.5 mg;
2013-04-02;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
ALLERGAN INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88390
BYSTOLIC;
02399024;
nebivolol (nebivolol hydrochloride) 20 mg;
2013-04-02;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
ALLERGAN INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88393
BYSTOLIC;
02399008;
nebivolol (nebivolol hydrochloride) 5 mg;
2013-04-02;
Oral;
Tablet;
24:24.00 – BETA-ADRENERGIC BLOCKING AGENTS;
Prescription;
ALLERGAN INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=88391
ATRIANCE;
02299925;
nelarabine 5 mg / ml;
2008-01-17;
Intravenous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
NOVARTIS PHARMACEUTICALS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78527
VIRACEPT -250MG;
02238617;
nelfinavir (nelfinavir mesylate) 250 mg;
1998-09-21;
Oral;
Tablet;
08:18.08.08 – HIV PROTEASE INHIBITORS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=62045
VIRACEPT;
02248761;
nelfinavir (nelfinavir mesylate) 625 mg;
2004-08-11;
Oral;
Tablet;
08:18.08.08 – HIV PROTEASE INHIBITORS;
Prescription;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=73129
NEOSTIGMINE OMEGA;
02230593;
neostigmine methylsulfate 0.5 mg / ml;
1999-05-28;
Intramuscular , Intravenous , Subcutaneous;
Liquid;
12:04.00 – PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS;
Prescription;
OMEGA LABORATORIES LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=49702
NEOSTIGMINE METHYLSULFATE INJECTION USP;
02475480;
neostigmine methylsulfate 0.5 mg / ml;
2019-03-26;
Intramuscular , Intravenous , Subcutaneous;
Solution;
12:04.00 – PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS;
Prescription;
MARCAN PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96586
NEOSTIGMINE OMEGA;
02230592;
neostigmine methylsulfate 1 mg / ml;
1999-06-23;
Intramuscular , Intravenous , Subcutaneous;
Liquid;
12:04.00 – PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS;
Prescription;
OMEGA LABORATORIES LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=49701
NEOSTIGMINE METHYLSULFATE INJECTION USP;
02475499;
neostigmine methylsulfate 1 mg / ml;
2019-03-26;
Intramuscular , Intravenous , Subcutaneous;
Solution;
12:04.00 – PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS;
Prescription;
MARCAN PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=96587
NEOSTIGMINE OMEGA;
02387166;
neostigmine methylsulfate 2.5 mg / ml;
2013-04-17;
Intramuscular , Intravenous , Subcutaneous;
Solution;
12:04.00 – PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS;
Prescription;
OMEGA LABORATORIES LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87274
NEVANAC;
02308983;
nepafenac 0.1 % / w/v;
2008-08-21;
Ophthalmic;
Suspension;
52:08.20 – NONSTEROIDAL ANTI-INFLAMMATORY AGENTS;
Prescription;
NOVARTIS PHARMACEUTICALS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=79459
ILEVRO;
02411393;
nepafenac 0.3 % / w/v;
2014-06-01;
Ophthalmic;
Suspension;
52:08.20 – NONSTEROIDAL ANTI-INFLAMMATORY AGENTS;
Prescription;
NOVARTIS PHARMACEUTICALS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=89601
NERLYNX;
02490536;
neratinib (neratinib maleate) 40 mg;
2019-12-20;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
KNIGHT THERAPEUTICS INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98057
AURO-NEVIRAPINE;
02318601;
nevirapine 200 mg;
2010-12-29;
Oral;
Tablet;
08:18.08.16 – NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS;
Prescription;
AURO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80408
MYLAN-NEVIRAPINE;
02387727;
nevirapine 200 mg;
2012-06-20;
Oral;
Tablet;
08:18.08.16 – NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS;
Prescription;
MYLAN PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87331
JAMP NEVIRAPINE;
02405776;
nevirapine 200 mg;
2013-06-03;
Oral;
Tablet;
08:18.08.16 – NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=89053
NIFEDIPINE;
00755907;
nifedipine 10 mg;
1988-12-31;
Oral;
Capsule;
24:28.08 – DIHYDROPYRIDINES;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=8376
ADALAT XL – SRT 30MG;
02155907;
nifedipine 30 mg;
1992-12-31;
Oral;
Tablet (Extended-Release);
24:28.08 – DIHYDROPYRIDINES;
Prescription;
BAYER INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19099
MYLAN-NIFEDIPINE EXTENDED RELEASE;
02349167;
nifedipine 30 mg;
2010-04-23;
Oral;
Tablet (Extended-Release);
24:28.08 – DIHYDROPYRIDINES;
Prescription;
MYLAN PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83448
PMS-NIFEDIPINE ER;
02418630;
nifedipine 30 mg;
2015-03-17;
Oral;
Tablet (Extended-Release);
24:28.08 – DIHYDROPYRIDINES;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90319
NIFEDIPINE ER;
02421631;
nifedipine 30 mg;
2015-01-13;
Oral;
Tablet (Extended-Release);
24:28.08 – DIHYDROPYRIDINES;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90628
NIFEDIPINE;
00725110;
nifedipine 5 mg;
1989-12-31;
Oral;
Capsule;
24:28.08 – DIHYDROPYRIDINES;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=9938
MYLAN-NIFEDIPINE EXTENDED RELEASE;
02321149;
nifedipine 60 mg;
2008-12-30;
Oral;
Tablet (Extended-Release);
24:28.08 – DIHYDROPYRIDINES;
Prescription;
MYLAN PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80655
PMS-NIFEDIPINE ER;
02416301;
nifedipine 60 mg;
2015-03-17;
Oral;
Tablet (Extended-Release);
24:28.08 – DIHYDROPYRIDINES;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90087
NIFEDIPINE ER;
02421658;
nifedipine 60 mg;
2015-01-13;
Oral;
Tablet (Extended-Release);
24:28.08 – DIHYDROPYRIDINES;
Prescription;
PRO DOC LIMITEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=90629
TASIGNA;
02368250;
nilotinib (nilotinib hydrochloride monohydrate) 150 mg;
2011-07-15;
Oral;
Capsule;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
NOVARTIS PHARMACEUTICALS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85322
TASIGNA;
02315874;
nilotinib (nilotinib hydrochloride monohydrate) 200 mg;
2008-09-30;
Oral;
Capsule;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
NOVARTIS PHARMACEUTICALS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=80138
TASIGNA;
02481715;
nilotinib (nilotinib hydrochloride monohydrate) 50 mg;
2019-05-17;
Oral;
Capsule;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
NOVARTIS PHARMACEUTICALS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97220
ANANDRON;
02221861;
nilutamide 50 mg;
1997-08-20;
Oral;
Tablet;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
CHEPLAPHARM ARZNEIMITTEL GMBH
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=43312
NIMOTOP;
02325926;
nimodipine 30 mg;
2009-07-24;
Oral;
Tablet;
24:28.08 – DIHYDROPYRIDINES;
Prescription;
BAYER INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=81127
OFEV;
02443066;
nintedanib (nintedanib esilate) 100 mg;
2015-06-29;
Oral;
Capsule;
48:02.00 – ANTIFIBROTIC AGENTS;
Prescription;
BOEHRINGER INGELHEIM (CANADA) LTD LTEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92756
OFEV;
02443074;
nintedanib (nintedanib esilate) 150 mg;
2015-06-29;
Oral;
Capsule;
48:02.00 – ANTIFIBROTIC AGENTS;
Prescription;
BOEHRINGER INGELHEIM (CANADA) LTD LTEE
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92761
ZEJULA;
02489783;
niraparib (niraparib tosylate) 100 mg;
2020-01-09;
Oral;
Capsule;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription;
GLAXOSMITHKLINE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97986
MDK-NITISINONE;
02457733;
nitisinone 10 mg;
2016-10-20;
Oral;
Capsule;
92:92.00 – OTHER MISCELLANEOUS THERAPEUTIC AGENTS;
Prescription;
MENDELIKABS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94477
NITISINONE TABLETS;
02458632;
nitisinone 10 mg;
2016-12-19;
Oral;
Tablet;
92:92.00 – OTHER MISCELLANEOUS THERAPEUTIC AGENTS;
Prescription;
CYCLE PHARMACEUTICALS LTD.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94578
ORFADIN;
02459728;
nitisinone 10 mg;
2017-02-17;
Oral;
Capsule;
92:92.00 – OTHER MISCELLANEOUS THERAPEUTIC AGENTS;
Prescription;
SWEDISH ORPHAN BIOVITRUM AB (PUBL)
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94701
MDK-NITISINONE;
02457717;
nitisinone 2 mg;
2016-10-20;
Oral;
Capsule;
92:92.00 – OTHER MISCELLANEOUS THERAPEUTIC AGENTS;
Prescription;
MENDELIKABS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94475
NITISINONE TABLETS;
02458616;
nitisinone 2 mg;
2017-01-13;
Oral;
Tablet;
92:92.00 – OTHER MISCELLANEOUS THERAPEUTIC AGENTS;
Prescription;
CYCLE PHARMACEUTICALS LTD.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94576
ORFADIN;
02459698;
nitisinone 2 mg;
2017-02-17;
Oral;
Capsule;
92:92.00 – OTHER MISCELLANEOUS THERAPEUTIC AGENTS;
Prescription;
SWEDISH ORPHAN BIOVITRUM AB (PUBL)
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94699
ORFADIN;
02459736;
nitisinone 20 mg;
2017-02-17;
Oral;
Capsule;
92:92.00 – OTHER MISCELLANEOUS THERAPEUTIC AGENTS;
Prescription;
SWEDISH ORPHAN BIOVITRUM AB (PUBL)
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94702
ORFADIN;
02469693;
nitisinone 4 mg / ml;
2018-07-10;
Oral;
Suspension;
92:92.00 – OTHER MISCELLANEOUS THERAPEUTIC AGENTS;
Prescription;
SWEDISH ORPHAN BIOVITRUM AB (PUBL)
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95850
MDK-NITISINONE;
02457725;
nitisinone 5 mg;
2016-10-20;
Oral;
Capsule;
92:92.00 – OTHER MISCELLANEOUS THERAPEUTIC AGENTS;
Prescription;
MENDELIKABS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94476
NITISINONE TABLETS;
02458624;
nitisinone 5 mg;
2017-01-13;
Oral;
Tablet;
92:92.00 – OTHER MISCELLANEOUS THERAPEUTIC AGENTS;
Prescription;
CYCLE PHARMACEUTICALS LTD.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94577
ORFADIN;
02459701;
nitisinone 5 mg;
2017-02-17;
Oral;
Capsule;
92:92.00 – OTHER MISCELLANEOUS THERAPEUTIC AGENTS;
Prescription;
SWEDISH ORPHAN BIOVITRUM AB (PUBL)
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94700
MOGADON;
00511536;
nitrazepam 10 mg;
1980-12-31;
Oral;
Tablet;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=3992
MOGADON;
00511528;
nitrazepam 5 mg;
1980-12-31;
Oral;
Tablet;
28:24.08 – BENZODIAZEPINES;
Targeted (Cdsa Iv);
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=3991
KINOX;
02451301;
nitric oxide 100 ppm / cylr;
2016-05-03;
Inhalation;
Gas;
24:12.08 – NITRATES AND NITRITES;
Prescription;
AIRGAS USA LLC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93756
INOMAX;
02270846;
nitric oxide 800 ppm / cylr;
2005-11-23;
Inhalation;
Gas;
24:12.08 – NITRATES AND NITRITES;
Prescription;
INO THERAPEUTICS
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=75619
KINOX;
02451328;
nitric oxide 800 ppm / cylr;
2016-05-03;
Inhalation;
Gas;
24:12.08 – NITRATES AND NITRITES;
Prescription;
AIRGAS USA LLC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93757
NOXIVENT;
02451425;
nitric oxide 800 ppm / cylr;
2016-03-10;
Inhalation;
Gas;
24:12.08 – NITRATES AND NITRITES;
Prescription;
PRAXAIR CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93767
NITROFURANTOIN;
00312738;
nitrofurantoin 100 mg;
1974-12-31;
Oral;
Tablet;
08:36.00 – URINARY ANTI-INFECTIVES;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=2093
MACROBID;
02063662;
nitrofurantoin 100 mg;
1993-12-31;
Oral;
Capsule;
08:36.00 – URINARY ANTI-INFECTIVES;
Prescription;
ALLERGAN INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=15173
TEVA-NITROFURANTOIN;
02231016;
nitrofurantoin 100 mg;
1997-05-02;
Oral;
Capsule;
08:36.00 – URINARY ANTI-INFECTIVES;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=50297
PMS-NITROFURANTOIN BID;
02455676;
nitrofurantoin 100 mg;
2018-04-25;
Oral;
Capsule;
08:36.00 – URINARY ANTI-INFECTIVES;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=94248
AURO-NITROFURANTOIN BID;
02466392;
nitrofurantoin 100 mg;
2017-10-23;
Oral;
Capsule;
08:36.00 – URINARY ANTI-INFECTIVES;
Prescription;
AURO PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95474
NITROFURANTOIN;
00319511;
nitrofurantoin 50 mg;
1974-12-31;
Oral;
Tablet;
08:36.00 – URINARY ANTI-INFECTIVES;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=2094
TEVA-NITROFURANTOIN;
02231015;
nitrofurantoin 50 mg;
1997-05-02;
Oral;
Capsule;
08:36.00 – URINARY ANTI-INFECTIVES;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=50295
NITROGEN 100%;
00572829;
nitrogen 100 %;
1911-12-31;
Inhalation;
Gas;
92:92.00 – OTHER MISCELLANEOUS THERAPEUTIC AGENTS;
Ethical;
AIR LIQUIDE CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=5683
LIQUID NITROGEN NF;
02297248;
nitrogen 100 %;
2008-01-21;
Topical;
Liquid;
92:92.00 – OTHER MISCELLANEOUS THERAPEUTIC AGENTS;
Ethical;
VITALAIRE CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78261
LIQUID NITROGEN;
02368218;
nitrogen 100 %;
2011-09-13;
Topical;
Liquid;
92:92.00 – OTHER MISCELLANEOUS THERAPEUTIC AGENTS;
Ethical;
N-TWO MEDICAL INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85318
LIQUID NITROGEN NF;
02436590;
nitrogen 100 %;
2015-10-20;
Topical;
Liquid;
92:92.00 – OTHER MISCELLANEOUS THERAPEUTIC AGENTS;
Ethical;
CRYOGEN NITROGEN DELIVERIES LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92092
NITROGEN NF 99%;
02014394;
nitrogen 99 %;
1993-12-31;
Inhalation;
Gas;
92:92.00 – OTHER MISCELLANEOUS THERAPEUTIC AGENTS;
Ethical;
PRAXAIR CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=13882
NITROGEN N.F.;
02154803;
nitrogen 99 %;
1995-12-31;
Inhalation;
Gas;
92:92.00 – OTHER MISCELLANEOUS THERAPEUTIC AGENTS;
Ethical;
MESSER CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19292
GASEOUS NITROGEN 99.0%;
00591645;
nitrogen 99.0 %;
1983-12-31;
Inhalation;
Gas;
92:92.00 – OTHER MISCELLANEOUS THERAPEUTIC AGENTS;
Ethical;
AIR PRODUCTS CANADA LTD/LTÉE.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=5221
NITROGEN NF;
02248173;
nitrogen 99.5 %;
2004-04-15;
Inhalation;
Gas;
92:92.00 – OTHER MISCELLANEOUS THERAPEUTIC AGENTS;
Ethical;
VITALAIRE CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=72506
TRANSDERM-NITRO 0.2;
00584223;
nitroglycerin 0.2 mg / hour;
1989-12-31;
Transdermal;
Patch (Extended Release);
24:12.08 – NITRATES AND NITRITES;
Ethical;
NOVARTIS PHARMACEUTICALS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=9858
NITRO-DUR 0.2;
01911910;
nitroglycerin 0.2 mg / hour;
1991-12-31;
Transdermal;
Patch (Extended Release);
24:12.08 – NITRATES AND NITRITES;
Ethical;
USPHARMA LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=11227
TRINIPATCH 0.2;
02230732;
nitroglycerin 0.2 mg / hour;
1999-04-01;
Transdermal;
Patch;
24:12.08 – NITRATES AND NITRITES;
Ethical;
PALADIN LABS INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=49993
MYLAN-NITRO PATCH 0.2;
02407442;
nitroglycerin 0.2 mg / hour;
2013-06-04;
Transdermal;
Patch (Extended Release);
24:12.08 – NITRATES AND NITRITES;
Ethical;
MYLAN PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=89213
NITROSTAT;
00037613;
nitroglycerin 0.3 mg;
1972-12-31;
Sublingual;
Tablet;
24:12.08 – NITRATES AND NITRITES;
Ethical;
UPJOHN CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=1254
NITROLINGUAL PUMPSPRAY;
02231441;
nitroglycerin 0.4 mg / act;
1998-07-31;
Sublingual;
Metered-Dose Pump;
24:12.08 – NITRATES AND NITRITES;
Ethical;
SANOFI-AVENTIS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=50758
RHO-NITRO PUMPSPRAY;
02238998;
nitroglycerin 0.4 mg / act;
2001-12-20;
Sublingual;
Metered-Dose Pump;
24:12.08 – NITRATES AND NITRITES;
Ethical;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=62447
MYLAN-NITRO SUBLINGUAL SPRAY;
02243588;
nitroglycerin 0.4 mg / act;
2001-08-23;
Sublingual;
Metered-Dose Aerosol;
24:12.08 – NITRATES AND NITRITES;
Ethical;
MYLAN PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=67506
TRANSDERM-NITRO 0.4;
00852384;
nitroglycerin 0.4 mg / hour;
1989-12-31;
Transdermal;
Patch (Extended Release);
24:12.08 – NITRATES AND NITRITES;
Ethical;
NOVARTIS PHARMACEUTICALS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=10116
NITRO-DUR 0.4;
01911902;
nitroglycerin 0.4 mg / hour;
1991-12-31;
Transdermal;
Patch (Extended Release);
24:12.08 – NITRATES AND NITRITES;
Ethical;
USPHARMA LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=11225
TRINIPATCH 0.4;
02230733;
nitroglycerin 0.4 mg / hour;
1999-04-01;
Transdermal;
Patch;
24:12.08 – NITRATES AND NITRITES;
Ethical;
PALADIN LABS INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=49995
MYLAN-NITRO PATCH 0.4;
02407450;
nitroglycerin 0.4 mg / hour;
2013-06-04;
Transdermal;
Patch (Extended Release);
24:12.08 – NITRATES AND NITRITES;
Ethical;
MYLAN PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=89214
NITROSTAT;
00037621;
nitroglycerin 0.6 mg;
1972-12-31;
Sublingual;
Tablet;
24:12.08 – NITRATES AND NITRITES;
Ethical;
UPJOHN CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=1253
NITRO-DUR 0.6;
01911929;
nitroglycerin 0.6 mg / hour;
1991-12-31;
Transdermal;
Patch (Extended Release);
24:12.08 – NITRATES AND NITRITES;
Ethical;
USPHARMA LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=11226
TRANSDERM-NITRO 0.6;
02046156;
nitroglycerin 0.6 mg / hour;
1994-12-31;
Transdermal;
Patch (Extended Release);
24:12.08 – NITRATES AND NITRITES;
Ethical;
NOVARTIS PHARMACEUTICALS CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=15572
TRINIPATCH 0.6;
02230734;
nitroglycerin 0.6 mg / hour;
1999-04-01;
Transdermal;
Patch;
24:12.08 – NITRATES AND NITRITES;
Ethical;
PALADIN LABS INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=49996
MYLAN-NITRO PATCH 0.6;
02407469;
nitroglycerin 0.6 mg / hour;
2013-06-04;
Transdermal;
Patch (Extended Release);
24:12.08 – NITRATES AND NITRITES;
Ethical;
MYLAN PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=89215
NITRO-DUR 0.8;
02011271;
nitroglycerin 0.8 mg / hour;
1993-12-31;
Transdermal;
Patch (Extended Release);
24:12.08 – NITRATES AND NITRITES;
Ethical;
USPHARMA LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=14742
MYLAN-NITRO PATCH 0.8;
02407477;
nitroglycerin 0.8 mg / hour;
2013-06-04;
Transdermal;
Patch (Extended Release);
24:12.08 – NITRATES AND NITRITES;
Ethical;
MYLAN PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=89216
NITROJECT INJ 5MG/ML;
00778869;
nitroglycerin 50 mg / 10 ml;
1988-12-31;
Intravenous;
Solution;
24:12.08 – NITRATES AND NITRITES;
Ethical;
OMEGA LABORATORIES LTD
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=10706
NITROUS OXIDE 100%;
00572845;
nitrous oxide 100 %;
1911-12-31;
Inhalation;
Gas;
28:04.16 – INHALATION ANESTHETICS;
Ethical;
AIR LIQUIDE CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=5685
NITROUS OXIDE USP 99%;
02014467;
nitrous oxide 99 %;
1993-12-31;
Inhalation;
Gas;
28:04.16 – INHALATION ANESTHETICS;
Ethical;
PRAXAIR CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=13887
NITROUS OXIDE U.S.P.;
02154811;
nitrous oxide 99 %;
1995-12-31;
Inhalation;
Gas;
28:04.16 – INHALATION ANESTHETICS;
Ethical;
MESSER CANADA INC.
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19262
OPDIVO;
02446626;
nivolumab 10 mg / ml;
2015-10-23;
Intravenous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription , Schedule D;
BRISTOL-MYERS SQUIBB CANADA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93204
OPDIVO;
02446634;
nivolumab 10 mg / ml;
2015-10-23;
Intravenous;
Solution;
10:00.00 – ANTINEOPLASTIC AGENTS;
Prescription , Schedule D;
BRISTOL-MYERS SQUIBB CANADA
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93205
AXID;
00778338;
nizatidine 150 mg;
1988-12-31;
Oral;
Capsule;
56:28.12 – HISTAMINE H2-ANTAGONISTS;
Prescription;
PENDOPHARM DIVISION OF PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=8915
ALLERGENIC EXTRACT NON POLLENS;
00299979;
non pollen 100000 unit / ml;
1963-12-31;
Intradermal , Subcutaneous , Percutaneous;
Liquid;
92:05.00* – ALLERGENIC EXTRACTS;
Schedule D;
ALK-ABELLO INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=1913
NON STANDARDIZED ALLERGENIC EXTRACTS – NON POLLENS;
02372428;
non pollen 40000 unit / ml;
2012-08-29;
Intradermal , Subcutaneous;
Liquid;
92:05.00* – ALLERGENIC EXTRACTS;
Schedule D;
GREER LABORATORIES INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=85754
RIXUBIS;
02431947;
nonacog gamma 1000 unit / vial;
2017-04-18;
Intravenous;
Kit , Powder For Solution;
20:28.16 – HEMOSTATICS;
Schedule D;
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=91641
RIXUBIS;
02431955;
nonacog gamma 2000 unit / vial;
2017-04-18;
Intravenous;
Kit , Powder For Solution;
20:28.16 – HEMOSTATICS;
Schedule D;
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=91642
RIXUBIS;
02431920;
nonacog gamma 250 unit / vial;
2019-01-15;
Intravenous;
Kit , Powder For Solution;
20:28.16 – HEMOSTATICS;
Schedule D;
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=91639
RIXUBIS;
02431963;
nonacog gamma 3000 unit / vial;
2018-09-25;
Intravenous;
Kit , Powder For Solution;
20:28.16 – HEMOSTATICS;
Schedule D;
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=91643
RIXUBIS;
02431939;
nonacog gamma 500 unit / vial;
2017-05-02;
Intravenous;
Kit , Powder For Solution;
20:28.16 – HEMOSTATICS;
Schedule D;
TAKEDA CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=91640
NOREPINEPHRINE BITARTRATE INJ 1MG/ML USP;
00893285;
norepinephrine (norepinephrine bitartrate) 1 mg / ml;
1991-12-31;
Intravenous;
Liquid;
12:12.12 – ALPHA-AND BETA-ADRENERGIC AGONISTS;
Ethical;
SANDOZ CANADA INCORPORATED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=11641
LEVOPHED;
02241981;
norepinephrine (norepinephrine bitartrate) 1 mg / ml;
2001-10-01;
Intravenous;
Solution;
12:12.12 – ALPHA-AND BETA-ADRENERGIC AGONISTS;
Ethical;
PFIZER CANADA ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=65651
NOREPINEPHRINE BITARTRATE INJECTION USP;
02485680;
norepinephrine (norepinephrine bitartrate) 1 mg / ml;
2020-05-04;
Intravenous;
Solution;
12:12.12 – ALPHA-AND BETA-ADRENERGIC AGONISTS;
Ethical;
GENERIC MEDICAL PARTNERS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=97591
MOVISSE;
02410303;
norethindrone 0.35 mg;
2015-06-30;
Oral;
Tablet;
68:12.00 – CONTRACEPTIVES;
Prescription;
MYLAN PHARMACEUTICALS ULC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=89495
JENCYCLA;
02441306;
norethindrone 0.35 mg;
2015-09-14;
Oral;
Tablet;
68:12.00 – CONTRACEPTIVES;
Prescription;
LUPIN PHARMA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=92570
NORLUTATE;
00023760;
norethindrone acetate 5 mg;
1961-12-31;
Oral;
Tablet;
68:32.00 – PROGESTINS;
Prescription;
ERFA CANADA 2012 INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=1401
NORFLOXACIN;
02229524;
norfloxacin 400 mg;
1998-07-20;
Oral;
Tablet;
08:12.18 – QUINOLONES;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=47429
AVENTYL;
00015229;
nortriptyline (nortriptyline hydrochloride) 10 mg;
1965-12-31;
Oral;
Capsule;
28:16.04.28 – TRICYCLICS AND OTHER NOREPINEPHRINE-REUPTAKE INHIBITORS;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=15
AVENTYL;
00015237;
nortriptyline (nortriptyline hydrochloride) 25 mg;
1965-12-31;
Oral;
Capsule;
28:16.04.28 – TRICYCLICS AND OTHER NOREPINEPHRINE-REUPTAKE INHIBITORS;
Prescription;
AA PHARMA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=16
SPINRAZA;
02465663;
nusinersen (nusinersen sodium) 2.4 mg / ml;
2017-08-29;
Intrathecal;
Solution;
92:18.00 – ANTISENSE OLIGONUCLEOTIDES;
Prescription;
BIOGEN CANADA INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95389
JAMP-NYSTATIN ORAL SUSPENSION USP;
02433443;
nystatin 100000 unit / ml;
2015-01-09;
Oral;
Suspension;
08:14.28 – POLYENES;
Prescription;
JAMP PHARMA CORPORATION
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=91783
NYADERM CRM 100000UNIT/GM;
00716871;
nystatin 100000 unit / g;
1979-12-31;
Topical;
Cream;
84:04.08.28 – POLYENES;
Otc;
TARO PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=8977
TEVA-NYSTATIN;
02194163;
nystatin 100000 unit / g;
1998-10-14;
Vaginal;
Cream;
84:04.08.28 – POLYENES;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=35795
RATIO-NYSTATIN;
02194228;
nystatin 100000 unit / g;
1996-11-28;
Topical;
Ointment;
84:04.08.28 – POLYENES;
Otc;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=35799
RATIO-NYSTATIN;
02194236;
nystatin 100000 unit / g;
1996-09-12;
Topical;
Cream;
84:04.08.28 – POLYENES;
Otc;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=35800
PMS-NYSTATIN SUSPENSION 100000 UNIT/ML;
00792667;
nystatin 100000 unit / ml;
1989-12-31;
Oral;
Suspension;
08:14.28 – POLYENES;
Prescription;
PHARMASCIENCE INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=9973
TEVA-NYSTATIN;
02194201;
nystatin 100000 unit / ml;
1996-09-12;
Oral;
Suspension;
08:14.28 – POLYENES;
Prescription;
TEVA CANADA LIMITED
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=35798
NYADERM VAG CRM 25000UNIT/GM;
00716901;
nystatin 25000 unit / g;
1979-12-31;
Vaginal;
Cream;
84:04.08.28 – POLYENES;
Prescription;
TARO PHARMACEUTICALS INC
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=9277

NOTICE

This page contains a copy of information from Health Canada’s Drug Product Database.
The author of this website is not responsible for any incomplete or erroneous information that may be found in the Health Canada database and / or on this page.

The AHFS class of active ingredients is regularly reassigned. The information on this page doesn’t always reflect these changes.

© All rights reserved. Pharmaceuticals database and data extracts.
Health Canada. Adapted and reproduced with permission from the Minister of Health, 2019.

⇡ Return to top

AVIS

Cette page contient une copie des informations de la base de données sur les produits pharmaceutiques de Santé Canada.
L’auteure de ce site web n’est pas responsable des informations incomplètes ou erronées qui pourraient être trouvées dans la base de données de Santé Canada et/ou sur cette page.


La classe AHFS des ingrédients actifs fait régulièrement l’objet de réaffectations.
Les informations sur cette page ne reflète pas toujours ces changements;

© Tous droits réservés. Base de données sur les produits pharmaceutiques et extraits de données.
Santé Canada. Adapté et reproduit avec la permission du ministre de la Santé, 2019.

⇡ Retour en haut